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Effect of salt intake on P-glycoprotein expression induced by cyclospo-
rifle A in circulating lymphocytes in rats. M. Anddjar, C. Ram frez, E.
Vergara, M. Gómez-Morales, A. Osuna, A. 0/mo, F. Arrebola, M.J. GarcIa-
Chicano, R. G. Del Moral, Department of Pathology, University Hospital,
Nephrology Service, Virgen de las Nieves Hospital, Granada, Spain. P-I 70
glycoprotein (P-gp) is a detoxicant system related with multidrug resis-
tance (MDR) in some tumors. The protein removes from the cell
hydrophobic substances such as chemothcrapeutic and immunosuppres-
sive agents, including cyclosporinc A (CsA). Exposure of the renal
parenchyma to therapeutic doses of CsA induces overexpression of P-gp in
this tissue; this phenomenon is related with the presence of drug deposits.
We developed a model of chronic CsA toxicity in Sprague-Dawley rats
treated with 25 mg/kg/day CsA for 2 months and maintained on a standard
diet or a sodium-free diet. We studied the percentage of cells positive for
P-gp and mean channel fluorescence in circulating lymphocytes, using flow
cytometly and indirect immunofluorescence (mAb JSB1, which recognizes
P-gp). Positivity was detected in lymphocytes from all groups; however, the
highest percentage; (61.3%; P < 0.001) and the highest mean channel
fluorescence (15.3; P < 0.05) appeared in rats treated with CsA and fed
the maintenance diet. Most groups of animals fed with the sodium-free
diet had lower levels of P-gp expression and mean channel fluorescence in
comparison with rats fed the maintenance diet. We conclude that CsA
treatment and feeding with a maintenance (standard) diet induce a
significant increase in P-gp expression in circulating lymphocytes in the
rat. Our findings suggest a possible osmotic induction effect of diets with
normal sodium content, and a potentially beneficial effect of restricted
sodium intake in transplant patients receiving CsA treatment.
Citraturia and formation of calcium oxalate deposits in renal tissue
following terminal ileon exclusion surgery: Experimental study. .J. Font, A.
Gascón, E. Iglesias, R. Burdeus, J.M. Mange, A. Ingelmo, S. Urology and
Nephrology, 0. Polanco General Hospital, Teruel, Spain. Partial ileal bypass
(PIB) surgery has been used since 1963 as treatment for severe cases of
hypercholesterolemia. The most frequent side effect of this type of surgery
are diarrhea and nephrolithiasis. The entrance of acid and hiliar salts to
the colon produces in these patients hyperoxaluria. PIB patients appear to
be at risk for kidney stone formation. The combination of reduced urinary
volume and calcium oxalate precipitation inhibitor substance with in-
creased calcium oxalate relative supersaturation produced an increase in
nephrolithiasis risk. The aim of the present study is to evaluate the
different renal hyochemical alterations induced by this type of surgery in
Wistar rats. We studied 70 Wistar rats aged 6 to 12 months. After feeding
with a high cholesterol diet for six months, ten of them were sacrifled and
used as a control group. A group of 30 rats underwent terminal ileon
resection. On another group of 30 rats terminal ileon by-pass was
performed. Alter 30, 90 and 180 days, they were sacrified for histological
study. Hyperoxaluria appeared in all the rats that underwent surgery.
Calcium oxalate deposits in renal tissue were not found in any of the cases.
The 24-hour urine citrate levels were normal. Diarrhea did not occur in
any of the rats. Calcium and phosphor levels were not altered during the
experience. In conclusion, hyperoxaluria resulting after terminal ileon
exclusion surgery indicates the importance of acid and biliar salts as
inductors of permeability in the colonic mucosa for oxalates. The absence
of diarrhea justifies normocitraturia in our study and the later absence of
calcium oxalate deposits in renal tissue.
Histological renal damage induced by hypercholcsterolemic diet in
Wistar rats: influence of terminal ileon exclusion surgery. 1. Font, A.
Gascón, E. Iglesias, R. Burdeus, A. Yague, A. Ingelmo, S. Urology and
Nephrology, 0. Polanco General Hospital, Teruel, Spain. Experimental
investigations have suggested an important role for abnormal lipid me-
tabolism as a factor in modulating progressive renal disease. Partial ileal
bypass (PIB) surgery has been used since 1963 as treatment for severe
cases of hypercholesterolemia. The most frequent side effect of this type of
surgery are diarrhea and nephrolithiasis. However, there are no experi-
mental studies about the effects of FIB surgery on renal histology. The
present study examined the histological alterations in renal tissue induced
by a high cholesterol diet. These arc also compared with those found when
cholesterol levels are normalized in plasma by FIB surgery. We studied 70
Wistar rats aged 6 to 12 months after feeding them a high cholesterol diet
for six months. Ten of them were sacrified and used as a control group.
The remaining 60 rats underwent terminal ileon exclusion surgery (resec-
tion or bypass), bringing their cholesterol to normal levels. After 30, 90
and 180 days, they were sacrifled for histological study. The high choles-
terol diet induced high cholesterol levels in plasma (68 9 vs. 119 14
mg/dl, P < 0.05). After terminal ileon exclusion surgery all the rats
experimented an important decrease of plasma cholesterol, ranging from
15 to 48%. Renal injury consisted in tubulointerstitial injury in 8 cases,
without signs of glomerulosclerosis. These findings were focal and bilat-
eral, and did not depend on the type of surgery. In 14% of the rats we
found lipid infiltration of the abdominal aorta. The control group pre-
sented the same renal damage identical in proportion and intensity. In
conclusion, we found very low histological renal injury, basically consisting
in tubulointerstitial nephropathy. In our study renal injury did not regress
when plasma cholesterol levels were normalized. This low incidence of
renal injury, without glomerulosclerosis, is probably in relationship with
the not excessively high plasma cholesterol levels. Although the degree of
renal injury seen in our study is modest, it indicated a potential relation-
ship between lipids and a progressive renal disease.
Expression of j31- and 2-isoforms of the Na,K-ATPase during com-
pensatory renal hypertrophy. N. Eleno, A. RodrIguez-Lopez, L.M. DIez-
Panero, P. Martln-Vasallo, f.M. LOpez-Novoa, Instituto Relna SofIa de
lnvestigacion NefrolOgica; Departamento de FisiologIa y Farmacologla, Univ.
Salumanca; Departamento de Bioqolmica y Biologla Molecular, Univ. La
I.aguna, Spain. One of the main adaptative mechanisms following renal
hypertrophy after a partial nephrectomy occurs with the sodium pump
activity. However, at the moment it is unclear whether compensatory
hypertrophy is associated to an increase in the number of the sodium
pumps. There arc few data about the evolution of a-subunit, but nothing
has been found about the possible modification in the expression of
13-subunit isoforms (131 and 132). Therefore, we studied the differential
expression of both 13 isoforms at the mRNA and protein levels in the renal
cortex of the hypertrophied remnant kidney after unilateral nephrectomy.
Under ether anesthesia, the left renal pediele was ligated in male Wistar
rats (253 6.9 g) and the kidney excised through a lateral incision. All
determinations were performed in the right kidney 1, 2, 3, 6, 10 and 13
days after left nephrectomy. Proteins and mRNAs were detected by
Western and Northern blots, respectively, using well characterized poly-
clonal antibodies and eDNAs. Na,K-ATPasc activity was determined as
ATP hydrolysis in niicrosomes of renal cortex. The fl subunit is a highly
glycosylated peptide; to confirm the specificity of the bands in immuoo-
blots, some protein samples were digested. The bands corresponding to
the fully glycosylated peptides (molecular wt —50) dissapeared after
digestion revealing instead the core peptides (molecular wt —35) and
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partially deglycosylated isoforms. Right kidney hypertrophy after left
nephrectomy was confirmed by comparing the total protein content and
the following relationships: weight of the right kidney/weight of the
animal, weight of the right kidney/weight of the left kidney. The specific
enzymatic activity of the sodium pump increased on the third day in the
cortex of the kidney undergoing hypertrophy. Immunoblots showed the
expression of the f31 glycopeptide in control kidneys until the 13th day.
The relative density of the bands (the same amount of protein was charged
in each lane) decreased the 1st, 2nd and 3rd days and recovered control
values from the 6th day after uninephrectomy. The (32 glycopeptide was
only specifically detected the 3rd, 6th and 10th days after left nephrec-
tomy. The signal for f31 and j32 mRNAs in the remnant kidney was
maximal the 3rd and 6th days after contralateral nephrectomy. Therefore,
the (31 isoform was constitutively expressed in the kidney whereas the (32
isoform was only expressed in the kidney undergoing compensatory
hypertrophy.
Linkage analysis using a2.adrenergic receptor gene polymorphisms in
families with essential hypertension. J. Calls, S. Lario, A. Cases, M. Bono,
J. Oriola, A. Torras, F. Rivera, A. Darnell, Nephrology Service and Hor-
monology Laboratory, Hospital Clinic i Provincial, Barcelona, Spain. An
increased platelet cs2-adrenergic receptor (cs2A-AR) density has been
described in nearly half of patients with essential hypertension (EH).
Furthermore, an increased density of these receptors has been reported in
normotensive children from hypertensive parents, suggesting that aSA-AR
may play a role in the genetic predisposition to hypertension. Our aim was
to investigate the possible relationship between the increased aSA-AR
density and the haplotypes determined by the 02A-AR gene polymor-
phisms in families with a positive history of hypertension. Six families with
a positive history of EH were included, and they included at least two
relatives with hypertension. nsA-AR density and affinity were measured in
intact platelets by radiolingand binding assay, using [3H-methylyohimbine
as a ligand. The linkage analysis was performed with the three polymor-
phisms described for the nsA-AR gene. Bsu361 and Dral polymorphisms
were determined by Southern blot analysis following hibridization with a
[32P]-labeled ADRA2R probe. The third polymorphism was detected by
PCR amplification and digestion with HhaI restriction enzyme. Twenty-
two hypertensive and 9 normotensive subjects were included; 19 Out of 22
hypertensive patients (86%) showed an increased nsA-AR density [296
14.5 binding sites per platelet (bsp)] compared to normotensives (162
10.5 bsp, P < 0.01). The haplotypes for the nsA-AR gene were informative
in 4 out of 6 families, but no haplotype was associated to EH or the
increased nsA-AR density. Our results suggest that the genetic factor
involved in the development of EH is not located in the a..2A-AR gene area.
However, we cannot exclude the aSA-AR gene as a candidate for EH,
because of the low number of families analyzed.
Unsuspected renal artery stenosis in 418 patients with peripheral
vascular disease. R. Maim, C. Diaz-Corte, J. Cosio, J.E. RodrIguez, A. Valle,
A. Barreiro, M. Sanchez, C. Glez-Porta4 F. Fdez-Vega and J. Alvarez-
Grande, Nephrology, Radiology and Vascular Surgery Services, Hospital
Central de Asturias, Hospital Covadonga, Oviedo, Spain. The aim of the
study was to evaluate the prevalence of renal artery stenosis (RAS) in
patients with peripheral atherosclerotic arterial disease and the clinical
implications of this association. Between November 1993 and April 1995
we prospectively studied the prevalence of RAS in 418 consecutive
patients undergoing angiography for peripheral vascular disease. We
obtained information about the demographic data, the prevalence of
cardiovascular risk factors, the serum ereatinine level, the severity of
vascular disease on the basis of angiographic findings (Ito III categories)
and the existence of another cardiovascular pathology. For statistical
analysis patients were divided in two groups according to the presence or
absence of RAS and the patients without RAS were the control group.
RAS was detected in 114 patients (27%); in 24 patients it was bilateral and
in 84 (74%) unilateral. The patients with RAS were older (72 10 vs.
65 12 years, P < 0.001), they had a higher prevalence of hypertension
[59% vs. 36%, odds ratio (OR) 2.5, 95% confidence interval (Cl) 1.6 to
3.9, P < 0.00 I], greater severity of arterial lesions in category III (66% vs.
38%, OR 3.1, CI 2.01 to 4, P < 0.001) and a higher serum creatinine level
(1.44 0.5 vs. 1.21 0.3 mgldl, P < 0.001). No differences were found in
the prevalence of hyperlipidemia, diabetes or smoking. Patients with RAS
had a greater prevalence of myocardial isehemia (26% vs. 13%, OR 2.4, CI
1.4 to 4.1, P < 0.01) and left ventricle hypertrophy (25% vs. 13%, OR 2.1,
CI 1.2 to 3.6, P < 0.05). Using stepwise logistic regression analysis, the risk
factors for RAS were the age, the presence of hypertension, the severity of
peripheral vascular disease and the existence of isehemie heart disease.
Hypertensive patients treated with angiotensin-converting enzyme (ACE)
inhibitors had a higher serum creatinine level than hypertensive patients in
therapy with others antihypertensive agents: 1.96 0.8 vs. 1.54 0.6, P <
0.05. Only when the stenosis was greater than 75% was hypertension and
a higher serum creatinine level more prevalent. We conclude that there is
an important prevalence of unknown RAS in patients with peripheral
vascular disease. There is a direct relationship between the presence of
RAS and the age, hypertension, severity of peripheral vascular disease and
isehemic heart disease in these patients. Hypertensive patients with
peripheral vascular disease who are treated with ACE-inhibitors had a
higher serum ereatinine level than hypertensive patients in therapy with
others antihypertensive agents. The arteriography, as part of the routine
evaluation for patients with atherosclerotic arterial disease, needs to
include the study of renal arteries.
Is there a J-shaped curve of renal morbidity in treated elderly hyper-
tensives? P. Aranda, R. Mann, L.M. Ruilope, P. Aijama, M. Luque, on
behalf of the Spanish Group. SEN and SEH, Madrid, Spain. We investi-
gated elderly patients who were diagnosed with mild to severe essential
hypertension (EEH), independently of the type of antihypertensives used,
and determined the effects of different degrees of blood pressure control
on their renal function. In a cross sectional, observational, and national
study on 2406 (62.8% females) treated EEH, men age 71.8 7 years old,
we evaluated the effects of different degrees of BP control on the lipid
profile and renal function, measured by lipoprotein profile and serum
creatinine levels, and the endogenous ereatinine clearance using the
Crockoft & Gault formula. After establishing the diagnosis of essential
hypertension, we measured BP (mean of 2 readings), H.R. and BMI, as
well as determined the levels of glucose in a fasting state, ereatinine,
t-eholesterol, triglycerides and lipoproteins. The mean time since the
diagnosis of having EH was 88.6 77 months. The mean values of BP in
the treated hypertensives was 151.3 12/87.4 7 mm Hg, the mean BMI
was 27.9 4, mean serum Cr was 1.04 0.31 mgdl and mean Cr clearance
was 68.9 20 mI/mm. Antihypertensives used (%) included: ACEI, 47.4;
CCB, 32.1; diuretics, 35.1; beta blockers, 6.1; and others, 9.44%. For the
evaluation, the sample was divided according to the following BP levels: 
or <160/95 mm Hg and <135/85 mm Hg.
BP
mmHg
DBP
N mmHg SBP
<135/85 191 76.5 6 129.9 6
P a a
<160/95 1573 84.5 8 151.2 15
P a a
160/95 642 101.3 6 175.9 14
BP Creatinine C.
mm Hg mg/dl
-
>1.3
<80 mI/mhz
<135/85 1.05 0.23 19.4 79
P c e c
<160/95 1.02 0.32 14.4 73.3
P e a NS
160/95 1.06 0.28 20.07 70.4
BP LDL-cholesterol Triglycerides
mmHg >165 >200
<135/85 34.1 13.9
P c NS
<160/95 45 11.8
P a a
160/95 54.5 17
(*)p < 0.001; (**)p < 0.01; (**)p < 0.05
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We conclude that, independently of the antihypertensives used, the
uncontrolled hypertensives (BP  160/95) as well as the elderly patients
with a BP < 135/85 mm Hg had a worse renal function. Although it is
necessary to perform longitudinal studies to corroborate these results,
excessive BP control might contribute to a more rapid decline of renal
function in treated elderly hypertensive patients.
20 mg/day, plus thiazide, 12.5 mg/day initial dose, in 24 patients with
diabetic nephropathy (DN). Eleven were male and 13 female, mean age
57 75 years, 5 with type I diabetes and 19 with type TI diabetes. Blood
pressure and biochemical parameters after 6 and 12 months of treatment
were as follows:
Spiral computer tomography angiography (CTA): Utility for the diag-
nosis of renal artery stenosis. C. Garcia Ruiz, T Sempere, A. Martinez, A.
Ramos, J. Palao, C. Peralta, J.A. Oliver, Departments of Nephrology and
Radiology, Universitaty Hospital Joan XXIII, University of Tarragona, Spain.
Recently, the utility of spiral CTA has been demonstrated a new,
minimally invasive technique with a sensitivity of 98% and specificity of
94% for the diagnosis of renal artery stenosis (RAS). To evaluate the
accuracy of CTA in the diagnosis of RAS-induced hypertension, we
studied 56 patients with suspected renal RAS, median age 56.1 years
(19—78). Twenty-three of them had renal failure with a median serum
crcatinine of 229 smol/liter (134—450). All of the patients had a spiral
CTA done with a continuously rotating X-ray tube of 7—10 cm, slice
thickness 2.7 mm, and a reconstruction interval of 1.4 mm. Contrast
medium 2 cc/kg wt was injected intravenously with a flow rate of 4 cc/seg.
Image analysis included not only a visualization of the axial images in a
cine-mode, but also using interactive multiplanar reformatting, maximum
intensity projections and three-dimensional reconstructions. The grading
of stenosis was defined as: Grade 0, no stenosis; Grade I, stenosis <50%,
Grade II, stenosis between 50—75%; Grade III, stenosis between 75—99%;
Grade IV, occlusion. CTA was performed in 56 patients, 130 renal arteries
were evaluated, 73% of them were normal, and stenoses of grade Ito IV
were detected in 27% of the renal arteries, 60% stenoses were grade I,
20% stenoses grade Il, 14.2% grade ITT and 5.7% stenoses grade IV. In 19
patients with pathologic CTA arteriography was performed that showed
the same stenoses grade in 16 and an overestimate in three. CTA was
complicated by an allergic contrast reactions in one patient. We suggest
that spiral CT angiography is a safe and minimally invasive method for the
diagnosis of renal artery stenosis, and using this technique could lead to
significant reductions in the number of diagnostic angiographies.
Prevalence and characteristics of diabetic nephropathy in diabetes
mellitus secondary to alcoholic pancreatitis. C. Morillas, A. Herndndez,
M.J. Morillas, fL. Górriz, L.M. PallardO, C. Cataldn, D. Lorente, Depart-
ments of Endocrinology and Nephrology, Hospital Dr. Peset, Valencia, Spain.
The incidence of diabetic nephropathy (DN) in diabetes mellitus (DM)
secondary to alcoholic pancreatitis remains controversial. A low preva-
lence has been reported in most of the studies, which could be due to a
short follow-up of the patients, and the fact that most of the studies did not
include microalbuminuria as marker for nephropathy. The aim of our
study was to determine the prevalence and characteristics of DN in a
group of pancreoprivic patients. We studied 40 patients (39 males and I
female) with DM secondary to alcoholic chronic pancreatitis, diagnosed
on the basis of clinical, morphological and functional criteria. Their mean
age was 53 8 years, mean alcohol consumption was 95 62 g
alcohol/day, and mean diabetes duration was 5.5 3.6 years. HbAlc was
8.01 2.29%. Microalbuminuria was determined by nephelomctry, taking
the average of three determinations after excluding urinary tract infection,
hypertension and exercise before micturition. Values greater than 30
mg/24 hours were considered pathologic. Microalbuminuria was 260
337 mg/24 hr, and >30 mg/24 hr in 21 patients (52.5%). Eight of them
(20%) had established nephropathy (albominuria >300 mg/24 hr) without
renal insufficiency, and 13 patients (32.5%) showed albuminuria between
30 and 300 mg/24 hr. We conclude that the presence of diabetic nephrop-
athy secondary to alcoholic pancreatitis is similar to that reported in
primary diabetes mellitus, and it was related to diabetes duration. Chronic
renal insufficiency is exceptional in DM secondary to alcoholic pancreati-
tis, probably due to its late onset and the short follow-up in this group low
survival rate patients.
Thiazides plus enalapril can be safely used in hypertensive diabetics
with nephropathy. A.M. Castelao, M. T Gonzalez, Nephrology Department,
H. Principes de Espaha, CSU Bellvitge, University of Barcelona, Spain. For
years thiazides were not considered as a first-line choice of treatment for
hypertension in diabetics, due to the possible deletereous effect on
metabolic control (hyperglycemia, hypcroricemia, hypercholestcrolemia).
We investigated the long-term effect of treatment with enalapril, initially
Sysolie blood pressure 175 25 156 24 154 23 0.001
Dyastolic BP mm Hg 89 13 82 10 78 14 0.002
Urea mmol/liter 12.1 4 12.6 5 15 8 0.009
Creatinine timol/liter 175 88 192 98 208 109 0.03
GFR mI/mm 52.3 24 44.8 25 44 26 0.002
Proteinuriag/day 3.07 3.7 3.27 4.4 2.18 2.8 0.07
Glucose mmol/liter 10 5.8 9.1 4 9.3 3.8 ns
Ale Hb % 7.6 1.8 8 1.4 7.8 1.5 ns
Insulin dose units/day 22 19 24 19 25 17 ns
Na mmol/liter 142 3.9 140 3 142 3.9 ns
K mmol/liter 4.9 0.5 4.8 0.5 5 0.7 ns
Uric acid mmol/liter 400 98 420 122 396 94 ns
Total cholesterol mmol/liter 6.34 1.1 6.06 0.8 5.88 1.2 0.06
Tryglicerides mmol/liter 2.4 2.2 2.8 2 2.3 1.4 ns
HDL-chol. mmol/liter 1.01 0.2 1.29 0.4 1.09 0.4 ns
LDL ehol. mmol/liter 4.23 0.68 3.65 0.6 3.61 0.8 ns
Hemoglobing% 12.6 0.2 11.9 3 12 2 ns
Fibrinogen mg/liter 6.12 t.8 6.04 1.3 5.65 1.6 0.02
Enalapril dose mg/day 20 8 24 9 26 7 ns
Thiazide dose mg/day 12.5 6.2 14.8 6.2 14.8 ns
In spite of the increase in plasma urea and plasma ereatinine and the
decline of GFR, plasma potassium was maintained within normal range.
All the patients hut one showed good tolerance to the treatment. We
stopped enalapril plus tyazide only in one patient, because of a skin rash
after 3 months of therapy. In conclusion, thiazides in association with
enalapril are well tolerated in DN patients without adding deletereous
effects in the metabolic control of these patients.
Inhibition by enalaprilat of the hydrogen peroxide production by
murine mesangial cells exposed to high glucose concentrations. L.M.
Ruiz-Muñoz, R. Muñiz, A. Soils, ML. Muñiz, M.P. Martinez, I. Lampreabe,
Department of Nephrology, Cruces Hospital; and Basque Country University,
School of Medicine and Dentistry, Lejona, Vizcaya, Spain. Angiotensin-
converting enzyme (ACE) inhibitors are drugs with a well-known renal
protective effect that is not fully related with its hypotensive action. The
effect of enalaprilat on hydrogen peroxide (H202) production by cultured
murine mesangial cells exposed to 5.5 (basal condition), 30 and 50 mri
glucose concentrations was examined over 8 hours. The H202 was
evaluated by microfluorimetry quantifying, in arbitrary units, the intracel-
lular dichlorofluorescein (DCFH) oxidation to the highly fluorescent
compound 2',7'-diehlorofluorescein (DCF) from the non-fluorescent
probe dichlorofloorescein-diacetate (DCFH-DA), incubated with mesan-
gial cells (20 mM) for 20 minutes and washed before the addition of study
eonditions. Experiments were repeated three times in quadruplicate wells.
H202 production by mesangial cells exposed to 50 m glucose was
significantly increased after one hour (P < 0.05) compared to cells
exposed to 5.5 and 30 m glucose. This observation was not reproduced
with 50 mi mannitol. The addition of 100 ng/ml enalaprilat to cells with
50 mM glucose significantly inhibited H202 production over the 8 hours of
the assay (P < 0.01). This response was similar to that obtained with 100
ng/ml catalase. Increasing enalaprilat concentrations (10, 50 and 100
nglml) also signilicantly decreased the constitutive H202 production with
5.5 mu glucose from the first hour (P < 0.05), the effect being more
intense with 50 and 100 nglml at the 8th hour (P < 0.01). We conclude that
the protective effect of enalaprilat may be related to an antioxidant action.
Analysis of percutaneous renal biopsy on allograft and native kidneys:
Risks and benefits. P.]. Gainza, ii. Minguela, M.P. Martinez, ML. Mufliz,
J,.M. Ruiz, 1. Lopez-Vidaur, R. Muñiz, I. Lampreabe, Nephrolo,ty and
Radiology Departments, Hospital de Cruces, Barakaldo, Bizkaia, Basque
Country, Spain. We conducted a prospective case-control study of the
Before T. 6 months 12 months P
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complication rate following percutaneous renal biopsy (RB), which was
ultrasound guided. We evaluated 225 consecutive biopsy procedures [122
on transplant kidneys (TK) and 103 on native kidneys (NK)j. Complica-
tions were evaluated by clinical, laboratory and ultrasonography studies
using color-coded Doppler US as previously reported. Hospitalization
time due to complications was recorded and economical considerations
performed. The results were evaluated in a retrospective analysis by
retrieving data from clinical records. The causes leading to RB in native
kidney patients were: acute renal failure in 6 cases, rapidly progressive
renal failure in 26, chronic renal failure in 12, nephrotic proteinuria in 53,
and asymptomatic urinary abnormalities in 6. In transplanted patients the
causes were: declining in renal function in 98 patients (47 from grafting to
the first 3 months) and proteinuria in 24. In the paraffin sample there was
(mean SD) 8.8 0.5 glomeruli. Histological findings: (1) led to a new
treatment in 24% of the cases, (2) confirmed one previously started
treatment in 9%, and (3) changed the therapy regimen in another 9%.
Taking NK and TK in comparison, renal biopsy provided therapeutic
value in 47 and 38%, merely prognostic value in 45 and 57%, and was
useless in 8 and 5%, respectively (x2; P = 0.028). Microscopic hematuria
was the most frequent complication (22.6% of procedures). Regarding
severe complications, bleeding (7.5%) and arteriovenous fistula (11.7%)
were more frequent in allograft than in native kidneys (P = 0.019). There
were neither nephrectomies nor deaths due to the RB. Twelve out of 84
patients (14%) admitted to perform RB remained hospitalized for a
period of 5.6 1.7 days due to complications. Percutaneous renal biopsy
remains a useful procedure in at least 9 out of 10 patients, providing
prognostic and/or therapeutic advantages. Severe complications occurred
in less than 20% of procedures and they were more frequent in transplant
patients.
Renal involvement in antiphospholipd syndrome without systemic
lupus erythematosus. A.E. Sirvent, R. Enriquez, C. Gonzalez, J.B. Cabezu-
do, A. Antolin, A. Teruel, A. Reyes, Nephrology and Pathology Sections,
Hospital General de Elche, Spain. There are scarce reports about nephrop-
athy in antiphospholipid syndrome (AS) without underlying systemic
lupus erythematosus (SLE). We describe the renal manifestations and the
follow up of five patients with AS who were studied from 1991 to 1995
because of renal failure and/or high blood pressure. As was diagnosed
according to Harris' criteria. No patient fullfilled ARA criteria for SLE.
Lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) were
searched in the presence of prolonged aPTI, thrombocytopenia, throm-
bosis, livedo reticularis or hemolytie uremie syndrome (HUS). LA was
determined by the Exner method or by a modified activated partial
thromboplastin time; aCL were measured by ELISA. The age range of the
patients, two women and three men, was 27 to 40 years. The span of the
follow-up was between seven months and five years. Both LA and aCL
were positive in three patients, only aCL in one and LA in another. The
main extrarenal findings were: thrombocytopenia in five cases, thrombotic
events (lower limb phlebitis, cerebral infarction, and celiac axis thrombo-
sis) in three, and livedo reticularis in two. All the five patients had renal
failure that followed an insidious course (serum creatinine stable around
1.5 mg/dl) in three cases. Two patients developed acute renal failure
within HUS; one of these presented oliguria requiring hemodialysis,
although afterwards her renal function improved (C 30—40 mi/mm), the
other one with malignant hypertension needed hemodialysis from the
beginning. Arterial hypertension of different severity, from mild to malig-
nant, was a general feature. Non-nephrotic proteinuria was present in four
patients, the urinary sediment revealed no abnormalities in four cases and
microscopic hematuria in the other. Renal angiography, made in four
patients, disclosed no significant changes. Kidney biopsy, performed in
four cases, showed a non-inflammatory microangiopathy, with variable
severity and chronicity; immunoglohulins and complement deposits were
not seen by immunofluorescenee study. All the patients were treated with
anhiplatelet agents, nne received warfarin, plasma exchanges were used in
the two HUS and steroids were initially given to two. We conclude the
following. (1.) The renal failure in AS revealed, generally, a non-
inflammatory microvaseular nephropathy. (2.) LA and aCL need to be
determined in HUS. (3.) Arterial hypertension, even with normal renal
arteries, is a frequent feature of AS and may be malignant. (4.) The
therapy of AS nephropathy consists of oral anticoagulants and antiplate-
lets agents; the best treatment is not established, and it might be
individualized according to the extrarenal events and the way and severity
of its presentation.
Anti-neutrophilic citoplasmic autoantibody-associated Glomerulone-
phritis. Clinical course and disease activity follow-up. M. T Hernandez,
J.R. Gomez-Martino, I. Castellano, A. Covarsi, R. Novillo, N. Marigliano, 0.
Sanchez, Hospital San Pedro de Alcantara, Caceres, Spain. We have
reviewed the ANCA and associated giomerulonephritis seen in our unit
between October 1990 and December 1995 (63 months). We performed a
total of 160 renal biopsies, of which 23 (14%) were ANCA associated GN:
10 idiopatic extracapillary glomerulonephritis and 13 GN secondary to
systemic vasculitis (2 Wegener's granulomatosis, 1 classic PAN, 10 micro-
scopic PAN). All patients were treated with bolus of 6-metil prednisolone
that was followed by prednisone and oral cyclophosphamide. Nine pa-
tients received additional treatment with plasmapheresis). Three patients
didn't receive treatment, two for death before starting the regimen and
one because he presented with severe damage of chronicity in the renal
biopsy. ANCA was reasured by RIA being 19 p-ANCA and 4 c-ANCA.
The follow-up was 14.8 months (20 days to 63 months). Of the 23 patients,
5 recovered "ad integrum" the renal function, 3 live with a mild chronic
renal failure (Crp < 2 mg/dl), one other patient had a moderate chronic
renal failure (Crp 2—4 mg/dl), 6 progressed to ESRD severe enough to
start renal replacement therapy, and 8 died by their illness or complica-
tions. The necrosis of the tuft, crescents in an upper 50%, and the
existence of diffuse alveolar hemorrhage were signs of bad outcome.
Differences between the patients treated with plasmapheresis or without it
were nonexistant. The follow-up of ANCA was made in 19 patients; 17 of
them (89%) were negative 3—54 months after the beginning of treatment.
We observed a rise in the ANCA titers, without evidence of clinical activity
in 3 patients. In conclusion, (1.) The percentage of ANCA-associated
glomerulonephritis in our unit in the studied time was 14%. The most
frequent association was with p-ANCA (82%) and the bigest incidence of
presentation was during March—April. (2.) The parameters that estab-
lished a bad outcome has been glomerular necrosis, crescents in a
percentage more than 50% and the existence or not of alveolar hemor-
rhage. (3.) The global patient survival rate at the end of the 63 months was
65%. We didn't find differences between patients with illnes autolimited to
kidney or those with systemic vasculitis. (4.) There weren't differences
between renal survival and patient survival when they received treatment
with plasmapheresis or not.
Chronic nephrotoxicity caused by cyclosporine A. Role of endothelin in
the induction of interstitial fibrosis. C. Ram frez, A. Olmo, M. Andujar, F.
O'Valle, F. Revelles, M.J. Garcia-Chicano, D. Aguilar, M. .4guilar, R.G. Del
Moral, Department of Pathology, University Hospital, Granada, Spain.
Chronic nephrotoxieity (CNT) caused by cyclosporine A (C5A) is charac-
terized by progressive renal insufficiency accompanied by interstitial
fibrosis and tubular atrophy. Although increased endothelin (Et) is known
to induce chronic isehemia, and may be important in the genesis of CNT,
other mediators of fibrogenesis have been implicated, such as, TGF-p and
angiotensin II. We studied the secretion of Eti and Et3 in the renal
parenchyma with immunohistochemical methods, and determined the
expression of mRNA with Northern blotting, in an experimental model of
CNT in Sprague-Dawley rats. We studied 20 animals divided into three
groups: CsA-treated (25 mg/kg/day), Cremophor-treated, and saline solu-
tion-treated (control), for 2 months. Histological lesions were evaluated
with conventional methods (vacuolization and tubular atrophy), and
interstitial fibrosis was quantified with an automatic image analysis
method (Fibrosis HR software, Master Diagnostica, Spain). Etl and Et3
were determined immunohistochemically with a specific polyclonal anti-
body (Peninsula Laboratories, USA). Treated animals showed significant
increases in BUN and serum ereatinine, and in characteristic tubulointer-
stitial lesions including a greater percentage of fibrosis, in comparison with
control animals. There was a general increase in Etl and Et3 in glomeruli
and tubules, although immunnstaining for Et3 [glomeruli, 4.7 1.3 (range
3—9) vs. 4.1 1.5, ANOVA P < 0.01; tubule, 2.7 0.6 (range 1—4) vs.
2.2 0.8, ANOVA P < 0.05] was greater than for Eti [glomeruli, 4.9
1.7 (range 3—9) vs. 5.4 1.8; tubule, 2.8 0.8 (range 1—4) vs. 2.5 0.61.
The relation between increased Et3 deposits and histological lesions was
highly significant (interstitial fibrosis 9.0 1.7% with slight deposits, vs.
11.7 0.8% with heavy deposits, ANOVA P < 0.05). This relationship
was not found for EtI deposits. The expression of mRNA for both EtI
(0.47 0.19 vs. 0.33 0.04) and Et3 (0.31 0.18 vs. 0.23 0.08) was
increased in CsA-treated rats vs. controls; this difference was significant
for Eti. In conclusion (1) in CNT caused by CsA, the intrarenal secretion
of Et is increased; this effect is related with the severity of histological
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lesions. (2) Increased Et3 (immunohistochemically determined) suggests
that this substance plays an important role as a paracrine inducer of
fibrosis in CsA-caused CNT. (3) The increase in mRNA for Eti, which was
not accompanied by a notable increase in immunohistochemical findings,
suggests that this mediator is released actively and rapidly into the vascular
spaces of the kidney, and that it may play an important role in the ischemia
that accompanies CsA-caused CNT.
Current use of renal biopsy in acute renal failure (ARF). Data from a
multicenter survey. J. Pascual and F. Liano for the Madrid ARF Study
Group, Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain.
Renal biopsy has had fluctuating roles in the diagnostic work-up of ARF.
After non-renal causes of ARF are excluded, the most common etiologic
factor of ARF is acute tubular necrosis (ATN). Patients with well-
established clinical and laboratoiy features of ATN receive no benefits
from a renal biopsy. Current performance of renal biopsy in community-
based studies including wide populations with ARF is not known. The 13
tertiary-care hospitals in Madrid (covered population 4.2 million people
over 14 years of age) underwent a prospective study of all ARF cases,
including a number of clinical and laboratory variables. ARF was diag-
nosed when a sudden rise in serum creatinine to more than 177 mol/liter
was found in patients with normal renal function or when the sudden rise
was observed in patients with previous mild-to-moderate chronic renal
failure (CRF). Absolute freedom for diagnostic work-up and treatment of
ARF was instituted by the study group. During 9 months 748 cases of ARF
were attended, an incidence of 209 cases p.m.p. Etiologies were ATN
(45%), prerenal (21%), acute onset of CRF (13%), obstructive (10%),
other (11%). Renal biopsy was performed in 46 patients (1 each 16 cases).
In 4 cases the patient had acute onset of CRF. Histologic diagnoses were
primary glomerulonephritis (GN) (N = 12.26%), vasculitis (N = 10.22%),
secondary GN (N = 6, 13%), ATN (N = 4.9%), acute tubulointerstitial
nephritis (ATIN) (N = 4.9%), atheroembolic disease (N 2.4%),
myeloma (N = 2.4%), other (N = 6.13%). Comparing with overall
etiologies and incidences, all primary GN, 90% of vasculitis and 50% of
secondary GN cases were diagnosed by biopsy at the time of ARF. Up to
15 patients were diagnosed as having ATIN, but only 4 (27%) were
biopsied. Only 4 of 337 patients with ATM (1.2%) underwent biopsy.
Renal biopsy has very limited indications in ARF. Only 6% of ARF
patients evaluated in 13 tertiary-care hospitals required it for accurate
assessment. A renal biopsy may be performed only to establish a specific
diagnosis such as acute or rapidly progressive GN, vasculitis or ATIN, for
cases in which an accurate diagnosis cannot be made clinically.
Increased glomerular nitric oxide synthesis in ischemic acute renal
failure. A role for uremia. f.M. Valdivielso, L. Rivas-Cabañero, M. Arévalo,
C. Crespo, J.R. Alonso, J.M. López-Novoa, Instituto Reina Sofia de Investi-
gación Nefrológica, Departamento de Fisiologla y FarmacologIa, Departa-
mento de Anatomia Humana e HistologIa, Departamento de BiologIa
Celulary Patologia, Universidad de Salamanca, Salamanca, Spain. Previous
works from our laboratory showed an increase in glomerular nitric oxide
synthesis in a model of 1 hour of ischemia and 24 hours of reperfusion, but
not in another group of rats which had the same time of isehemia and 2
hours of reperfusion. The aim of this study was to determine if it is the
ischemia or the uremia the responsible for this increased nitric oxide
synthesis. Isehemia was induced by clamping one or both renal arteries.
Also, nitric oxide synthesis was inhibited by adding L-NAME (4 mg/k/day)
in the drinking water. Groups resulted as follows: S Group, sham operated
rats; SN group, sham operated rats with L-NAME in the drinking water;
BT group, rats with bilateral ischcmia; BIN group, rats with bilateral
ischemia and L-NAME in the drinking water; UT group, rats with
unilateral ischemia; UIN group, rats with unilateral ischemia and L-
NAME in the drinking water. Renal function was measured in all the
groups 24 hours before and after inducing the ischemia. Glomeruli from
rats which did not drink L-NAME were isolated at the end of the
treatment and glomerular nitrite production was determined (in the UI
group glomeruli were isolated separately from ischemic and nonischemic
kidney). Also, a hystochcmistiy for NADPH diaphorase activity and an
immunohystochemistry for inducible nitric oxide synthase (iNOS) were
made in slices of kidneys from rats which did not drink L-NAME; a
Western blot analysis for the same protein was also made in glomeruli
from these groups. A histologic study was also made in all the groups,
staining the slices with the PAS technique. Only glomeruli from rats of the
TB group showed an increase in nitrite production and NADPH diapho-
rase activity. iNOS was neither detected with Western blot nor by
immunohystochemistry. After L-NAME treatment, morphological and
functional damage was more severely aggravated in the BI group than in
all the others. All these results suggest that the increased nitric oxide
synthesis observed in ischemic acute renal failure is due to both ischemia
and the developing uremia, and that this increase is not due to the INOS
activity. The inereased nitric oxide synthesis plays a protective role in
ischemia-induced renal damage.
Involvement of phospholipase A2 in gentamicin.induced rat mesangial
cell activation. C. MartInez-Salgado, A. RodrIguez-Barbero, D. Rodriguez-
Puyol, M. RodrIguez-Puyol, J.M. López-Novoa, Instituto Reina SofIa de
Investigacion Nefrologica, Departamento de FisiologIa y FarmacologIa,
Universidad de Salamanca, Salamanca, and Departamento de FisiologIa,
Universidad de Alcalá de Henares, Madrid, Spain. Gentamicin induces
mesangial cell contraction and proliferation; both effects seem to be
mediated, at least in part, by platelet activating factor (PAF). Phospho-
lipase A2 (PLA2) is a membrane-associated enzyme involved in prosta-
glandins and PAF synthesis. We have studied the role of PLA2 in the
gentamicin-induced mesangial cell activation. The decrease in planar cell
surface area induced by gentamicin (10 M), after 60 minutes of
incubation, was partially blocked by a PLA2 inhibitor, aristolochic acid
(AA) (1.5 X i0 M), by a PAF blocker, BN-52021 (BN) (5 X 10 M) and
by a calcium channels antagonist, verapamil (V) (10- M). These sub-
stances also inhibited the effect of gentamicin on 3H-thymidine incorpo-
ration into DNA, and on cell proliferation. The two-fold increase on
3H-acetate incorporation into PAF induced by gentamiein was completely
blocked by AA, BN and V. When PAF was added in addition with
gentamicin, there was a threefold increase on 3H-acetate incorporation
into PAF. Gentamicin increased the TXB2 and PGE2 production by
mesangial cells; these increases dissappeared in the presence of either AA
or V. BN diminishes the PGE2 production induced by gentamiein, but
there was no effect on TXB2 production. When PAF was added in addition
with gentamicin, the TXB2 and PGE2 production were increased eight-
and fourfold, respectively. The present study demonstrates that gentami-
cm-induced rat mesangial cell activation is mediated, at least in part, by
the activation of PLA2.
Decreased acute renal failure (ARF) following allogenic bone marrow
transplantation (TMO) with use of imipenem.cilastatin. E. Gruss, C.
Bemi J.F. Tomás, F. Salvanés, fL. Motellón, A. Figuera, E. Muñoz, G.
Barril, iA. Sdnchez-Tomero, V Alvarez, J.M. Femández-Rahada, iA.
Traver, Departments of Nephrology, Hematology and Investigation Unit,
Hospital de Ia Princesa, Madrid, Spain. ARF is a common complication
following allogenic BMT. The veno-occlusive disease (VOD) and cyclo-
sporine (C5A) use are correlated with this finding. Cilastatin an inhibitor
of the tubular brush border enzyme dehydropeptidase is a added in a fixed
combination to antibiotic imipenem. Cilastatin has been demonstrated in
different animal models and in one clinical trial to reduce the nephrotox-
icity associated with CsA by two mechanisms: preventing intracellular
accumulation of CsA and/or stimulating hepatic metabolism. To evaluate
a possible nephroprotective effect of cilastatin following allogenic BMT we
conducted a retrospective analysis of 104 patients transplanted from
January 1991 to January 1995. ARFwas defined by two conditions: at least
a doubling of baseline ereatinine and by reaching levels higher than 2
mgldl. Imipenem/cilastatin (1/C) was employed in 64 patients along that
period. ARF was diagnosed in 32 patients (30%). ARF was not associated
with sex distribution, sepsis, conditioning regime, underlying disease and
age. Veno-occlusive disease was presented in 12/32 (37.5%) of patients
with ARF, whereas it was presented in only 7/72 (9.7%) of patients
without ARF (P < 0.0007). Neither ARF was correlated with aminogly-
cosides, vancomycin, ciprofloxacine, ceftazidime and amphotericin-B.
However, 13 patients of 64 exposed to I/C (20.3%) developed ARF versus
19 of 40 (47.5%) who were not exposed to I/C (P < 0.003; OR t).28). The
mean cyclosporine levels in I/C group were significantly decreased
(208.6 64.9) versus non-I/C group (265 118). We conclude that these
results suggest I/C could counteract acute cyclosporine nephrotoxicity
following BMT.
is survival in acute renal failure patients requiring hemodialysis
dependent on the type of membrane used? F. Liabo and J. Pascual for the
Madrid ARF Study Group, Department of Nephrology, Hospital Ramón y
Gala1, Madrid, Spain. Recent published data have pointed Out significantly
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higher survival with biocompatible membranes in conventional hemodial-
ysis for acute renal failure (ARF). The hypothesis in these studies is that
the use of synthetic, biocompatible membranes will reduce mortality.
During a 9-month period, a collaborative prospective protocol was
developed to assess all ARF episodes attended in the 13 tertiary-care
hospitals in Madrid (covered population 4.2 million people over 14 years
old). One of the objectives was to assess the influence of the type of
membrane used in survival of ARF patients requiring acute hemodialysis.
During the study period, ARF was diagnosed in 748 patients and 270 of
them (36%) needed dialysis. Conventional hemodialysis was used in 162
and other techniques in the remainder. In 134 of the conventionally
hemodialyzed patients the type of membrane was recorded and constitute
the study group:
Cellulosic(N84) Synthetic(N=50)
Survivors N % 34 (40.5) 17 (34)
Nonsurvivors N % 50 (59.5) 33 (66)
Severity index" 0.52 0.24 0.47 0.26
Number of procedures 6.5 7.0_(1—34) 6.5 7.4 (1—36)
According to our equation (Nephron 63:21—31, 1993)
All comparisons between both groups were not significant.
Our multicenter ARF study did not confirm higher survival with biocom-
patible membranes in conventional hemodialysis for ARF. Mortality was
similar with cellulosic and synthetic membranes, with comparable severity
of ARF episodes in both groups. The effect of dialysis membrane on
survival is open for further research.
Predictive value of APACHE II score in acute renal failure (ARF) in the
intensive care unit (ICU). F. Verde, F. Ruiz, M. C. Vozmediano, I. Lorenzo,
R. Perez, E. Junco, P. RodrIguez, L. Inchaustegui, J.E. Guerrero, F.
Valderrábano, Department of Nephrology and Intensive Care, Hospital
General "Gregorio Marañón," Madrid, Spain. The APACHE II score is a
prognostic index used in critically ill patients. However, the predictive
value of APACHE II in ARF is still unclear. Fifty-five patients (40 M/15
F; mean age = 62 13 years) with ARF admitted into medicosurgical
ICUs of our Hospital were prospectively analyzed for 6 months. APACHE
II scores were determined at the initial clinical evaluation for nephrolo-
gists. Twenty-two patients (40%) required dialytic treatment (Group A)
and the remaining 33 (60%) did not need it (Group B). There were no
differences in age, sex and etiology of ARF between groups. Acute tubular
necrosis was the more frequent cause of ARF in the two groups (72% and
54%). Continuous renal replacement therapies were the most used in the
treatment for critically ill patients (76%), followed by intermittent hemo-
dialysis (20%). Mortality rate was higher in group A compared to group B(68% vs. 42%; P < 0.05), but no differences were found in APACHE II
scores between groups (22 6 vs. 22 6). This score was useful to predict
outcome in group B (survivors 19 8vs. non-survivors 26 4; P < 0.01).
Flowever, no differences were found in group A (survivors 20 5 vs.
non-survivors 23 7; NS). Prediction of mortality could be made in group
A with a sensitivity and specificity of 60% and 57%, respectively, when
selecting a cutpoint that maximized both. In contrast, sensitivity and
specificity were 93% and 68%, respectively, in the other group. In
conclusion, APACHE 11 score is a useful prognostic index in non-dialyzed
patients with ARF; however, this score has a poor predictive value in
dialyzed patients.
Register of 319 central venous catheters (CVC): Complications and
their actuarial survival in an acute care unit of nephrology. A. Soils, J.J.
Minguela, F.]. Gainza, J.M Urhizu, if. Amenabar, I. Lampreahe, Nephrol-
ogy Department, Cruces Hospital, Baracaldo, Bizkaia, Basque Country,
Spain. The arteriovenous fistulac of Cimino-Brescia is established as the
preferred blood access method for hemodialysis (HD). I lowever, the
required maturation or the difficulty of a surgically created vascular access
being available makes the use of CVC necessary. In order to evaluate the
complication rate and actuarial survival of catheters (Kaplan-Mcier
method) a register was established and 319 successive CVC who were
placed or rechanged to the Seldinger technique were followed through in
171 patients from June 94 to March 96 (age range 16 to 85 years). The
CVC was placed for chronic HD (41%), intermittent acute HD (18%),
continuous HD (31%) or other uses (10%). The preferred localization was
the right femoral vein (4t).9%), followed by right subclavian (13.8%), rightjugular (13.2%), left subclavian (8.8%), left jugular (5%) and femoral
artery for HDCAV (0.6%). The temporal accesses were made of polyure-
thane, all of them except 4 were double lumen. Regarding the length, 238
were of 20 cm, 77 of 15 cm and 4 longer than 20 cm (subcutaneous soft
silicon rubber catheters for long-term dialysis). The CVC actuarial survival
at the end of 7 days was of 65%, 14 days 48%, 21 days 34%, and a month
21%; the right jugular route of access presented significantly the best
results. The main cause of catheter removal was flow dysfunction (33%).
The main complications were: 22 infection episodes, venous thrombosis
due to CVC in 5 cases, hemorrhage or significant hematoma in 6 (2.1%),
pneumo- or hemothorax in 3 (1%). Two deceases were directly attributed
to the procedure of insertion (a jugular attempt with carotid tear and a
femoral artery for HDCAV with peritoneal hemorrhage). We conclude
that the preferred site for CVC is the femoral vein and the right side is
preferred in all circumstances. The CVC actuarial survival at the end of a
month is low, and the right jugular presented the best results. Severe
complications appeared in more than 10% of the cases with fatal results in
almost 1% of the procedures.
Effect of the treatment with verapamil, trandolapril and veratran on
glomerulosclerosis development in rats with 5/6 nephrectomy. 0. Flores,
S. Vidal, M. Arévalo, B. Gallego, F. Hidalgo, and J.M. López-Novoa,
Instituto Reina SofIa de Investigacion Nefrológica, Departamento de Fisio-
logla y Farmacologla, Departamento de Anatomla e Histologla Humanas,
Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain. The
aim of this study has been to assess the effects of the addition of a calcium
channel blocker, verapamil, at a nonhypotensive dose (20 mg/kg/day) to an
ACE inhibitor, trandolapril, at a hypotensive dose (0.7 mg/kg/day) on
glomerular and interstitial fibrosis in rats with 5/6th nephrectomy. Tran-
dolapril markedly increased the survival ratio, which after six months
reached 87%. No mortality was observed in rats treated with the combi-
nation of verapamil and trandolapril. Trandolapril treatment prevented
the development of hypertension. The combination of verapamil with
trandolapril did not induce a further reduction on systolic or diastolic
blood pressure, as compared with trandolapril alone. Control untreated
group showed an urinary protein excretion that was increasing with time,
reaching values 320.2 54.7 mg/day after six months of follow-up. The
trandolapril group showed an important reduction in proteinuria and it
was maintained in treatments of 70 mg/day. The verapamil + trandolapril
group showed a proteinuria significantly smaller than that of all the other
groups (25.9 9.45 mg/day) at the end of the study. Morphological studies
by light microscopic analysis showed that more than 70% of the glomeruli
showed sclerotic lesions in the control group. Interstitial fibrosis was
observed mainly located around the more severed damaged corpuscles
and tubules. The trandolapril group had a marked reduction in glomerular
and tubulointerstitial alterations, while the verapamil + trandolapril
group had a preserved architecture and tubulointerstitial space alterations
were markedly reduced in most glomeruli. Quantitative determinations of
glomerular (GF) and interstitial fibrosis (IF) performed with the sofware
Fibrosis. HR (Master Diagnostica®) on Syrium red stained renal sections,
demonstrated that intraglomerular (OF) and interstitial fibrosis (IF) were
reduced when rats were treated with trandolapril (OF = 2631 62 jim2,IF - 68736 214 jim2) and especially with verapamil + trandolapril(GF = 2287 47 jim2; IF 5665 154 jim2) when they were compared
to untreated animals values (OF 3063 65 jim2; IF 9359 331
jim2). Verapamil treatment neither reduced glomerular fibrosis (GF =
3230 65 jim2) nor interstital fibrosis (IF = 12271 492 jim2). We
conclude that verapamil given in addition to trandolapril produces addi-
tional protection against progressive renal injury associated to subtotal
nephrectomy, a protection that cannot be explained by a further decrease
in arterial pressure.
Oxidative stress in patients undergoing hemodialysis. M.J. Barrero,
M. C. MartIn Mateo, E. del Canto, J. llustamante, A. de Paula, Department
de Bioqulmica, Facultad de Ciencias, Universidad de Valiadolid, Hospital
Cilnico Universitario de Valladolid, Spain. We studied the possible oxida-
tive stress suffered by patients with chronic renal failure undergoing
peritoneal hemodialysis and dialysis, relating to three types of membrane
in order to better understand their biocompatibilities. In this way,
concentrations of malonildialdehyde in these patients red blood cells were
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considered a highly significant index to show cellular membrane lipid
perioxidation. Malonildialdehyde concentrationes in patients are then
used first to analyze the three forms of glutation (total glutation, oxidase
glutation and reduced glutation), and secondly, to analyze the biomol-
ecules in charge of both maintaining cell permeability and preventing
Fe + from oxidizing into Fe * * in the hemoglobin. Finally we investi-
gated peroxidase glutation concentrations in red blood cells and in these
patients' plasma. By comparing the values obtained from a control group
of blood donors, we observed that glutation values are much lower, and
that the molonildialdeyde values are much higher than those in the control
group of blood donors. Accordingly, peroxidase glutation concentrations
in plasma are smaller, especially in the CAPD, and most significantly of
all, in the red blood cells. These results indicate that these patients suffer
from an important oxidative stress.
Expression of activation antigens CD25 and HLA-DR in the TCRa+
and TCRy+ peripheral blood T-lymphocytes: Immunomodulatory ef-
fects of dialysis. A. Gascón, A. Orjào, J. Lerma, J. Ciudad, A. Lopez, E.
Iglesias, f.M. Tabemero, S. of Nephrology and Cytomety, University Hospi-
tal, Salamanca, Spain. Little is known about the uremia and dialysis
immunomodulatory effects in the TCR/CD3 receptor complex, which
represents a key molecule in the process of antigen recognition and T-cell
activation. In addition, both a major defect in the accessory cell system and
a state of uremic-induced T and NK-cell preaetivation have recently been
found in these individuals. The aim of the present study was to analyze the
coexpression of the CD25 and HLADR activation-associated antigens in
both the TCRa/3+/CD3+ and the TCRyb+/CD3+ T-cells in both
patients in ESRD and individuals undergoing dialysis (CAPD and HD). A
total of 42 patients (9 in ESRD, 8 in CAPD, 25 in HD; 14 with cuprophan
and 11 with biocompatible membranes) were studied. A group of 18
healthy volunteers was analyzed as controls. PB samples were analyzed at
flow cytometry using a panel of direct conjugated monoclonal antibodies
with FITC, PE and Per-CP, against CD3, TCRaj3, TCRyb, CD25 and
HLA-DR antigens. Patients on ESRD and undergoing dialysis (CAPD
and HD) showed a marked decrease (P < 0.0001) in the absolute number
of PB lymphocytes with respect to the controls. The distribution of the
T-cell subsets analyzed are shown in the following table (absolute numbers
and percentage of total either the Ta/I or the Tyb subpopulations in
brackets):
TCRa/3+ cs/3CD25+ cs/3DR+
CONT 1439 347(24%) 153(11%)
IRCT 1030 267(26%) 192 (19%)
CAPD 954 349(37%) 164 (17%)
HD 960 365 (38%) 138 (14%)
CUP 908 361 (40%) 137 (15%)
BlOC 1026 368 (36%) 139 (13%)
ANOVA-test P < 0.01 P < 0.01
TCRyb+ ybCD25+ yb/DR+
CONT 78 18 (23%) 10(13%)
IRCT 104 5 (5%) 25 (24%)
CAPD 43 4(9%) 9(21%)
HD 32 4(13%) 5 (16%)
CUP 27 5 (19%) 4(15%)
BTOC 39 3 (8%) 6(15%)
ANO VA-test P < 0.01
In summary, our results show that there is an increased percentage of
T-cells that coexpress the CD25 and HLA-DR activation antigens in
patients undergoing dialysis; this rise of CD25 and HLD-DR expression is
greater with cuprophan membrane HD and CAPD, respectively. Interest-
ingly, the expression of the lILA-DR antigen on both the yb and n/I T-eell
subsets, hut not the CD25 antigen, is also increased in the FSRD group of
patients. These results indicate that ESRD and dialysis induce an activa-
tion of both the nfl and yb T-cells, although a different pattern of reactivity
for the CD25 and HLA-DR antigens is detected, suggesting that different
mechanisms maybe involved on the activation of nfl and yb T-cells in both
pathologic conditions.
Differentiation by flow cytometry of peripheral blood cells with natural
killer cell activity in uremic and dialysis patients. A. Gascón, A. Orfao, J.
Le,ma, f. Ciudad, A. Lápez, E. Iglesias, f.M. Tabernero, S. Nephrology and
Cytometiy, University Hospital, Salamanca, Spain. The antigens used most
extensively as NK-cell "markers" are CD56 and CD16. CD3 is not present
on NK cells, which do not rearrange TCR genes nor express T cell
receptor heterodimers. Most CD56+ peripheral blood (PB) NK-cells
coexpress CD16, and the remaining cells mainly corresponding to the
CD16— CD56+ phenotypes. Whether this NK-eell subset represents the
precursors of the more numerous CD56+ CD16+ NK cells or are a
discrete NK cell subpopulation with unique functional attributes is
presently unclear. The aim of the present study was to analyze both the
distribution of different NK-cell subsets (CD3—CD16+
CD56+,CD3—CD16+CD56—, CD3 —CD16--CD56+) and their func-
tional cytotoxic activity in the PB of patients with ESRD and patients on
dialysis (CAPD and HD). A total of 42 patients (9 in ESRD, 8 in CAPD,
25 in HD; 14 with cuprophan and 11 with biocompatible membranes) were
studied. A group of 18 healthy controls was also analyzed. PB NK-
phenotypes were analyzed at flow cytometry, and NK-cell activity was
evaluated by a conventional eytotoxieity assay. Both the ESRD patients
and the individuals undergoing dialysis showed a marked lymphopenia
(P < 0.0001) with respect to controls. Mean values expressed as absolute
numbers and percentages of the total NK-cells were as follows:
Total NK CD16+CD56+ CDI6+CDS6- CD16—CD56±
CONT 351 301 (87%) 30 (8%) 20 (5%)
IRCT 224 174(77%) 21(10%) 28(13%)
CAPD 176 78 (44%) 26 (15%) 72 (41%)
HD 191 97(49%) 39(20%) 61(31%)
CUPR 170 79 (44%) 42(23%) 60(33%)
BlOC 214 117(54%) 36(17%) 61(29%)
ANOVA: P < 0.01 P < 0.001 P < 0.04 P < 0.003
In addition, the NK activity was directly correlated with the
CD3—CD16+CD56+ NK-eells (P < 0.001) in patients undergoing dial-
ysis. In summary, our results show that dialysis as compared with ESRD
elicits a greater redistribution of the PB NK-cell subsets, with a marked
decrease of the mature CD3 — CDI6 +CD56+ cells. A significant increase
is seen in the inmature or precursor CD3—CDI6--CD56+ NK compart-
ment in patients on dialysis. There is no correlation between these cells
and NK-cell activity in dialysis patients. These findings confirm the
possible existence of a correlation between antigen phenotype and NK-eell
activity.
Prevalence of hepatitis C virus in pre-dialysis patients in 25 Spanish
hospitals. Spanish multicentric study. C. Barril and J.A. Traver (Co-
ordinators), Hospital de Ia Princesa, Madrid, Spain. There is a high
incidence of new HCV positive patients initiating renal replacement
therapies (RRT) each year. Therefore, we decided to study the prevalence
of HCV antibodies in predialysis patients to analyze the potential risk
factors involved in its infection. We studied 709 patients with creatinine
clearance less than 20 mI/mm from 25 Spanish nephrology departments. In
every patient, we have analyzed age, sex, cause of end-stage renal failure
(ESRF), time to develop ESRF, HCV antibodies, screening and confir-
mation test, antecedents of hcpatopathy, blood transfusions, surgery,
catheterization and hepatie or renal biopsy. The prevalence of HCV
antibodies in pre-dialysis patients was 7.9% compared to 1.2% in our
healthy population.
HCVAb(+) P HCVAh(—)
57.4Mean age 54.4 NS
Sex: male % 78% 0.05 60%
female % 22% <0.05 40%
Months to ESRF 93.5 NS 94.4
There is a statistically significant difference between both groups regarding
antecedents of blood transfusions and the number of them. Antecedents
of surgery appears in 70% of HCV (-t-) patients compared to 30% of VHC
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(—). The percentage of HCV (+) patients with ESRF caused by glomer-
ulonephritis is also higher (P < 0.05). A total of 77% of VHC (+) patients
had no history of clinically evident acute hepatitis, and 78% of the
ultrasound studies performed in 60 VHC (+) patients were considered
normal. Hepatic biopsy revealed cirrhosis in 5 patients and chronic active
hepatitis in 1. We conclude that a higher prevalence of VHC antibodies in
pre-dialysis patients exists compared to healthy population. The number
of blood transfusions received and the antecedent of surgery seem to be
risk factors to HCV infection. There is not any difference between HCV
(+) and HCV (—) patients regarding age, but it seems that HCV (+)
antibodies are more frequent in male patients and those whose ESRF is
secondary to glomerulonephritis.
Effect of antihypertensive treatment on progression of renal insuffi-
ciency in non-diabetics patients (Espiral Trial). R. MarIn, L.M. Ruilope, P.
Aljama, P. Aranda, J. DIez, on beha If of the 26 participating centers, Sociedad
Espaflola de NefrologIa, Sociedad Espanola de I-Iipertension. A three-year
long-term randomized, multicenter and prospectively opened trial is being
developed with the aim of studying the influence of antihypertensive
therapy on chronic renal failure progression in non-diabetic patients. The
study will compare the effects of an angiotensin converting enzyme
inhibitor, fosinopril, with a slow release calcium antagonist, nifedipine
GITS. Two hundred and fifty patients, with progression of renal function
decline, evidenced by an increase of serum creatinine (Sr) of at least 25%
in a period of 2 years preceding study entry, and S, levelsbetween 1.5 and
5.0 mg/dl, will be included. The primary end point of the trial will be to
compare the evolution of S, (mg/dl/month) and the reciprocal of serum
creatinine concentration (l/Sr) over time. The secondary end point will
be to evaluate the percentage of patients who double Scr, progress towards
dialytic therapy, or die during the study. Patients with nephrotic syndrome
(serum albumin concentration <3 g%), systemic disease (including dia-
betes), severe cardiac or hepatic dysfunction, malignant or renovascular
hypertension, obstructive nephropathy, initial serum potassium concen-
tration >5.8 mmol/liter, will be excluded. After "wash Out" period of four
weeks, patients with arterial blood pressure 140/90 will be assigned
either to fosinopril (10 to 30 mg/day) or nifedipine GITS (30 to 60
mg/day). In case of insufficient blood pressure control, Frusemide will be
added in a first step and then atenolol and/or doxazosine in order to
maintain arterial blood pressure control under 140/90. Patients with
LDL-cholesterol 160 mg/dl will be treated with pravastatina. The
relation between chronic renal failure progression and ambulatory blood
pressure during 24 hours will be eventually studied.
Impact of rHu-EPO therapy on the quality of life in predialysis chronic
renal failure (CRF) patients. J.M. Lopez-Gomez, R. Jofre, F. Moreno, D.
Sanz-Guajardo, F. Valderrahano, and the Spanish Cooperative Renal Pa-
tients Quality of Life Study Group. The effect of rHu-EPO therapy on the
quality of life (QL) and progressive decrease rate of renal function was
evaluated in predialysis CRF. A total of 103 patients (72 treated with
rHu-EPO and 31 untreated) were included in a multicenter, prospeeti'e
and controlled study. The OL was assessed at baseline, and after 3 and 12
months using the Karnofsky Scale (KS) and the Sickness Impact Profile
(SIP) questionnaire. A lower SIP score and higher KS score indicated a
better QL. The impairment of renal function was evaluated with the slopes
of the regression lines of 1/Cr and time, 12 months before and after the
Onset of the study. At baseline, there were no significant differences in age,
gender, etiology of CRF, blood pressure and serum creatinine between
both groups, but hematocrit (Hte) was lower in the treated group. At 3
months, Hte, KS and the three dimensions (physical, psychosocial and
global) of the SIP were as follows:
With rHu-EPO No rHu-EPO
Baseline 3 Months Baseline 3 Months
Hte %
KS
Physical
Psyehosoc
Global
24.8 2.7
66.6 21.0
17.8 17.3
16.0 13.1
17.5 12.0
31.4 5.0"
74.1 12.4'
12.5 11.4
12.6 10.8"
14.2 9.9"
29.8 4.2
84.7 13.9
7.4 8.5
19.7 23.0
12.2 10.1
28.9 4.5
82.5 15.2
11.2 16.7
16.4 17.2
14.3 14.1
Among those patients who were still with no dialysis therapy at 12 months,
no significant changes in Htc or QL assessment were found compared with
the 3 month data. The slopes of the regression lines of renal function
before and after the beginning of the study in both groups did not show
significant changes. In conclusion, the partial decrease of anemia in
predialysis CRF patients treated with rHu-EPO results an improvement in
QL. rHu-EPO in these patients does not result changes in the progression
rate of renal function impairment.
Are the complementary tests (for localization and/or function) of the
parathyroid glands in refractory hyperparathyroidism necessary before
doing parathyroid surgery? X Cuevas, J. Sala, M. Fuiquet, M Chine, M.
Ramirez de Arellano, I. Llado, 0. Ibrik, .1. Viladoms, C. isamat, Nephrology,
Surgery, Radiology, H. de Mollet, CTD. Hospital de Tenassa, Barcelona,
Spain. We wanted to know if complementary tests for localization and/or
function of the parathyroid glands (PG) condition the decision about
surgery. Thirteen complete surgical parathyroidectomies (PTx) were done
with autotransplantation in 12 patients from a fragment of the PG into the
opposite forearm of the AVF. The patients had refractory secondary
hyperparathyroidism (5HPT) to the medical treatment [all received pulses
of 1,25(OH)2D3]. Twelve patients were in HD treatment and 1 in
predialysis, 7/7q, age 51.2 12.5 years. HD time was 73.3 46.1
months. Follow-up time post-PTx was 8.3 7.7 months. By ultrasonog-
raphy parathyroid (7.5 MHz) was realized on 13 patients, cervical CT scan
on 9 patients and °9Tc" MIBI scan on 7 patients. Every PG was weighed
on a precision scale (weight  0.005 g). All the PTx were effective, with
presurgical i-PTH levels being 892 417 (405—1840) pg/mI for 13 patients
and post-surgical levels 130 138 (6—396) pg/mI for 12 patients at
3 months, at 6 months 193 127 (32—302) pg/mI for 6 patients, at 12
months 198 127 (22—390) pg/mI for 4 patients. One patient had
only 3 PG, 2 p. had 2 PG and the 10 remaining had the 4 PG removed.
No eetopic PG were found. The total weight PG/patient was 4.35
3.45 (0.79—11.48) g. The weight and localization of each PG was related
to the complementary tests (ultrasonography, CT scan, 99Tc' MIBI),
demonstrating that no test, either isolated or together with the others,
conditioned the surgical decision nor the posterior evolution. For 8
patients with a post-operative time PTx 10.5 3.1 (3—27) months, s9Tcm
MIBI autotransplant and cervical were performed; there was no
evidence of glandular activity in any patient despite showing an i-PTH
of 173 160 (6—390) pg/mI at the time of testing (in 4 patients the
i-PTH levels were between 4 and 7 times higher than normal). In
conclusion, (1) the complementary tests for localization and/or function
of the hyperplastic parathyroid gland in refractory secondary hyper-
parathyroidism do not condition either the decision or the type of
PTx surgery. (2) Further cases are needed to: (a) determine if it is
necessary to continue these pre-surgical tests or if they should only
he used to rule out hyperfunctioning ectopic parathyroid glands;
and (b) determine the usefulness of the 99Te" MIBI scan as a viable
test.
Effect of desferrioxamjne and deferiprone (LI) on bone cell MG-63
proliferation and on phosphatase alkaline activity. ML. Naves, MA.
Canteros R. Elorriaga, E. Sanchez, J. B. Cannata, Bone and Mineral
Research Unit, Instituto Reina SofIa de Jnvestigación, Hospital Central de
Asturias, Oviedo, Spain. It has been demonstrated that ehelators such as
desferrioxamine (DFO) may interfere with cell proliferation. It is known
that this effect likely applies also to bone. The aim of this work was: (a) to
evaluate the effect of different concentrations of DFO and deferiprone on
osteoblasts proliferation (MG-63) and to determine the possible role of
iron on the proliferation and, (b) to analyze the effect of both chelators on
the metabolic activity of these cells using the alkaline phosphatase activity
as enzymatic marker of activity or cellular differentiation. The cell
proliferation and the effect of the concomitant addition of iron were
evaluated with different concentrations of DFO (1,2, 5, 10, 20,40 and 100
/.LM) and deferiprone (1, 2, 20, 100, 120, 150, 180, 200 and 300 /zu) at 24
and 48 hours, while the phosphatase alkaline activity was studied at 24, 48
and 96 hours after the addition to the culture medium of DFO (20 and 100
LLM) and deferiprone (150 and 300 p.M). Cellular proliferation was
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completely inhibited with 100 jiM of desferrioxamine and 300 jiM of
deferiprone. In both cases this effect was corrected by means of coincu-
bation with iron citrate. In the second phase, using the same doses that
inhibited the bone cell proliferation, we did not observe an impairment in
the production of the enzyme. On the contrary, according the time
of incubation increases (96 hours), desferrioxamine and deferiprone at
its higher dose (the same which inhibits bone cell proliferation) increased
the alkaline phosphatase activity, reaching values even higher than those
observed in the maximum values of controls. These results demonstrate
that both desferrioxamine and deferiprone inhibit the proliferation
of osteoblast-like cell line MG-63, and the effect seems to be related
with the chelation of some fraction of available iron. In spite of the
effect on bone cell proliferation, the ehelators seem do not impair cellular
activity.
Effect of the aluminum overload on PTH levels and PTH mRNA
synthesis. S. Barreto, C. Gómez, C. DIaz-Corte, A. Canteros, A. Herndndez,
J.B. Cannata, Bone and Mineral Research Unit, Instituto Reina Sofia de
Invesligacion, Hospital Central de Asturias, Oviedo, Hospital Universitario de
Canarias, Spain. The inhibitory effect of aluminum (Al) on parathyroid
function has been demonstrated clinically and experimentally. However,
there are doubts still about the main mechanisms implicated. Does Al
affect PTH synthesis or PTH release? The aim of this study was to evaluate
the effect of different levels of Al overload on PTH levels and also in the
glandular expression of PTH mRNA in rats with chronic renal failure
(CRF). Nephrectomy (5/6) was performed in 36 male Wistar rats, aged
three months, 441 16 g of weight. After 5 weeks the rats were divided
into three homogeneous groups according to the ereatinine clearance:
group I (N = 11) received CI3A1 (32.5 mg/kg of Al), i.p. in two doses;
group H (N 13) received CI3AI (16.25 mg/kg of Al); group TI! (N = 12)
received placebo. The animals were sacrificed two weeks later. PTH,
serum and urine Ca, P, Cr and Al were performed before and after Al
exposure. The parathyroid glands were removed, weighted and used to
measure Al concentration and PTH mRNA. The levels of CRF, Ca and P
were similar in the three groups. The weight of the parathyroid glands
after the sacrifice was group I 0.86 0.4 mg, group 111.18 0.7 mg, and
group III 1.73 0.25 mg (P < 0.05 between groups I and III). The overall
PTH values increased 5 weeks after nephrectomy from 16.95 13.44 to
24.33 18.54 pg/mI, showing a significant decrease after the maximum Al
overload in group 1(24.46 10.4 to 16.27 7.8; P < 0.01). No differences
were found in the other two groups. The mRNA expression was lower in
group I (Mx Al overload). Serum Al was significant different between the
three groups (group 1405.9 85.6 jig/liter, group II: 184.2 83.2 jig/liter
and group III: 4.4 1.8 jig/liter; P < 0.01), similar findings were observed
in the Al and in the parathyroid glands (group 1132.3 0.7, group II
21.4 3, and group III 7.9 2.1 jzg/g; P < 0.01). The correlation between
Al in parathyroid glands and in serum was significant, r = 0.88, P < 0.05.
A reduction in glandular size, PTH levels and PTH mRNA expression was
observed in the severe Al intoxication, suggesting that Al could have a
direct action on PTH synthesis.
Mineral bone density variation in hemodialysis patients: Non-fraction-
ated heparin (NFH) versus low molecular weight heparin (LMWH). C.
Bemis, A. Garcia Vadillo, F. Muñoz de Bustillo, A. Fernández, A. Cirugeda,
I'. Sanz, E. Gross, G. Bath4 iA. Sanchez Tomero, V Alvarez, J.A. Traver,
Nephrolory and Rhcumatolo,ry Departments, Hospital de Ia Princesa, Ma-
drid, Spain. Heparins inhibit type I collagen and DNA synthesis and can
aggravate osteoporosis in hemodialysis (HD) patients. Some experimental
data suggest that new LMWH induce less negative effects over bone
formation than NFH. We studied 30 patients initiating HD, 23 of whom
completed a 2 year follow-up. They were assigned to receive LWMH or
NFH (13 and 10 patients, respectively). Both groups were similar accord-
ing age (56 14 vs. 61 12; P NS), PT!! levels (352 132 vs. 262 134;
P NS) and both received similar doses of caleitriol (0.30 0.3 vs. 0.5 0.5;
P NS). Bone mass at baseline and at two years was determined with a Dexa
Hologic QDR 1000 densitometer (variation coefficient 0.5%). Results arc
expressed in absolute values: bone mineral density g/cm2 (BMD), BMD
variation (var BMD), percentage of the peak bone mass of young normal
sex-matched adults (PBM%), PBM% variation (var PBM%); or standard
deviations from the mean of age and sex-matched normal Spanish subjects
(Z-seore) and Z-score variation (var Z score).
NFH
Basal
—0.013 0.02a
—0.5 2.4
—0.048 0.11
24 months
0.848 0.2
81.1 20
—0.73 1.5
BMD
var BMD
PBM%
var PBM%
Z score
var Z score
0.862 0.2
81.6 20.6
—0.63 1.6
LMWH
Basal 24 months
BMD
var BMD
PBM%
var PBM%
Z score
var Z score
0.923 0.1
88.2 13
—0.73 0.9
+0.003 0.2
+1.7 3.4
+0.15 0.3
0.927 0.1
89.3 13
—0.57 0.7
ap < 0.1
The group receiving NFH tend to lose more bone mineral density,
showing a worsened Z score and BMP compared to the group assigned to
LMWH, whose patients slightly improved those parameters. Further
studies designed with more patients and for a longer time are needed to
confirm these preliminary findings.
Modifications in the bone disease biochemical profile in patients
transfered from hemodialysis (HD) to peritoneal dialysis (PD). E. Lopez
Ruhio, C. GOmez Roldán, L. Sanchez Tárraga, E. Gallego, J. Portolés, E.
Olivas, F. Llamas, M. Orts, A. Serrano, E. Andrés, Division of Nephrolopy,
Hospital General, Albacete, Spain. Different types of bone disease in
patients on dialysis have been observed. We evaluated possible changes in
the biochemical profile of the bone disease of patients who changed
dialysis therapy. We retrospectively researched 16 patients who changed
from HD to PD and 5 from PD to HD. The analysis of urea, creatinine
(Cr), calcium (Ca), ionic calcium (Ca++), phosphate (P), alkaline
phosphatase (AP), intact PTH (iPTH), hematoerit (Hct), hemoglobin
(Hb) and albumin (Aib), before the change, and after 3, 6 and 12 months
under the new therapy. Results are analyzed by the paired data Student's
1-test.
Urea Cr Ca Ca P AP iPTFI
3 months
HD
DP
144 52
116 41C
11 2
11 3
9.2 2 1.09 6.3 221 251
9.2 2 1.17 4.9' 31 i" 144k'
Het I-lb Alb
3 months
HD
DP
30.6
372h
9.4 4
1 14" 35b
Urea Cr Ca Ca P FA PTHi
9.1 1.09 6.5 227 268 19(1
9.2 1.16 4.8 366" 253 356
6 months
HD
DP
143 54
123 44
11.5 2
11.1 3
Hct Hh Aib
6 months
HD
DP
31.2
39.5 9C
9.5 4.1
12.2c 3.8
'P < 0.05, "P < 0.01, p < 0.001.
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After 12 months with PD there were no significant differences except for
the persistent correction of anemia. When they began PD, the mean KtV
was 1.72 and NPCR was 0.86. The small number of patients transfered
from PD to HD did not allow us to make adequate comparisons, in
conclusion, (1) after 3 months with PD there is a decrease in iPTH. At
the same time phosphate decreases and ionic calcium increases. (2)
Eventually every parameter comes to the initial point. Among the possible
causes, we consider that an increase in the dialysis dose that we provided
with PD compared with HD over the previous weeks, as the most
influential.
Lipid profile changes in our continuous ambulatory peritoneal dialysis
population. V Pérez-Banasco, P. Perez del Barrio, F.J. Borrego-Utiel, MV
Camacho-Reina, C. Sdnchez-Perales, A. Liébana, S. GarcIa-Marcos, M.J.
GarcIa-Cortés, J. Borrego-Hinojosa, P. Serrano, Senicios de Nefrologia y
Bioquimica, Hospital General de Especialidades "Ciudad de Jaén," Jaén,
Spain. Changes in lipid profile are usual in patients with chronic renal
failure who are on continuous ambulatory pcritoneal dialysis (CAPD). We
tried to analyze that profile in our patients on CAPD. This study included
all of our patients on CAPD: 32 patients total, 13 males (41%) and 19
females (59%). Of them, 8 (25%) were diabetic, 24 (75%) were hyper-
tensive patients and 12 (37.5%) obese. The average age was 59 13
(28—82) years with 37 44 (3—186) months on dialysis. Nune of them
received hypolipidemic treatment during the two weeks to the prior to the
inseption of this study.
Healthy
CAPD controls
Pmg/dl
Total cholesterol 217 53 160 30 <0.001
Triglycerides 180 62 111 20 <0.001
HDL-chol 42 8 60 15 <0.001
LDL-chol 138 45 130 39 NS
Apo Al 97 12 135 18 <0.001
Apo B 97 26 100 15 NS
Lipo (a) 42 22 20.5 2.3 <0.001
Albumin gIdi 3.8 0.5
Oncotic pressure 21 22.5
(1) Sex had influence on the level of HDL (male 37 9 vs. female 44
7 mg/dl, P < 0.05). (2) Age correlated with the value of albumin (r =
—0.50, P < 0.01). (3) In the diabetic patients the level of albumin was
lower (34 6 vs 39 4 g/liter, P < 0.05). (4) The hypertensive patients
had higher levels of Apo B (102 26 vs. 80 19 mg/dI, P < 0.05). (5) In
obese the triglycerides were higher (212 66 vs. 161 SI mg/dl, P <
0.05). (6) We found a correlation between total serum cholesterol and
triglyceride levels (r = 0.48, P < 0.01), and between total serum
cholesterol and Lipo (a) levels (r = 0.36, P < 0.05). (7) Also, a correlation
exists between triglycerides and HDL-chol levels (r —0.49, P < 0.01),
triglycerides and LDL-chol levels (r 0.38, P < 0.05), and triglycerides
and Apo B levels (r = 0.51, P < 0.05), (8) Also, we found a correlation
between LDL-chol and the Lipo (a) levels (r = 0.38, P < 0.05). (9) We
didn't find a correlation between lipid levels and oneotic pressure, and
between lipid levels and the load of glucose (daily intraperitoneal dose of
glucose). We conclude that: (1) the lipid profile is significantly altered in
the patients on CAPD. (2) Lipo (a) is the most modified parameter. (3)
The load of intraperitoneal glucose doesn't seem to influence the lipid
parameters.
Mortality in a multicenter registry of peritoneal dialysis. C. Gómez
Rolddn, A. Miguel, R. Garcia, I. Alvariho, M. Lanuza, R. Lopez, J. Perez
Contreras, F. Tornero, J. Olivares, Multicenter Study Group on Peritoneal
Dialysis from Albacete, Cuenca and Autonomic Communities' of Valencia
and Murcia, Spain. From 1992 our work group has carried Out a registry of
patients with chronic renal failure on peritoneal dialysis (PD). As of
December 31, 1995 there were 526 patients. Between January 1, 1992 and
December 31, 1995 there were 111 deaths (21%) and they are the study
objective; 53 (47.7%) were women and 58 (52.3%) were men. The mean
age was 65.5 10.6 years when they began the technique, and mean
permanence on PD was 30.74 24.25 months (range 1.6—106.7). There
were 28 (25.2%) patients who spent less than one year on PD, 45 between
1 and 3 years, 23 between 3 and 5 years and 15 (13.5%) for more than 5
years. The mean weekly Kt/V was 1.86 0.48 and the mean PCRN was
0.97 0.37 (measured in 28 patients only). Death was due to cardiovas-
cular disease (16, 14.4%); cerebrovascular disease (14, 12.6%); infection
(21, 18.9%); peritonitis (5, 4.5%); withdrawal from dialysis (5, 4.5%);
other causes (22, 19.8%) and in 28 (25.2%) the cause was unknown.
Between 1993 and 1995 there were 79 patients alive. There were 68
peritonitis episodes in 42 patients (one case of peritonitis in 30 patients,
two peritonitis in 3 patients and three or more in 9 patients). There were
27 admissions for peritonitis; admission duration was 11.4 12.8 days/3
years. There were 148 admissions (other causes) in 67 patients. Admission
duration was 11.6 11.3 days, and 21.7 days per patient/3 years. There
were 28 patients, 16 men and 12 women, on PD for less than one year. The
mean age was 63.8 13 years (range 33—83), mean permanence was
5.73 3 months, mean weekly Kt/V was 2.39, and mean PCRN was 0.93.
Death was due to cardiovascular disease (14.2%), cerebrovascular disease
(21.4%), infection (21.4%), peritonitis (7.1%), withdrawal from dialysis(3.5%), other causes (18.2%), and in 14.2% the cause of death was
unknown. There were 13 admissions (5.85 days per patient during 3 years).
There were 15 patients, 9 women and 6 men, on PD for more than 5 years.
The mean age was 64 8.7 years, mean duration was 75.9 months, mean
weekly Kt/V was 1.76, and mean PCRN was 1.01. Death was due to
cardiovascular disease (6.6%), cerebrovascular disease (13.3%), infection
(13.3%), peritonitis (13.3%), withdrawal from dialysis (20%), and in
33.3% the cause was unknown. There were 21 hospitalizations of 8.76 days
(12.26 days per patient during 3 years). In conclusion, (1) 21% of the
patients included in the study died during 4 years (5%/year). (2) The mean
permanence on PD of this group is slightly less than all the patients
enrolled. (3) The most frequent causes of death were unknown, vascular
and infectious diseases. (4) Withdrawal from dialysis is a very significant
cause of death. (5) Hospital admission was higher in patients with longer
tenures on PD.
Short term evolution of the residual renal function in patients in
continuous ambulatory peritoneal dialysis. R. LOpez-Menchero, A. Miguel,
R. Garcia RamOn, Department of Nephrology, University Clinical Hospital of
Valencia, Spain. Residual renal function is a fundamental factor to obtain
indicators of optimum for doses of dialysis as well as nutritional Status.
The purpose of the study was (1) to study the evolution of the residual
renal function in patients in continuous ambulatory peritoneal dialysis
(CAPD) in the first months of treatment, and (2) to evaluate this evolution
with the residual clearance at the beginning of the treatment. We studied
the evolution of the residual renal function (RRF, average of the
clearances of urea and creatinine) in 24 patient on CAPD for a minimum
of 12 months of treatment (16 male and 8 women, mean age 55.1 17.3
years). We measured the dose of dialysis (peritoneal and renal Kt/V) and
the nPCR (formulation of Ronco). The values are expressed as mean
so, and the comparisons between variables were accomplished through
nonparametric methods (Mann-Whitney and Friedman). The global re-
sults were the following:
Month I Month 6 Month 12 P
6.19 3.33 5.36 3.38 4.28 3.25 < 0.01
2.42 0.54 2.35 0.53 2.18 + 0.54 <0.01
1.11 0.30 1.13 0.32 1.03 0.30 = 0.05
The data of 14 patients to 18 months are: RRF 3.65 4.18 mI/mm; weekly
Kt/V 2.04 0.47; nPCR 0.97 0.20 g/kg/day. Three (12.5%) patients had
lost their renal function at 12 months, and 5 of 14 studied to 18 months
(35.7%). This evolution with the residual clearance at the beginning of the
treatment was also studied (group A, RRF < 5.45 mI/mm, N = 12; group
B, RRF > 5.45 mI/mm, N = 12).
RRF ml/mi;i
Kt/V weekly
nPCR g/kg/day
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Age years RRF KIN nPCR
Month I
Group A 60.2 18.4 4.02 1.24 2.23 0.44 1.00 0.32
Group B 49.9 15.1 8.36 3.37 2.61 0.57 1.22 0.32
P NS (P = 0.1) <0.01 = 0.05 NS (P = 0.1)
Month 12
Group A 2.61 2.31 1.93 0.36 0.83 0.10
Group B 5.95 3.26 2.42 0.59 1.23 0.30
P <0.05 = 0.05 <0.001
After 1 year 3 patients who had completely lost the RRF were in group A.
In conclusion (1) the patients on CAPD maintain a high percentage of the
initial residual renal function during the short term. (2) The precocious
beginning of the dialysis, with its important residual renal function, allows
the nephrologist to maintain the patient's optimum dialysis dose and
nutritional status during the course of treatment.
Supraventricular arrhythmias (SVA) in hemodialysis (HD). E. Verde,
A. Perez de Prado, MC. Vozmediano, R. Perez, R. Jofré J.M. Lopez, E.
Junco, J. Almendral, J. Osende, F. Valderrábano, Department of Nephrology
and Cardio1o, Hospital General "Gregorio Marañón," Madrid, Spain.
Supraventricular arrhythmias (SVA) have been poorly characterized in
HD patients (pts). The aim of the present study was to analyze the
incidence and type of SVA and premature atrial contractions (PAC) in
HD. Eighty-two pts in sinus rhythm (44 M/38 F; mean age 58 13 years)
were studied with ECG-Holter monitoring during 6 consecutive sessions
of HD (mean time 15.9 2.5 hours). Hemodiafiltration was used in 8 pts.
M-mode and 2-D echocardiograms were performed on a non-dialysis day.
The prevalence of hypertension and diabetes were 68% and 26%,
respectively, and 26 pts had ischemic heart disease. The total incidence of
SVA was 46.3%. Supraventricular tachycardia was the most frequent SVA
(33 pts), followed by atrial flutter (6 pts) and finally atrial fibrillation (3
pts). Moreover, PAC of significative density (>1 PAC/1,000 heats) were
documented in 51% of the pts. SVA and PAC were recorded mostly in the
last hours of HD. This feature correlated to lower potassium and ionic
calcium serum levels. Non-sustained-SVA were recorded in hemodiafil-
tration patients. The echocardiograms showed a high prevalence of left
ventricular hypertrophy (72%) and left atrial dilation (87%). Right atrial
dilation (34%) was correlated with a high incidence of SVA and PAC.
Conversely, left ventricular hypertrophy was not associated with SVA. In
conclusion, HD pts have a high incidence of SVA, especially in the last
hours. This feature could be associated with electrolytic changes during
dialysis. Pts treated with hemodiafiltration have a decreased incidence of
SVA. Right atrial dilation could be a risk factor for SVA.
Nerve conduction speed (NCS) as a method for monitoring suitable
dialysis over 5 years. fL. Lerma, T. Lopez-A lburquerque, J.L. Sanchez
Rodriguez, B. Martin, .1. Diego, f.M. Tahernero, Servicios de NefrologIa y
IVeurologIa, Hospital Universitario, Salamanca, Spain. NCS is a test peri-
odically implemented to assess the suitability of the amount and quality of
dialysis. However, few recent works have addressed its usefulness in series
or its repercussions in dialysis. This study was designed to (1) correlate
neurological exploration and NCS; (2) to determine the correlation
between NCS, suitable dialysis parameters and the type and duration of
HD; (3) to assess the influence of NMS on treatment (dose of lID, change
of membrane). Seventy-six patients on HD and 3 on CAPD were studied
(51 men, 28 women, with a mean age of 59.9 14.9 years over five years).
Subjects were divided into 2 groups: (1) with diabetes mellitus (DM) N =
15; (2) without DM, N 64. Serial electrophysiologieal studies were
performed annually; these consisted of measuring NCS, amplitude, and
the mean latency time of the common peroneal nerve. At the same time,
neurological assessments were made for Kt/V, PCR, TAC. Statistical
significance was evaluated with ANOVA and correlation and simple linear
regression studies, comparing the evolution of NCS over time with the
different parameters studied. We found that (I) no significant variations
were observed over time in the neurophysiological parameters analyzed
[mean latency time, motor conduction speed (MCS) amplitude]; (2)
patients with clinical signs of polyncuropathy Aehilean areflexia at the
start of the study displayed a significantly reduced MCS (40.9, N = 56 vs.
37.8, N = 23, P < 0.03); (3) of the 35 patients with MCS < 40 in the first
study, 23 continued with the same time and dialysis membrane in the
second study and in 14 the MCS became normalized or improved; (4) of
the 15 diabetics, only 4 had normal MCS values at the start of the study;
(5) the women (N 27) had significantly greater MCS values than the
mean (N = 52) (41.9 vs. 39.1, P < 0.04); (6) the patients dialyzed with
PAN (N = 17) had greater MCS values than those dialyzed with
cuprophane (N = 59), although statistical significance was not reached
(41.6 vs. 39.9; NS); (7) there was no correlation between the MCS and KtV
(P < 0.55). In conclusion, we determined that (1) Aehilean areflexia was
the exploratory finding that best correlated with the reduction in MCS; (2)
there were no significant differences between the patients dialyzed with
cuprophane and polyacrylonitrile, nor between KtV and MCS; (3) in the
group with DM, MCS deteriorated progressively and was not suitable as a
marker of suitable dialysis; (4) MCS was considered to be a complemen-
tary datum and few therapeutic decisions were made based exclusively on
its assessment; (5) currently, there are simpler, more accurate and more
reproducible ways of assessing suitable dialysis.
Efficacy of the therapy to eradicate Helicobacter pylon in dialysis
patients evaluated by C13 urea breath test and serology. E. Muñoz de
Bustillo, J.A. Sánchez-Tomero, J.C. Sanz, A. Fernández, A. Cimgeda, V
Alvarez, G. Barril, C. Bernis, J.A. Moreno, I. Jimenez, M. LOpez-Brea, J.A.
Traver, Nephrology, Microbiology, and Gastroenterologl' Departments, Hos-
pital Universitario de la Princesa, Universidad A utOnoma, Madrid, Spain.
The prevalence of Helicobacter pylon (HP) infection in our unit reaehs a
62%. It is well known that certain therapies that eradicate this infection
prevent the development of peptic ulcer, but there is limited information
concerning the application of this therapies to hemodialysis (HD) pa-
tients. In order to assess the efficacy of this therapeutical regimen, we
studied 34 HD patients prospectively during 18 months, determining HP
infection through C13 urea breath test (UBT). The patients' mean age was
63 10.6 years, 16 were female and 18 male. Those positive patients
referring with dispepsia, antecedents of peptic ulcer or who were included
in the transplantation list were treated with amoxieillin, 500 mg/8 hr and
omeprazol 20 mg/12 hr for two weeks. At six months the UBT was
repeated, and those patients who were still positive received ehlaritromicin
250 mg/12 hr plus Omeprazol 20 mg/12 hr. In addition, 24 patients were
evaluated with serology (Igpiloriset Diagnostica) at months 0, 6 and 18. In
this group 24 of 34 patients included were positive with UBT; 16 of them
were treated with the first therapeutic regimen, and 8 became negative.
The rest received the second regimen, and 5 more responded. Thus, after
both regimens, HP infection was eradicated in 88.5% of patients, with
extremely good tolerance. Only one patient negative at beginning of the
study acquired the infection during the study period. One positive patient
who was not treated became negative spontaneously. Regarding serology,
no changes were observed in those 9 patients with negative UBT who were
still negative at 18 months, nor in those 5 positive untreated. The patient
who became positive raised his titration (+66%). In 10 patients success-
fully treated, the antibody titration decreased only 8.8% at 6 months (from
2424 3522 to 2612 2796; P = NS),but was at 63.6% at 18 months (to
638 619; P < 0.001). The response of HP infection to amoxicillin or
chlaritromicin plus omeprazol is satisfying and well tolerated. Even when
it is difficult to diagnose the infection by serology because the cut-off is
difficult to determine, the evolution of the antibody titration at 18 months,
but not at 6, could be useful to evaluate the response to treatment in those
centers that lack the spectrophotometer needed to perform the C13 UBT.
Echocardiographic findings in patients with episodes of hypotension in
hemodialysis. M. Ruiz-Nodar, .4. Cirugeda, C. Berni.c, J. Enero, E. iturralde,
G. Barril, iA. Traver, Departments of Nephrology and Cardiology, University
Hospital of La Pnince,sa, Madrid, Spain. Intradialytic hypotensive episodes
are a serious problem that increases in elderly patients. Echoeardiography
may be a valuable tool for the diagnosis and treatment. Left ventricular
hypertrophy (LVH) has a high frequency and is an important determinant
of survival, more so than coronary artery disease. It is also more amenable
to therapeutic intervention. Of 70 patients in our hemodialysis unit, we
performed an echocardigraphic study involving the 21 patients with
episodes of hypotension. All used a bicarbonate-containing dialysis solu-
tion. Mean age 67.3 years (SE 10.5); 62% male; 57% hypertension and
14% diabetic. Mean time on dialysis 43.7 months. A total of 29% had
isehemic cardiac disease (19% acute myocardial infarction and 10%
angioa peetoris), and 9% atrial fibrillation. The etiology of end-stage renal
disease was: 24% chronic pyelonephritis, 19% nephrosclerosis, 14%
glomerulonephritis, 9% diabetic nephropathy, 5% systemic diseases, 5%
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polycystic renal and 24% unknown. The study showed the following
echocardiographic findings: 52% left atrium dilation; 62% degenerative
valvular changes; reduction in ejection fraction and LVH (Table 1);
septum thickness 14.4 mm 2.8 (N < 11); posterior wall thickness 13.6
mm 2.8 (N < 11). Doppler echocardiographic showed a reduction of
ventricular relaxation of 57%, restrictive patter by ventricular stiffness 5%,
and normal was 38%. This study showed diastolic dysfunction in 58% and
systolic dysfunction in 19%.
Light Moderate Severe Normal
5%
9.5%
Most patients with hypotensive episodes during dialysis show diastolic
dysfunction in LV, and diastolic failure by LVH is the most important
cause. The echocardiographic study in these patients is very important for
the maintenance and treatment while they are on hemodialysis treatment.
Quality of life (QL) in diabetic dialysis patients: A Spanish cooperative
study. Spanish Cooperative Renal Patients Quality of Life Study Group.
Coordinators: F. Moreno, D. Sanz-Guajardo, f.M Lopez, R. Jofre, F.
Valderrábano, Hospital Principe de Asturias, Hospital Puerta de Hierro,
Hospital General Universitario Gregorio MarahOn, Madrid, Spain. At the
present moment, 18% of the patients starting renal replacement therapy
in Europe are diabetic. In this study, the QL of 1,023 stable patients on
chronic dialysis, selected randomly on a national level, was evaluated. The
evaluation of QL was done by the Karnofsky Scale (KS) and the Sickness
Impact Profile (SIP). A lower KS score and a higher SIP score indicated
a lower QL. Comorbidity was evaluated by the Friedman Comorbidity
Index (CI). Eight percent of the patients studied were diabetic (N = 82);
17% were on DPA and 83% on hemodialysis. Of these, 65% used
bicarbonate dialysis and 37% used synthetic membranes. Twenty percent
were blind and 37% showed intermittent claudication. Principal comor-
bidity factors were the loss of vision, hypertension, osteomuscular-loco-
motive and gastrointestinal pathologies and cardiac insufficiency. The
mean age and CI of the diabetics (D) were higher than those of the
non-diabetics (ND) (mean so; age, D 56 13 vs. ND 53 15, P < 0.05;
CI, D 6.4 3 vs. ND 4.5 3, P < 0.0001). There were no differences in
hemoglobin level, Kt/V or PCR. The diabetic patients showed lower scores
on all the global QL indicators used median and 25, 75 percentiles; KS,
D 60 (50, 70) vs. ND 80 (60, 90); SIP Physical Dimension, D 18 (6, 32) vs.
ND 6.5 (2, 15); SIP Psycho-Social Dimension, D 17 (8, 28) vs. ND 9.3 (4,
19); Global SIP, D 20(11,32) vs. ND 11(6,20)1. The differences persisted
after adjusting the scores to differences in age, sex, hemoglobin, educa-
tional level and socio-economic level (P < 0.001 in all). After including the
adjustment of the CI covariables blindness and intermittent claudication,
the differences between D and ND were reduced, although significant
differences in the SIP Physical Dimension (P < 0.05) and KS (P < 0.001)
were maintained. In conclusion, diabetic patients on dialysis show severe
limitations in independence and functional state. The comorbidity related
to diabetes plays a crucial role in the deterioration of their quality of life.
Factors related to the quality of life (QL) of ESRD patients on dialysis.
F. Moreno, D. Sanz-Guajardo, J.M. LOpez, R. Jofre, F ValderrOhano, on
behalf of the Cooperative Spanish QL Study Group. We evaluated 1023
patients on dialysis, randomly selected from among 42 hospitals and their
extrahospitalary dialysis clinics. The criteria for selection were: over 15
years of age; a minimum of three months on the same therapy; three
months since the last major complication; if they received EPO, at least
three months of treatment; absence of vascular access problems. The
evaluation of QL was done on the Karnofsky Scale (KS) and the Sickness
Impact Profile (SIP), both self reported. The SIP items were grouped to
obtain a Physical Dimension, a Psychosocial D, and a Global Score SIP.
Comorbidity was measured on the Friedman Index (CI). A multivariate
analysis through stepwise linear regression was carried Out. Among the
independent variables included were personal characteristics, socio-eco-
nomic and cultural levels, CI, type of substitute therapy, hemoglobin,
Kt/V, PCR, previous unsuccessful transplant, time on dialysis, type of
dialysis center, type of dialyzer membrane and dialysis solution, and
treatment with EPO. Factors related negatively to QL according to the
Physical D and the Global Score of the SIP were: first, the CI and age, and
second, the presence of diabetes and the female sex. Factors related to a
better QL according to the same indicators include level of studies,
socio-eeonomic level, and higher level of hemoglobin (R2 Ln Global SIP,
0.28; R2 Ln Physical D, 0.34). The KS factors related to a lower QL were
age, CI, the presence of diabetes and blindness. A higher socio-econimie
level and a higher level of studies were related to a better score on the KS
(R2 Ln KS: 0.31). Kt/V, dialysis technique and type of dializer membrane
or dialysis solution showed no relation to QL in this study. Comorbidity
and age are the factors most strongly related to a lower QL in dialysis
patients. A higher cultural and economic level and a higher hemoglobin
level are related to better QL.
Quality of life in dialysis patients. Spanish national study on quality of
life in dialysis. F. Moreno, J.M. Lopez, D. Sanz-Guajardo, R. Jofre, F.
Valderrdhano, on behalf of the Cooperative Spanish QL Study Group(CSQLSG). The objective of this study was to evaluate the QL in patients
on chronic dialysis. The transversal study was carried out nationally and
1023 patients on dialysis, randomly selected from among 42 hospitals and
their extrahospitalary dialysis clinics, were evaluated. The criteria for
selection were: (1) age >15; (2) at least 3 months on the same therapy; (3)
3 months since the last major complication; (4) if on EPO, at least 3
months of treatment; (5) absence of vascular access problems. The
evaluation of QL was done through the Karnofsky Scale (KS) and the
Sickness Impact Profile (SIP), all were self-reported. The SIP evaluates
illness-related behavioral dysfunction and includes a Physical Dimension,
a Psychosocial D and a Global Score; a higher score indicated a lower OL.
The mean age was 53 15; 41% were 60 years old; sex, 56% M and 44%
F; 8% were diabetic; 88% were on hemodialysis (HD) in center, 0.7% on
home HD, 7% on hemodialfiltration and 4% on DPA; 73% received EPO.
The average hematocrit (Ht) was 30% and 12% had Ht lower than 25%.
The results of the QL indicators are the following (the median and the 25
and 75 percentiles are shown): KS, 70 (60—90); Physical D, 7 (2—17);
Psychosocial D, 10 (4—20); Global Score of the SIP, 12 (6—21). A total of
26% of the patients scored 20 on the SIP Global Score and 31% <60 on
the KS. No significative influence was found relating to dialysis technique,
dialysis solution (acetate vs. bicarbonate), nor the use of a synthetic or
cellulose dialyzer membrane. Twenty-six percent of the patients in this
study showed an important adverse effect of the disease on their QL (SIP
Global Score 20). No differences on QL were found among patients with
different renal substitutive therapeutic modalities, nor in the type of
dialyzer membrane or dialysis solution.
Renal replacement therapy with hemodialysis in patients over 65 years
of age. M. C. Sanchez Perales, M.J. Garcia Cones, F.J. Borrego Utiel, A.
Liebana Canada, J. Borrego Hinojosa, S. Garcia Marcos, P. Serrano Angeles,
V. Perez Banasco, Servicio de Nefrologia, Hospital General de Especiali-
dades, Jaén, Spain. A greater life expectancy in general population and
improvements in dialysis techniques are providing more acceptance of
elderly patients in dialysis programs. The aim of present study was to
evaluate potential differences in epidemiologic data, morbidity, survival as
well as biochemical parameters that have been reported to correlate with
nutritional status and morbidity such as hemoglobin (Hb), creatinine (Cr),
urea and serum albumin (Ab) in patients older 65 years included on
hemodialysis. We studied the population included on hemodialysis from
January 1988 to December 1994. Patients who had undergone prior
transplantation, transferred from other dialysis facilities or from other
forms of dialysis were excluded. Follow-up began at the start of hemodi-
alysis and ended on transplantation, death, transferring to other center,
change in dialysis modality or closing of the study on December 1995. We
analyzed differences among patients below or above 65 years about
follow-up at our center prior to starting dialysis, cause of end-stage renal
disease, concomitant and intercurrent diseases as well as survival and
hospitalization as the index of morbidity. Biochemical parameters were
evaluated at start of hemodialysis and final of follow-up. We examined the
relationship between morbidity and baseline biochemical parameters. A
total of 157 patients had been included on hemodialysis and 28% (N 44)
of them were older 65 years at the start of treatment. Their inclusion
Reduction ejection fraction
LVH
9.5% 9.5% 76%
33.5% 38% 19%
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increased from 8.5% in 1988 to 45.7% in 1994. We found statistically
significant differences in the elderly patients: (1) They were referred to our
center in very advanced stage of chronic renal failure (59% vs. 37% of
younger patients, P < 0.05; (2) A higher frequency of hypertensive
nephrosclerosis in etiology of end-stage renal disease (23% vs. 5%) as well
as cardiovascular comorbid conditions (27% vs. 8%) P < 0.01 (3) Baseline
serum albumin (g/dl) was 3.86 0.64 vs. 4.21 0.53, P < 0.001; final,
4.17 0.52 vs. 4.47 0.48, P < 0.01; baseline creatinine (mgldl), 9.08
1.87 vs. 10.22 2.20, P < 0.01 final, 8.77 1.5 vs. 10.41 2.27,P < 0.001.
(4) More intercurrent diseases (86% vs. 62%, P < 0.01) due to infection
and cardiovascular causes and higher use of permanent catheter for
vascular access (24% vs. 5%, P < 0.01). (5) Greater number of hospital
admissions per year: 2.95 3.40 versus 1.67 2.02, P < 0.05. (6) Baseline
levels of Hb, Urea and Cr did not correlate with hospitalization rate. By
multivariate linear regression analysis, morbidity correlated inversely with
initial serum Albumin and directly with age at the start of dialysis (r =
0.47; P < 0.001). (7) Lower survival rate. At 1 year, 79.48%, 5-years,
52.77% versus 1 year 95.32%, 5 years 84.94% (Log-rank test: P < 0.001).
In summary, hemodialysis patients older than 65 years at the start of
treatment were found to have: (1) increased acceptance in the hemodial-
ysis program; (2) late referral to our Nephrolgy Unit; (3) more vascular
and cardiac disease that increases morbidity and disables to get a vascular
access; (4) lower initial serum albumin as a nutritional marker associated
with increased risk of morbidity.
Valvular heart calcification on chronic hemodialysis patients: Preva-
lence and related factors. M. Salgueira, 0. .Jarava, V. Marti A. Monroy, N.
Aresté, R. Moreno Alba, J.A. Milan, Nephrology & Cardiology Services,
Hospital Universitario Virgen Macarena, Seville, Spain. Valvular heart
calcification (VC) appear frequently and prematurely in patients (pts) who
have been receiving maintenance hemodialysis (HD). The etiologic factors
are: aging, dialysis duration, metabolic and hemodynamic factors. We
wanted to identify valvular disease in our pts on chronic HD and evaluate
the role of different related factors. Seventy unselected pts (38 M/32 F,
aged: 50 15 years, dialysis duration, 86 62 months). Serum level of
total and bone alkaline phosphatase (TAP, BAP), BGP, iPTH, calcium
and phosphorus had been measured for the three preceding years.
M-mode, two dimensional and Doppler echocardiography was performed
in all pts. We stratified the pts according to age (><60 years) and
treatment duration (><72 months). The results showed (1) valvular heart
disease, mitral stenosis (4%) and insufficiency (22%); aortic stenosis
(11%) and insufficiency (10%). (2) Valvular heart calcification were seen
in 28 pts (40%): aortic valve 10%, mitral valve 54%, and both 36%. (3) Pts
with valvular calcification (VC+) were older (P < 0.01) and showed more
peripheral vascular calcification (P < 0.0001) compared with VC— pts.
Sex, arterial pressure, diabetes or cardiac output were not differents in
both groups. (4) Pts VC+ younger than 60 were on HD for a longer time
(P < 0.05). (5) Ca-P product were significantly higher in VC+ pts older
than 60. (6) Mitral annular calcification didn't show a stadistical relation-
ship with any biochemical marker of osteodystrophy. (7) Pts younger than
60 with aortic annular calcification showed higher PTH (P < 0.05), TAP
and BAP (P = NS). In conclusion, (1) In the incidence of VC among our
dialysis patients is high (40%), and mitral annular calcification is the most
frequent. (2) Age and dialysis duration (mainly in younger patients) seem
to play a role in the development of VC. (3) Abnormal calcium-
phosphorus metabolism doesn't show up as an important factor related to
our patients.
State of adrenergic system and renin-angiotensin system in chronic
hypotension associated to uremia. N. Esfbrzado, A. Cases, M. Bono, J.
López-Pedret, L. Revert, A. Darnell, Nephrology Unit, Hospital Clinic i
Provincial, Barcelona, Spain. To study the pathophysiology of chronic
hypotension (CH) in uremic patients, the state of adrenoceptors and of
the renin-angiotensin system (RAS) in ESRD hemodialyzed patients were
evaluated. Plasma catecholamine levels, plasma angiotensin II levels (Ang
'I) plasma renin activity (PRA) and a,-(a2A) and 2-(2A) adrenocep-
tor density were measured, in 14 normotensive hemodialysis (HD) pa-
tients (NHC), 14 chronic hypotensive HD (HHP) patients and 17 normo-
tensive control subjects. Plasma catecholamine levels were elevated in
both HD groups (P < 0.01 vs. controls). Epinephrine levels were higher in
chronic HHP (P < 0.05vs. normotensive HD patients). PRA and Ang lIi,
were elevated only in chronic HHP patients (P < 0.05 vs. normotensive
HD patients and controls). a2A and G2A densities were lower in HHP
than in normotensive HD patients (P < 0.05). In all HD patients, mean
blood pressure (MBP) correlated with a2A (r = 0.46, P < 0.01) and G2A(r = 0.43, P < 0.05) density. In HD patients, MBP also correlated with
PRA (r =
—0.59, P < 0.01) and Ang III, (r = —0.80, P < 0.01). In a
hypotensive HD subgroup of 10 patients, plasma epinephrine levels were
very high (P < 0.01 vs. normotensive patients), whereas the PRA and Ang
III, were within the normal range (no differences vs. normotensive
patients). In the hypotensive HD subgroup (N 4 patients) plasma
epinephrine levels were similar to normotensive HD patients, whereas the
PRA and Ang III, were very elevated (P < 0.01 vs. normotensive patients).
Finally, plasma epinephrine levels were inversely correlated with PRA
(r =
—0.78,P < 0.01) and with Ang II (r = —0.66, P < 0.05) only in the
hypotensive HD group. Although the adrenergic system impairment
seems to be the main etiopathogenic mechanism of chronic hypotension in
hemodialyzed patients, a renin-angiotensin system alteration could also be
important in a small subgroup of hypotensive hemodialyzed patients.
Doppler spectrum analysis of the lower limb arteries and risk factors
for atherosclerosis in patients on dialysis. A. Tato, J. Pascual, F.J. Burgos,
V Gómez, T. Cano, G. F. Juárez, L. Orofino, F. Liaño, J. Ortuño, Servicios
de Nefrologia y Urologia, Hospital Ramón y Cajal, Madnd, Spain. The
prevalence of atheromatosis of major arteries and associated morbidity
and mortality in ESRD patients is very high, and constitutes the most
important issue for the evaluation of a potential renal allograft recipient.
It is not known whether Doppler spectrum analysis of lower limb arteries
is useful in this evaluation. The correlation between vascular risk factors
and this analysis is also unknown. Fifty-one dialysis (95.3% hemodialysis)
patients underwent a Doppler ultrasound spectrum analysis of lower limb
arteries (femoral, popliteal and posterior tibial). Mean age was 42 5
years and time on dialysis 34 6 months; 84% were hypertensive taking
drugs; 47% were smokers (27 4 cig/day during 162 54 months).
Acceleration (AC), mean velocity (MV), peak systolic (MxSV) and
minimal diastolic (MnDV) velocities, pulsatility (P1) and resistance index
(RI) were measured. RI and PT were maximal, and MxSR, MV and AC
were minimal at the popliteal level. The number of cig/day was inversely
correlated with perfusion parameters at popliteal and posterotibial arter-
ies (r = —0.78 for PSR, —0.77 for AC and —0.68 for MnDR, all P < 0.05).
Cholesterol levels were inversely correlated with posterotibial MV (r =
—0.43). Systolic and diastolic BP and time of hypertension were directly
related with RI at the femoral artery (r = 0.38/0.43). Fifteen patients
received cadaveric transplantation. RI at the popliteal and posterior tibial
arteries increased (1.5 vs. 1.7 and 1.2 vs. 1.6), as a result of significant
reductions of perfusion velocities (popliteal, MV 4.1 vs. 0.2 and MxSV
28.7 vs. 23.4; post.tibial, MV 6.2 vs. 0.2 and MxSV 32.6 vs. 15.2 cm/sc).
Doppler spectrum analysis of the lower limb arteries is a useful tool for the
evaluation of the vascular situation of patients on dialysis. This technique
could be useful in interventional pharmacological studies in this high risk
population, and in the evaluation of these anastomosis without a high risk
of further claudication.
Hypercatabolism induced by dialysis session and urea nitrogen gener-
ation: Effect of different dialysis membranes. C. Garcia Canton, R.
Palomar, A. Moreno, A. Toledo, S. Suria, P. Rossique, N. Esparza, MD.
Checa, Servicio de Nefrologia, Hospital Insular de Gran Canaria, Spain. It is
known that the hemodialysis procedure can produce a hypercataholic
stimulus that could increase urea nitrogen generation on dialysis days, and
this effect can be affected by the biocompatibility of the membrane used.
Our aim was to compare the rate of urea generation on a group of patients
on dialysis days and non-dialysis days, studying the influence of the type of
dialysis membrane used. We prospectively studied two groups of 20 stable
chronic hemodialysis patients. Group 1, 12 males, 8 females, average age
49 18, mean duration on dialysis 22 27 months were studied for two
weeks using euprophane dialyzers in the first week and then AN69
dialyzers, maintaining the other dialysis parameters unchanged. Group II,
13 males, 7 females, average age 49.9 14, mean duration on dialysis 16
17 months were dialyzed with cellulose diacetate one week and poliamida
dialyzers the other week. During each week of treatment the time between
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the second and the third dialysis sessions was divided into two different
periods: period I includes the first 22 hours postdialysis after urea rebound
and period lithe rest of the time until the next dialysis. The rate of urea
generation was calculated in both periods for each membrane used.
Group 1
Cuprophane
AN69
Group 2
Cellulose diacetate
Poliamida
A nonstatistical significant difference was observed in a weak urea
nitrogen extraction between the different membranes. We calculated the
difference between the rate of urea generation in period I and period II
that was significatively higher with the less biocompatible membranes:
cuprophane 2.49 17 vs. AN69 1.04 1.9; P < 0.01; cellulose diaeetate
2.6 1.7 vs. poliamida 1.08 1.4; P < 0.005. There was no difference in
the protein intake measured by dietetic register between period I and
period II. Our results suggest that the rate of urea generation is higher in
the period immediately postdialysis than in the rest of the interdialysis
period, probably because of the catabolic stimulus induced by dialysis, and
this was higher with cuprophane and cellulose diacetate than with AN69
and poliamida, suggesting a more hypercatabolic stimulus with the less
biocompatible membrane.
Lipoprotein (a) reduction in dialysis patients after androgen therapy.
J.L. Teruel, MA. Lasunción, A. Tato, T Tenono, M.E. Rivera, A. Aquilera,
R. Marcén, J. Ortubo, Department of Nephrolot and Biochemistry-Research,
Hospital Ramón y Cajal, Madrid, Spain. Lipoprotein (a) fLp(a)I, is
currently regarded as an independent risk factor for cardiovascular
disease. It is deemed better than traditional lipidic indicators for prognos-
tic value. Current hypolipemic drugs have little effect in Lp (a) concen-
tration. We have studied the lipoprotein profile in two groups of patients
after partial correction of anemia. Fourteen males aged between 50 and 75
years were treated with nandrolone decanoate (200 mg/week for six
months) and 12 patients (8 females and 4 males) between 23 and 79 were
treated with erythropoietin (EPO; 200 UI. subcutaneously, posthemodi-
alysis). The increase of hemoglobin was similar in both groups: 10.8 1.7
vs. 7.9 0.9 g/dl in the Androgen group, and 10.8 1 vs. 7.7 0.9 in the
EPO group (P < 0.01 in both groups). We recorded an Apo B increment
(141 51 vs. 121 30 mg/dl) and HDL2 cholesterol reduction (5 3.9
vs. 13.1 11.9 mg/dl) in the Androgen group (P < 0.05), and no
significant variations in cholesterol, triglycerides, Apo A, and HDL3
cholesterol. However, the most relevant finding was a 74% reduction in Lp
(a) levels (7.1 vs. 19.8 mg/dl, median, P < 0.01). Lp (a) concentration
decreased in all but three patients, who had a very low Lp (a) basal
concentration (less than 7 mg/dl). We did not notice any correlation
between Lp (a) and other lipidic parameters or hemoglobin variations.
Changes in the lipidic profile were reversed two months after nandrolone
suspension. in the EPO group, we did not record changes in the lipidic
profile after partial correetion of anemia. Androgens cause an important
decrease in Lp (a) serum concentration in hemodialysis patients. This
action is independent on the effect on anemia and could have therapeu-
tical impact in selected groups.
Abnormalities in lipoproteins in hemodialysis patients: Comparison of
low molecular weight heparin (LMWH) vs standard heparin (SH). R.
Perez-Garcia, L. Rovina, F. Verde, C. Vazmediano, F Anaya, F. Junco, M.
Ortiz, F. Valderrahano, Service IVefrologia, Ilosp. Gregorio Maraflon, Ma-
dod, Spain. The aim of this study was to compare lipid parameters,
including Lp(a), between patients on hemodialysis (HD) with LMWI-I and
SH as anticoagulant. Thirty-two patients, 18 men and 14 women, with a
mean age of 58 16 (28—80) years (mean SD) on I ID were studied. The
1-ID schedule was 3 hours, 3 times per week, blood flow 350—400 mI/mm,
using in 15 of patients high flux dialyzers. All of them were with
bicarbonate dialysate, containing glucose 1.5 g/liter. The patients were
randomly assigned to one of two groups. In Group LMWH, 16 patients
were changed from SH to LMWH as anticoagulant treatment for HD for
a year. Group SH, 16 patients continued on SH, as control group. Serum
lipid parameters and atherogenie risk ratios were measured at basal, first,
2nd, 3rd, 6th and 12th months, pre- and post-HD. During the basal time
11 out of 32 patients had increased serum triglycerides and 8 hypercho-
lesterolemia. Patients had decreased levels of ApoAl and HDL choles-
terol and increased levels of Lp(a) compared to controls. Hypertriglycer-
idemia was more frequent in diabetics (7/12). Total dosage of SH per
session (54.3 9.4 UI/kg) did not change in group SH during study; in the
patients of group LMWH the total dose of LMWH per session was 38.6
13.2 UaXa/kg (70% previous dose) with sufficient anticoagulation ob-
tained at all times. The total cholesterol decreased significantly (P < 0.01),
to a mean value of 26 mg/dl at 1 year in patients of group LMWH but not
in group SH. HDL cholesterol decreased significantly (P < 0.01), to a
mean value of 5 mg/dl at 1 year in both groups. Serum triglycerides,
LDL/HDL, LDL/ApoB, HDL/ApoAl, and total cholesterol/HDL did not
change in any group during study follow-up. We observed a raised Lp(a)
concentration in HD patients, 42.3 61 mg/dl, compared to controls, with
a high variability between each patient. The Lp(a) did not appear to he
affected by change from SH to LMWH. No correlation between the Lp(a)
level and other lipid parameters was found. In conclusion, a significant
decrease in total cholesterol level in the group with LMWH was found, but
without changing either atherogenic risk ratios or Lp(a) levels.
Does the activation of the antiproteinase system depend on the
biocompatibility of the hemodialysis membrane? R. Bustamante, A.
Mendiluce, J. Nuñez, f.M. Briso-Montiano, N.S. Jabari, J.A. Hemizo, L.
Sanchez, J. Bustamante, Sereicio de Nefrologla, Hospital Universitario,
Valladolid, Espana. Nine plasma proteins control the proteolytic activity in
blood and tissues. The a antitrypsin and the macroglobulin are the
principal plasma anti-proteins that inactivate proteolytic activity, cancel-
ling the granulocyte elastase. Plasma levels were studied in 25 patients
(aged 40 5.6 years) who have used various dialyzers for 48 13 months
throughout hemodialysis, at 0, 15, 30 120 and 240 minutes of the
procedure: 10 patients used cuprophan, 5 polyacrylonitrile (PAN), 5
ethylenvinyl alcohol (EVAL) and 5 patients used polysulfone dialyzers.
The determination of the granulocyte elastase was accomplished by
enzymoimmunoassay, and that of the a1 antitrypsin and a, macroglobulin
by nephelometer. A significant increase (P < 0.001) of the granulocyte
elastase was produced in the 4 groups in relation to the levels before
hemodialysis. The a antitrypsin is lower in all the groups in relation to the
predialysis levels, hut the decrease was significant only in the euprophan
group (P < 0.05). The 02 macroglobulin was lowered in the four groups in
relation to the control levels at the start of the procedure, the decrease
being significant only in the cuprophan group (P < 0.001). During the
hemodialysis the granulocyte elastase was not significantly modified with
the polysulfone membrane; however, it was significantly increased (P <
0.01) from 30 minutes on in the groups using EVAL, PAN, and cuprophan
dialyzers. In conclusion, the decreases in the 01 antitrypsin and the a,
macroglohulin are more important in the cuprophan group, where the
elevations of the elastase are greatest. The decrease may he due to the
antiproteasas effect on the granulocyte elastase. This phenomenon also
occurs in the other three groups, hut with lesser values.
HCV infection in dialysis. Results of the Spanish four.year prospective
study. HCV Spanish Study Group, G. liarril and J.A. Traver ((Jo-ordinators)
Department of Nephrolo, Hospital Universitario de Ia Princesa, Madrid,
Spain. Since 1991 until 1994, we prospectively studied the prevalence of
ITCVAb in 91, 88, 88 and 97 Spanish centers, respectively. The number of
patients has been 5228, 5441, 5644 and 6581, respectively, meaning a 43%
of the global Spanish dialysis population. The study parameters included:
type of renal replacement therapy (RRT) (hemodialysis, lID, in hospital,
satellite unit, home HD or cAPD), number of seroconversions eaeh year
and new HCV(+) patients initiating RRT. The prevalence in the renal
unit staff and the risk to develop HCV Ab after professional accidents
were also evaluated. Results are shown in the table.
Bun generation
period I mg/mm
Bun generation
period II mg/rn in
6.63 2
5.3 1.6
7.2 1.8
6.3 1.7
P
<0.001
<0.05
<0.001
<0.05
4.4 2
4.2 2
4.6 25.1 2
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199! P 1992 P
Total 33.1% <0.05 31.1% <0.001
HD 36% <0.05 33.7% <0.001
HD Hospital 36.3% <0.05 33.8% <0.001
HD Satellite Unit 35.4% NS 33.5% <0.001
Home HD 17.6% NS 17% NS
CAPD 10.6% NS 13.4% NS
1993 P 1994
Total 25.8% NS 25.2%
HD 28% NS 27%
HD Hospital 28.2% <0.05 26.4%
HD Satellite Unit 27.5% NS 28.5%
Home HD 16.6% <0.05 32.3%
CAPD 11% NS 20.5%
The incidence has been 2.86, 1.39 and 1.29, respectively. There is a high
prevalence of new HCV(+) patients initiating RRT (362 in three years).
The number of centers that have adopted isolation measures has increased
during these four years (21, 29, 43 and 51, respectively). In spite of these
measures, a considerable number of patients seroconvert each year,
though during last two years the number of seroconversions has decreased
(141 in 1992, 79 in 1993 and 85 in 1994), regardless of a higher dialysis
population. In these four years, 149 accidents have been reported and 4 of
those cases have become VHC (+). Nurses are the staff most exposed to
this risk of infection. We conclude that the prevalence of VHC is still very
high. Even when more centers adopt isolation measures, the number of
seroeonversions is still important. The high prevalence of VHC (+) in
dialysis patients is affected by the high prevalence of the infection in
patients initiating RRT. Nurses arc at higher risk to be infected by
professional accidents than the rest of members of the renal unit staff.
Control of secondary hyperparathyroidism in hemodialysis with oral
calcium supplements and low-calcium dialysate. J.L. Teruel, A.M Tato, T.
Tenorto, R. Marcén, F.F. Liaño, T. Cano, .1. Ortuño, Department of
Nephrology, Hospital Ramón y Cajal, Madrid, Spain. The possibility of
controlling secondary hyperparathyroidism with low-calcium hemodialysis
solution and without calcitriol is widely debated. We studied the evolution
of PTH levels in low-calcium hemodialyzed patients treated with oral
calcium supplements. Thirty patients who did not previously receive
vitamin D supplements began hemodialysis therapy with a low-calcium
solution (2.5 mEq/liter). All of them were treated exclusively with calcium
carbonate. We assumed that the control of hyperparathyroidism was
adequate if intact PTH (iPTH) levels were lower than 250 pg/mI. A global
and progressive drop of iPTH levels was observed along the first year in
hemodialysis [356 179, basal; 236 183,3 months; 215 158, 6 months;
215 169, 9 months; and 199 196 12 months; P < 0.01 (ANOVA)I.
PTH levels inereased only in four patients during the first year of
treatment, and only two required calcitriol. Serum aluminum concentra-
tion at the end of the first year was very low: 7.7 jLg/liter. At the
beginning of the study hyperparathyroidism was controlled in 9 patients
(30%), and after 12 months of therapy 22 patients (73%) showed adequate
PTH concentration. We did not notice differences in sex, age, initial PTH
levels, serum phosphorous concentration, or the calcium-phosphorus
product between the two groups. However, the mean serum calcium
concentration was significantly lower in patients with hyperparathyroidism
(8 1 vs. 9.3 0.6 mg/dl, P < 0.05). In conclusions, (1) an appropriate
control of hyperparathyroidism is possible with calcium carbonate supple-
ments and low-calcium dialysate (2.5 mEq/liter). (2) Serum calcium
concentration is the main factor in hyperparathyroidism evolution.
Trabecular bone mass and 2.5 mEq/liter dialysate calcium concentra-
tion in hemodialysis patients with nonaluminic adynarnic bone disease.
M. C. Sanchez Perales, Mi. Garcia Cones, S. Fernández Martinez, P. Perez
dcl Barrio, F. Bornego Utiel, V. Perez Bañasco. Servicio de Nefrologia,
Hospital General de Especialidades, S. Radiologia, JaCn, Spain. Nonalumi-
nic adynamic bone disease is known to be associated with low PTH
secretion. Positive balance calcium (Ca) by calcium carbonate or dialysate
calcium concentration (DCa) might play a role in the parathyroid gland
suppression, and a decrease in DCa to 2.5 mEq/1 or lower has been
proposed. Its long-term effect on bone mass has not been established. The
aim of the present study was to evaluate the effect of lowering calcium
dialysate in hone mass by computed tomography (QCT) in hemodialyzed
patients with nonaluminic adynamic bone disease. We prospectively
studied 22 patients with intact PTH below 120 pg/mI, using 3 mEq/liter
DCa and CaCO3 as the sole phosphate binder. None of them had previous
renal transplantation, aluminic toxicity nor had undergone parathyroidec-
tomy. They were randomized in two groups (GI and Gil), with similar age,
sex, and time on dialysis. There were no differences among groups in the
levels of PTH, Ca, P (phosphate) and PA (alkaline phosphatase). Group
I (N = 12) was transferred to 2.5 mEq/liter DCa and Group II (N 10)
continued using 3 mEq/liter. Bone mineral density (BMD) of the lumbar
spine was assesed with single energy computed tomography at baseline (no
differences among groups) and 12 months later. Ca, P and PA were
measured monthly and PTH every three months during one year. Results:
Three patients did not conclude the study.
G1(N=r 11)
DCa 2.5 mEq/liter
GII(N=8)
DCa 3 niEq/liter
BMD B/P 133 49/Ill 46 P< 0.05 146 53/146 46
FTH B/F 43.1 23/100.6 68P <0.05 47.9 30/80.1 54.7
Ca B/F 10.55 0.8/10.0 0.8 10.77 0.9/10.02 0.7
P B/F 5.0 0.99/5.9 0.95 454 1.91/5.76 1.68
PA B/F 121 46/152 38.5 P <0.05 123 41/137 40.3
CaCO3/ 1633 964 g//4.54 2.6g/day 1086 987 g//3.O1 2.7g/day
Accum/
Day
Abbreviations are: B, baseline; F, final.
a
mg/cc; Ca and P, mg/dl; PA, UI/liter; Intact PTH, pg/mI.
In conclusion, the use of 2.5 mEq/liter dialysate calcium concentration in
hemodialysis patients with nonaluminic adynamic bone disease resulted
in: (1) loss of trabecular vertebral bone mass measured by QCT; (2)
increase in PTH secretion and biochemical markers of bone formation
(PA); (3) a greater calcium carbonate dose.
Treatment of secondary hyperparathyroidism with intravenous (i.v.)
calcitriol. Factors related with the lack of response to treatment. M.
Goicoechea, MC. Vozmediano, R. Perez Garcia, MI. Vazquez, M4. Ruiz, E.
Verde, F. Valderrabano, Department of Nephrology, Hospital Gre gorio
Maraflon, Madrid, Spain. Intravenous calcitriol is know to directly suppress
PTH secretion and release. However, there is confusion nowadays regard-
ing the therapeutic handling of intravenous calcitriol and about the factors
implicated in the lack of response. We studied 36 hemodialysis patients
(18 males and 18 females) with moderate-to-severe hyperparathyroidism
(iPTH 836 58 pg/mI, mean SEM), who underwent treatment with iv.
calcitriol at starting doses of 2 jrg after each hemodialysis session. The
mean follow-up time was 9.2 2.3 months. Two patients were excluded of
the study because they receiving a kidney transplant. All of them were
dialyzed with bicarbonate hemodialysis and a calcium concentration of 2.5
mEq/liter in the dialysate. Twenty-five patients (73.5%) responded ade-
quately to the treatment, with PTH levels lowered more than 50% (Group
A). Nine patients (26.5%) did not obtain the 50% lowering of PTH
(Group B). In group A, 12 out of 25 patients were able to maintain PTH
levels to about 250 to 300 pg/mI (Group Al) and 13 of them were not able
to do so (Group A2). Total serum calcium increased significantly in the
responder patients (from 9.8 0.15 to 11 0.3 mg/dl) as did serum
phosphate in the nonresponder patients (from 5.7 0.5 to 11 0.3
mg/dl). Pretreatment serum iPTH (951 91 vs. 650 60 pg/mI) and
alkaline phosphatase (632 89 vs. 329 37 lU/liter) were significantly
higher in Group A2 patients vs. Group Al. Hypercalcemia appeared in 23
patients (64%) and hyperphosphoremia in 20 patients (55.5%). Hypercal-
cemia was more frequent between patients from Group Al (69%) and A2
(66%). Hyperphosphoremia was more frequent between patients from
Group A2 (62%) and Group B (78%). Patients who developed hypercal-
cemia and hyperphosphoremia had a higher pretreatment serum calcium
(10 0.12 vs. 9.5 0.2 mgldl) and serum phosphate (6.3 0.3 vs. 4.9
0.2 mg/dl) than the rest of the patients. In conclusion, iv. calcitriol
60-
Dialysis fluids Al (p911)
60- 2Dp&I— —j
1
1990 1992 1994 1990
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suppresses PTH secretion in patients with severe secondary hyperpara-
thyroidism, but long-term complications due to therapy limits its thera-
peutic use. The absence of response to i.v. calcitriol is mainly associated
with a poor control of serum phosphate levels.
Longitudinal multicenter study (1991—1995) of aluminum concentra-
tion in dialysis fluid: Effect on serum aluminum. C. DIaz-Corte, M.A.
Canteros, J.L. Ferndndez-MartIn, M. Serrano, S. Barreto, lB. Cannata, Bone
and Mineral Research Unit, Instituto Reina Sofia de Investigación, Hospital
Central de Asturias, Oviedo, Spain. Aluminum (Al) intoxication had its
maximum incidence in the last decade. Although the acquisition of
effective measures of prevention have significantly reduced its prevalence,
recent studies show that despite of such measures, in most of the
European countries and USA about 20% of patients still have high values
of serum aluminum and/or are diagnosed of Al overload. The aim of this
work was to analyze the evolution of Al in dialysis fluid and in serum
throughout last 5 years in 10 Spanish centers (total number of samples =
3458). Throughout the 5 years the mean of aluminum in dialysis fluid was
of 3.82 j.rg/liter (range: 1.0 to 86.1 jLg/liter). The percentage of samples
with low Al (< 2 j.sg/liter) was 59.6%, with borderline Al (2—6 .sg/liter)
25.4%, and with high Al (> 6 .rg/liter) 15.1%. Independently of other
likely sources of Al exposure (cx. oral) the changes of Al in the dialysis
fluid have influenced the levels of serum Al. Along the 5-year follow-up
period only 33.2% of patients maintained serum Al lower than 20 j.sg/liter
(normal values), 46.2% had values between 20 and 60 pg/liter (borderline)
and 20.6% had high levels (>60 tg/1iter). Through the 5 years of follow-up
we noticed a decrease in the highest values of serum Al, hut not in the
other groups.
These results show that still is necessary to make efforts to reduce even
more the concentration of Al in dialysis fluid with the objective that the
majority of our patients can reach serum Al levels lower than 20 j.rg/liter.
Ultrafiltrable aluminium after very small doses of desferrioxamine
(DFO). A. Canteros, C. DIaz-Corte, J.L. Fernández-MartIn, E. Gago, C.
Merayo and J.B. Cannata, Bone and Mineral Research Unit, Renal Unit,
Instituto Reina Sofia, Hospital Central de Asturias, Oviedo, Spain. The
treatment of aluminium (Al) overload is based on strict policies of
prevention of Al exposure and on effective removal of the metal by means
of increasing the ultrafiltrable (dialysable) Al with DFO. Even though it
has been suggested that 5 mg/kg of DFO are effective removing Al, recent
in vitro published results demonstrate that even lower doses can be useful.
The aim of this study was to evaluate and compare the amount of
ultraliltrable (dialyzable) Al achieved in 5 hemodialysis (HD) patients
(mean basal serum Al, 44.6 16.6 zg/liter) who sequentially received and
once per week, 3 different doses of DFO (5.0, 2.5, and 0.5 mg/kg)
throughout the 5 week study, according to the following scheme. The
order of the three different doses was randomly assigned (0.5, 2.5 or 5.0
mg/kg).
DFO (0.5 or 2.5 or 5.0) DFO (0.5 or 2.5 or 5.0) DFO (0.5 or 2.5 or 5.0)
HO HO HO HO HO HO HO HO HO HD HO ND HO HO HO
DIyeio Week I Week 2 Week 3 Week 4 Week 5
All doses were effective achieving a significant increase in the percentage
of ultrafiltrable aluminium (Table).
Post-DFO Post-DFO Post-DFO
Pre-DFO (0.5) (2.5) (5.0)
Ultrafiltrable 14.6 6.9 45.6 11.7 55.6 8.2 58.4 5.9
Al %
The results demonstrate that a dose lower than 5.0 mg/kg/week, even ten
times lower at 0.5 mg/kg/week, could be used to efficiently remove Al from
Al-intoxicated patients. The use of such a small dose may definitely avoid
any adverse effect of DFO, also give more flexibility to use DFO due both
to the short time of infusion and also to the possibility of using different
schedules of administration.
Erythropoietin's role in the immunity of hemodialyzed patients. R.
Bustamante, M Arranz, J. Nuñez, A. Mendiluce, N.S. Jabaiy, IA. Herruzo,
J. Martin, I Bustarnante, Se,vicio de NefrologIa, H. Universitario, Valladolid,
Spain. Human recombinant erythropoietin (rh-Epo) seems to affect the
immunity of uremic patients. To partially evaluate this, we studied
interleukin 2 soluble receptors (1L2-R), lymphocytes and lymphocyte
subpopulations in 20 subjects; 10 hemodialysis patients treated with
rh-Epo and 10 hemodialysis patients without this treatment were analyzed
and compared. The mean ages were 53 14.7. There were 9 males and 11
females who were dialyzed with non-cellulose membranes with 1 m2
surface area, 4 hours 3 times per week. The two groups were similar in age,
sex, and hemodialysis techniques. Samples drawn at 9 am, in all patients.
Lymphocytes were determined by standard laboratory methods, lympho-
cyte subpopulations by immunofluorescent staining with monoclonal
antibodies, and 1L2-R and EPO levels by ELISA. The mean doses were 45
U/kg after HD. The plasmatic levels of EPO and hematocrit (Hct) were
similar for the two groups (with Hct 28.7 3.2% and 28.9 5.4% and
hemoglobin 9.6 1.3 mg% and 9.4 1.8 mg%. We did not see a
significant decrease of 1L2-R in the group with rh-Epo treatment. There
was a significant decrease of the T4 lymphocyte and T4 cells/T8 cells ratio
(P < 0.05) in the group with rh-Epo treatment. In this group EPO levels
had a significant correlation with T lymphocyte levels. In conclusion, there
was a decrease of T4 cells and the T4/T8 cell ratio, and a nonsignificant
decrease of 1L2-R.
Lipoprotein (a) levels in maintenance hemodialysis (HD): Modifica-
tions with rh-EPO treatment. M. Arranz, R. Bustarnante, N. Jabari, L.
Sanchez, A. Mendiluce, J. Nuñez, I Herruzo, J. Bustamante. Servicio de
NefrologIa, H. Universitario, Valladolid, Spain. Alterations in the lipidic
profile are shown in hemodialysis. To partially evaluate this we studied 19
HD patients (9 males and 10 females), the mean age of whom was 56.2
years; 9 had rh-Epo treatment, 9 had diabetes mellitus and 10 control HD
patients. The hemodialysis techniques were similar but with bicarbonate
or acetate (AC)-containing dialysis solutions. Triglycerides and choles-
terol were determined by enzymatic methods, HDL and VLDL + LDLby
electrophoresis, Apo A, Apo B, ApoE and Lp(a) by nephelometric
method, and EPO by ELISA. The Lp(a) levels were lower in the group
with EPO treatment (30.7 2 vs. 68.2 5 mgldl, P < 0.01) and were
greater in the diabetic group (64.2 43.6 vs. 38.5 31, P < 0.01). The
HDL level was greater in HD with AC (46.8 2 vs. 27.3 3) and in the
diabetic group (36.2 6 vs. 27.7 3, P < 0.05). The VLDL + LDL levels
were lower in HD with AC (65.9 5.6 vs. 73.6 3, P < 0.01), and there
was a significant decrease in the group without diabetes (65.1 6 vs.
76.2 1). Apo A was greater in HD with AC (147.6 33 vs. 119.5 22)(P < 0.005) and with diabetes (151.1 9 vs. 44.9 1, P < 0.001). in
conclusion, there was a significant increase of Lp(a) levels in diabetic
patients and HD patients receiving rh-EPO treatment. We saw a signifi-
cant decrease of HDL and VLDL + LDL levels in the group with rh-EPO
treatment and diabetes.
Relationship between the intensity of hemodialysis and the response to
erythropoietin. Mi. Garcia Cortés, M.C. Sanchez Perales, Fl Borrego Utiel,
P. Perez del Barrio, J. Borrego Hinojosa, V. Perez Banasco, S. de NefrologIa,
Hospital Gral de Especialidades, Jaen, Spain. Several causes of resistance to
erythropoietin (EPO) in hemodialysis patients have been defined, but the
contribution of uremic inhibitors of erythropoiesis to this resistance is
unknown. This study was designed to assess the relationship between the
intensity of hemodialysis and the response to erythropoictin therapy in
hemodialysis. Seventy-five hemodialysis patients treated with EPO, with
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initial serum ferritin >80 ng/ml and MVC 80—100 fi were divided in two
groups: GI, KtV < 1.3 (N = 59) and GIl, KtV  1.3 (N = 16).
Hemoglobin, Hct, ferritin, TS, albumin, aluminium, dose of EPO (U/kg!
week), KtV, PCR and URR were measured. The level of dialysis (dialyzer,
Qb, duration of each hemodialysis) was increased in GI patients for 12
weeks. At the end of this period the same parameters were estimated. The
target Het was 30%. We found that patients with a KtV < 1.3 needed
more EPO than patients with KtV  1.3 (82.7 43.9 vs. 56.1 27.1
U/kg/week, P < 0.01) to maintain the same Hct. There were no differences
in aluminium, ferritin and albumin between these groups. After 12 weeks
the efficacy of dialysis didn't increase in 11 patients (GA), and it increased
in 48 (GB), 32 of them had a KtV of <1.3 at the end of the study (GBI)
and 16 had a KtV 1.3 (GBII). Het only increased in those groups in
which the efficacy of dialysis increased (GI, Gil) without modification of
EPO doses.
GAN=11 GBIN=32 GBIIN=16
KtV l.i6±0.l2/l.l3±O.l2 0.97±0.16/1.11 ±0.12
"If
Hct 31.0 2.9/30.1 3.6 29.3 3.3/30.9 3.0C 28.0 3.2/31.2 2.5*
i/f
EPO 88.2 53.0/80.1 49.9 77.2 28.5/79.5 33.3 89.9 61.1/74.1 46.3
i/f
Inc. —2.5 2.0% 16.4 21.0% 38.0 31.0%
KtV
lncr. —2.4 10.9% 6.5 15.3% 12.6 16.1%
Het
a p < 0.001; P < 0.01; C p < 0.05. Abbreviations are: i, initial; f, final;
me, increase.
In conclusion, (1) inadequate hemodialysis could be a cause of resistance
to erythropoietin therapy in hemodialysis patients; (2) heniodialysis
efficacy must be monitored in hemodialysis patients who have a subopti-
mal response to erythropoietin.
Serum transferrin receptors and iron kinetics with 59Fe as indicators of
erythpropoietic activity in HD patients with CRF treated with rHuEPO.
.1. Deira, M. Martin, S. Sanchez, B. Martin, J.M. Tabernero, Servicio de
Nefrologia, Medicina Nuclear and Hematologia, Hospital Clinico de
Salamanca, Spain. Serum transferrin receptor (TfR) levels serve as a new
tool of great use in the evaluation of erythropoietic activity. The serum
levels of this receptor are directly related to the activity of the compound,
and measurement of TfR values could offer a feasible way to assess
eythropoietic activity instead of, or as a complement to, iron kinetic
studies using 59Fe. To evaluate both parameters, the following investiga-
tion was designed. In 22 patients on HD we evaluated erythropoiesis
before and at 4 months after treatment with rHuEPO by: (1) hemoglobin
(Hb) in g/d liter, hematocrit (Het) in %, and retieuloeytes (Ret); (2) TfR
levels in mg/liter; and (3) plasma iron clearance (TJ/,), plasma iron
turnover (PIT) in /.Lmol/Iiter whole blood/day, and transferrin uptake by
the Erythron (ETU) in /.Lmol/liter whole blood/day. The existence of
ferropenia, secondary hyperparathyroidism and aluminium intoxication
was ruled out.
Day Hb Hct Ret )< 1000 TfR
0 9 1.4 26.3 4 75.4 29 2.17 0.8
15 2.68 0.8*
30 9.8 1.6 28.6 5 100.8 62 2.97 0.8"
45 3.24 0.8"
60 10.6 1 31.4 5 95 22.8 3.13 07*
90 U 1.8 32.4 5 97 35 3.10 0.7
120 11.3 1 33.5 4 77.4 20 2.94 0.8"
Day
--
T112 ETU
0 135 49 0.38 0.12 30.4 17
15
30
45
Day T112 PIT ETU
60
90
120 97 31" 0.53 0.3" 49.9 3
a P < 0.05 vs. day 0
In conclusion, (1) with rHuEPO, blood and TfR values increased, and iron
kinetics were activated, with T1,2 decreasing and PIT and ETU increasing.
These observations point to an increase in erythropoietie activity. (2) In
the first stages of the study (day 30 of treatment with rHuEPO) there was
a positive correlation between Hb and Hct and TfR levels (r = 0.51) and
the number of reticulocytes (r = 0.55). However, this did not occur before
initiation of treatment with rHuEPO or in later stages of the study. (3)
Although 5'1Fe kinetics and TfR are useful for assessing erythropoietie
activity, the results obtained from their measurement are not equivalent
since there was no correlation between TfR levels and iron kinetics either
before or after treatment with rHuEPO.
Effect of route of administration of rHUEPO on erythropoietic activity
evaluated with serum transferrin receptors (Rif) and iron kinetics with
59Fe in patients on HD. J. Deira, M. Martin, S. Sanchez, B. Martin, J.L.
Lemma, f.M. Ta be mnero, Servicio c/c Nefrologia, Medicina Nuclear and
HematologIa, Hospital ClInico de Salamanca, Spain. Recent reports have
highlighted the greater efficacy and lower costs of subcutaneous EPO
administration as opposed to the i.v. route. However, the effect of the
route of administration on erythropoietie activity remains unknown. The
aim of the present work was to evaluate erythropoiesis when EPO was
administered s.c. as compared with iv., studying its activity by analyzing
TfR levels and iron kinetics with 5'1Fe. Eleven patients with "suitable
dialysis" parameters on HD were studied. The presence of ferropenia,
secondary hyperparathyroidism and aluminium intoxication was ruled out.
The patients were treated over four months with EPO s.c. Following this,
after informed consent had been granted and a I month washout period
without EPO had elapsed, the drug was administered again for four
additional months, this time with iv. administration. In all of the patients,
the following parameters were measured monthly: (1) usual blood param-
eters; (2) iron metabolism; (3) basal Tfr levels and these levels at 15, 30,
45, 60, 90 and 120 days in mg/liter, and (4) iron kinetics [plasma iron
clearance (T112), plasma iron turnover (PIT) and transferrin uptake by the
Erythron (ETU), both in j.cmol/L whole blood/day). The mean dose of s.c.
EPO was 24 lU/kg/session; in the i.v. route, this was 31 lU/kg/session.
Day 0
-__15 30
Hb s.c. 9.1 1
i.v. 9.2 1.2
s.c. 2.6 .9
i.v. 1.4 .4
s.c. 130 40
iv. 131 49
s.c. .39 .12
10.3 2
Day 45 60 90 120
Hb s.c.
iv.
11.1 2*
10.6 1"
11.3 1*
10.7 1*
11.7 1*
10.9 9*
TfR s.c.
i.v.
3.4 .9
2.1 .3
3.4 .8
2.0 .3
3.3 .7
2.1 .4
3.3 .9
2.0 .3
Ti,, S.C. 102 25
iv. 88 32
PIT s.c.
iv.
0.43 .1
0.85 .35
ETU s.c.
iv.
37.7 15.8
49 44
TfR
T11,
PIT
3.2 .7
1.7 3
9.6 1
3.3 .6
2.0 .4
iv. 0.71 .2
ETU s.c. 32.4 19
iv. 59±3
* P < 0.05 vs. day 0.
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Summaiy and conclusions: (1) Both administration routes elicit a similar
increase in Fib; (2) erythropoietic activity was greater and appeared earlier
on with the iv. route as evaluated by RIT values; (3) the iron kinetics
parameters point to a similar rise in erythropoietic activity with both
routes of administration but do not show in which it was higher; (4) in both
groups, an inverse correlation was seen between RIT values and iron
deposition. The present findings suggest that the i.v. route elicits greater
erythropoietic activity, although Hb levels similar to those obtained with
the s.c. route are achieved; this could be interpreted as indication of a
component of inefficient erythropoiesis.
Hematocrit level (Hct) and quality of life (QL) in hemodialized patients
with rHuEPO. f.M. Logroho, M. V Ejea, R. Virto, C. Laviades, Section of
Nephrology, "San Jorge" Hospital, Huesca, and Department of Pharmacol-
ogy, University of Zaragoza, Spain. The optimum Hct level with rHuEPO
remains a matter of debate. Several authors indicated that 30% Hct
average can be insufficient and, probably, with Het levels near to normal
can further improve the QL indicators in hemodialized patients (HDP).
This was a prospective study designed to assess the QL on two different
Hct levels (32 vs. 38%). Nineteen patients (pts; 13M/6F; aged 58 14
years; 5.1 2.5 Friedmand comorbility index) clinically stabilized on HD
since 40 31 months treated with intravenous (8p: 3 times/week) or
subcutaneous (lip: 2 times/week) rHuEPO, and stable Hct concentration
(30—33%) were selected. Afterwards, these pts continued receiving doses
of rHuEPO (6.25—12.5 V/kg/day evexy 4—8 weeks) higher than previously
administered until they increased their Hct level to about 38%. The pts
acted as their own controls and the study period was for one year. QL was
evaluated at the beginning of the study and after 1 year of follow-up using
the Karnofsky Scale (KS) and the Sickness Impact Profile (SIP) question-
naire. A high KS score and a low SIP score indicated better QL. Moreover,
the iron parameters, the changes blood pressure, the left ventricular mass
index (LVMI by Eco Doppler), the efficacy of dialysis (Kt/V) and the
thrombosis of arteriovenous fistulae were also regularly analyzed. Data
were compared by Wilcoxon and simple regression tests.
Parameters Prestudy 1 year P
Hematocrit % 32.3 2.9 38.0 2.1 <0.01
Dose EPO U/kg/week 102.3 74.7 135.5 79.9 <0.01
Route iv. 135.9 89.5 182.8 96.5 NS (< 0.1)
Route s.c. 68.7 37.2 101.1 43.3 <0.05
LVMI (8 pts route iv.) 162.0 52.0 120.9 36.7 <0.01Quality of life: SIP
D. overall 17.0 11.8 14.0 10.9 <0.01
D. physical 11.9 13.3 8.8 12 <0.01
D. psychosocial 15.2 12.7 14.0 12.7 MS
Quality of life: KS 68.4 13 73.6 16.4 <0.05
The categories of SIP that improve significantly were: sleep and rest,
mobility, communication and eating.
It is concluded that higher Hct levels during rHuEPO treatment decrease
the miocardie mass and improve the QL significantly for most QL
indicators used. Moreover, we do not find any clinically important side
effects, although the dose of rHuEPO needed to he increased by up to
40% by route iv. and 50% by route s.c.
Relationship between secondary hyperparathyroidism (HPT) and su-
praventricular arrhythmias (SVA) in hemodialysis (HD). E. Verde, A.
Perez de Prado, MC. Vozmediano, R. Perez, R. Jofre, J.M. Lopez, E. Junco,
M. Barambio, J. Almendral, F. Valderrábano, Department of Nephrology and
(7ardiology, Hospital General "Gregorio MarahOn," Madrid, Spain. It has
been suggested that HPT may play a role in the development of cardiac
diseases. Arrhythmias are increased in HD patients (pts) with IIPT.
Sixty-four pts in sinus rhythm (34 M/30 F; mean age, 58 14 years) were
studied with ECG-Ilolter monitoring during 6 consecutive sessions of HD,
The aim of the present study was to analyze the incidence and type of SVA
and premature atrial contractions (PAC) in HD. Standard blood tests
were taken along HD sessions. Echocardiograms were performed on a
non-dialysis day. HD pts were divided into 2 groups according to i-PTH
levels; 23 pts had i-PTH levels less than 200 pg/mI (Group A) and the
remaining 41 pts had i-PTH > 200 pg/mI (Group B). There were no
statistical differences in age, gender and BMI between groups. No
differences were found in mean time on dialysis treatment (61 75 vs.
47 53 months; NS). The prevalence of cardiovascular risk factors was
similar in the two groups: hypertension (70% vs. 49%); diabetes mellitus
(35% vs. 27%) and smoking (56% vs. 49%). No differences were found in
left ventricular mass index between groups (177.7 50.4 g/m2 vs. 191.2
65.1 g/m2). ECG-Holter results and electrolytic changes are shown in the
following table:
Group A Group B P
SVA 30% 56% <0.05
Significative PAC 26% 65% <0.01
K decreased mEq/liter 2.35 0.49 2.26 0.73 NS
HC03 increased mEq/liter 5.05 1.90 5.39 1.82 NS
Initial Ca mmol/liter 1.05 0.10 1.05 0.08 NS
Final Ca mmol/liter 1.21 0.08 1.14 0.07 <0.01
In conclusion, HD pts with higher i-PTH levels are prone to develop SVA
and PAC. A less pronounced increase of ionic calcium levels along HD
may play a significant role in the development of these arrhythmias.
Treatment of anemia with androgens in male patients aged over 50
years. J.L. Teruel, A. Tato, T. Tenorio, G. Fernández, R. MarcCn, F. Liaho,
M. Rivera, J. Ortuño, Department of Nephrology, Hospital Ramón y Cajal,
Madrid, Spain. In a retrospective study in hemodialyzed patients treated
with nandrolone decanoate, we observed that the anemia response is
related to the age of the patients, and excellent results might be obtained
in elderly patients. After our observations, in 1990 we instituted the
following protocol for the treatment of anemia in hemodialyzed patients:
androgens are to be used in male patients aged over 50 years, and
recombinant human erythropoietin is to be used in male patients below
this age and in women. The aim of this study was to prospectively analyze
the effectiveness of androgen therapy in this population. Thirty-nine
hemodialyzed patients aged between 50 and 84 years received a cycle of
200 mg i.m. of nandrolone decanoate once a week for six months. The goal
was to reach a hemoglobin concentration higher than 9.5 g/liter. We
observed a global increase of hemoglobin from 7.4 0.9 to 10.5 2 g/liter(P < 0.001). Only two patients did not show an adequate response to
androgens, nor to erythropoietin. The target hemoglobin was reached in
28 (72%) patients. In addition to erythropoietic action, we recorded
beneficial anabolic effects, such as an increase in dry weight (64.7 10 vs.
66.8 10 kg, P < 0.001) and in serum albumin concentration (3.9 0.4
vs. 4.3 0.4g/liter, P < 0.01). Improvement in anemia with androgens did
not produce an elevation in blood pressure: blood pressure control
improved in three patients and only increased in one patient. We did not
see any case of hepatotoxicity associated to the use of nandrolone
decanoate. Nandrolone decanoate is a good alternative in the treatment of
anemia in elderly male patients on chronic hemodialysis. The anabolic
effects may have a therapeutic use in the treatment of malnutrition of
dialyzed patients.
Parenteral iron: Distribution in hemodialysis patients. M.J. Garcia
Cortés, F.J. Borrego Utiel, M. C. Sanchez Perales, A. Liebana, P. Serrano
Angeles, S. Garcia Marcos, V Perez Bañasco, S. de Nefrologia, Hospital Gral
de Especialidades, Jaen, Spain. Iron deficiency is the most important cause
of resistance to erythropoietin in hemodialysis patients. In order to avoid
it we need to know iron stores, iron required to achieve target hemoglobin
and efficacy of iron administered. This study attempted to assess the
distribution of sodium-ferric glueonate (Na-Fe-G) given intravenously
(iv.). Forty-nine hcmodialysis patients with an initial serum ferritin < 200
ng/ml or TS < 20% were treated with Na-Fe-G during the period of two
months. Patients with ferritin < 50 ng/ml received 1500 mg divided in
24 iv. doses; patients with ferritin > 50 or ferritin > 200 and TS < 20%
received 500 mg divided in 8 doses. Hemoglobin, ferritin, TS, and iron
stores were measured at baseline and revised two months later. Iron stores
were estimated by the empirical formula of Cook modified by Anastassia-
des: Iron stores = 400 * (Ln ferritin i — Ln 50). Iron needed for new
hemoglobin synthesis was calculated considering that a rise of 1 g/dl in
circulating hemoglobin uses 150 mg of iron. All estimated parameters
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increased significantly at the end of the study. A total amount of 915.8
457.4 mg of iron was administered; 119.6 238.7 mg (14.5 33.0%) were
used for hemoglobin synthesis and 574.6 507.4 mg (57.1 47.0%)
increased iron stores; 221.5 423.1 mg (28.6%) couldn't he measured. It
could be due to dialyzer and gastrointestinal losses characteristic in
hemodialysis patients. More than 70% of iron administered as Na-Fe-G
become measurable as iron stores or used for hemoglobin synthesis.
Androgens in the treatment of anemia in elderly patients on hemodi-
alysis: Effects on lymphocyte subsets. A. Gascón, A. Orfao, J.J. Belvis, A.
Lopez, J. Ciudad, J. Font, E. Iglesias, F. Bensa, S. Nephrology, General
Hospital, Teruel, S. Cytometty, University Salamanca, Spain. Androgens
have been used in the treatment of anemia in patients on hemodialysis
(HD) for years. Nevertheless, since the introduction of therapy with
recombinant human erythropoietin (EPO) its use has practically been
abandoned in daily practice. The aim of the present study was to analyze
within a group of HD patients, all over 60 years, the influence that
androgens have in lymphocyte activation of peripheral blood (PB) CD4
and CD8 T-lymphoeytes, as well as in CD1 9+CDS + B-lymphocytes, that
are inhibiting B-cells of the immunoglobulin formation. We studied 7
patients on HD, with a mean age of 69 years. All patients were in a stable
clinical situation and with adequate dialysis criteria. Erythropoietin was
suspended 15 days before beginning therapy with nandrolone decanoate.
The dose used was 200 mg/week by intramuscular administration. Uro-
logic control previous to treatment was performed; this was done every
two months and consisted in digital rectal examination and levels of
specific prostatic antigen. Before beginning the first weekly session of HD,
and after four months of treatment, we studied the PB lymphoid subsets.
PB samples were analyzed by three-color flow eytometric analysis. The
distribution of the subsets analyzed are shown in the followings tables
(absolute numbers of cells/tl, and percentage in brackets):
CD4+
CD4+
CD25+ CD4+Ia+
CD4+
CD25+Ia+
Basal 717(41%) 448(64%) 99(13%) 36(5.7%)
Mes 4° 608(36%) 184(32%) 72(14%) 20(3%)P <0.005 <0.05
CD8+ CD8 + Ia +
Basal
Mes 4°
p
398 (22%)
381 (21%)
25 (6%)
8 (2.7%)
<0.05
111 (25%)
121 (32%)
CD8+
CD25+la+ CD19+
CD19+
CD5+
Basal 1(0.3%) 91 (5.6%)
Mes 4° 2 (0.8%) 72 (4.8%)p <0.05
This table reflects a significant decrease in the activated CD4 T-cells
(CD4+/CD25+ and CD4+/CD25-f/la+), which would be in relation to a
lower level of lymphoid preaetivation. There is also a significant decrease
in CD8+/CD25+ T-cclls. Furthermore, we observed a significant decrease
in the CDI9+/CD5+ B-cells, which seem to play a part in inhibiting the
production of immunoglobulins. HD induces a ThI-type of immune
response (increased secretion of IL-2 and INF-y) that is characterized by
increasing cytotoxieity and inhibiting immunoglobulin production. Thi
seems to become inhibited by androgen therapy for this type of immune
response. In conclusion, androgen therapy of anemia in HD as well as
increasing erythropoiesis seems to provide an immunologic benefit by
lowering levels of lymphocyte preactivation of CD4+ and CD8+ T-
lymphocytes. It also lowers CDI9+/CD5+ B-lymphocytes, which can
inhibit imunoglohulin formation.
Androgens in the treatment of anemia in aged patients on hemodialy-
sis: effects on nutritional parameters. .4. Gascón, if. Belvis, f. Font, A.
Perez, V. Ruhio, F. Berisa, Service of Nephrology, Obispo Polanco General
Hospital, Teruel, Spain. Androgens have been used in the treatment of
anemia in patients on hemodialysis (HD) for years. Nevertheless, since the
introduction of therapy with recombinant human erythropoietin (EPO)
their use has practically been abandoned in everyday practice. The aim of
the present study was to analyze within a group of HD patients, all over 60
years, the influence that androgens have on nutritional parameters. We
studied 7 HD patients, average age 69 years. All patients were in a stable
clinical situation and with adequate dialysis criteria. EPO was suspended
15 days before beginning therapy with nandrolone decanoate. The dose
used was 200mg/week by intramuscular administration. Patients under-
went urologie control previous to therapy; this was done every two months
and consisted in performing digital rectal examination and obtaining levels
of specific prostatie antigen. Every two months we studied levels of Hgb,
Hcto, EPO, ferritio, creatinine, total proteins, albumin, transferrin, cho-
lesterol, HDL and LDL, triglycerides, and apolipoproteins Al and B.
Anthropometrie parameters included cutaneous tricipital (CTF) and
subseapular fold (CSF), arm circumference (AC) and arm muscular
circumference (AMC), weigh (W) and body mass index (BMI).
_______
Hgb Het EPO Creat
Pre-Tto 10 1 30.1 5 10.9 2 9.6 2
Mes 2° 10.7 1 31.6 5 14.9 3 12.7 2
Mes 4° 11.3 1 33.4 6 20.3 13 12.7 3
P < 0.02 P < 0.005
Pro Tot Album Transferri
Pre-Tto 6.6 1 3.9 0.4 173 15
Mes 2° 6.7 1 3.7 0.3 175 40
Mes 4° 6.7 1 4 0.1 216 36
Cholest HDL LDL
Pre-Tto 216 52 43 12 136 51
Mes 2° 216 63 29 4 138 47
Mes 4° 214 58 28 7 135 54
P < 0.005
Triglie AP-Al AP-B
Pre-Tto 169 102 206 23 112 43
Mes 2° 214 120 120 14 114 35
Mes 4° 288 199 100 24 104 40
P < 0.0001
CTF CSF AC
Pre-Tto 11.2 2 15.6 6 28.9 2
Mes 2° 12.1 3 15.8 6 30.2 2
Mes 4° 10.4 3 16.4 7 30.5
°P < 0.01
These results show that androgens increase levels of Hgh and Het even in
patients like ours who have extremely good levels from the beginning.
Endogenous EPO increases in a significant way. We observed an increase
in the muscular mass of these patients, with significant increases of
creatinine, AC and AMC. Levels of total proteins remained stable or even
increased, as was true with albumin and transferrin, As for lipid metabo-
lism, the results were less positive; there was an increase in triglyceride
CD8 +
CD25+
37 (42%)
14 (20%)
<0.002
AMC
Pre-Tto 25.3 1
Mes 2° 26.4 1
Mes 4° 27.2 1
P < 0.05
Weight BMI
69.1±9 25.9±2
70.6±9 26.6±2
70.7±9 26.9±2
°P < 0.001 °1' < 0.001
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levels and a significant decrease in HDL and apo-Al levels. Androgens
may be an alternative to EPO in elderly male patients on HD, because the
nutritional parameters of these patients are improved with this treatment.
However, one must keep a close watch upon the prostatic and lipid
parameters.
Hemodynamic response of radiocephalic fistula to different diameter
dialysis needles. E. Gallego Valcarce, f.M. Portoles, F. Llamas, A. Serrano,
S. Tallon, E. Andres, C. Gomez, E. Olivas, L. Sanchez Tarraga; Servicio de
1%/efrologia, Hospital General Albacete, Spain. We studied the influence of
different needles (14 and 15 gauge (G)) producing different blood flow
rates (BRFr) on diverse parameters: venous pressure (VP), arterial blood
pressure fall (AP), actual blood flow rate (BFRa), recirculation and
dialysis efficacy. Eighteen patients were studied: 16 men and 2 women.
Mean age was 54.3 17.38 years. Mean time on dialysis was 87 66.5
months.
Hemodynamic parameters
BFRr (mI/mm) 200 250 300 350 400
VP 15G 62.2 81.5 103.5 126.9 149.2
(mm Hg)
140 44.3 59.0 76.0 89.0 109.8
Reduction 28.7 27.6 26.5 29.8 26.4
PV (%)
APfall 15G —50 —69 —97 —130 —162
(mm Hg)
14G —31 —44 —64 —85 —108
Reduction 39 37 35 35 34
AP(%)
BFRa 15G 194 239 280 321 359
(mi/mm)
140 194.5 243 288 330 370
300 350 400
Recirculations
Method 1: "stop flow". Method 2: Contralateral arm puncture.
15 G Method 1
BFRr (mI/mm) 200 300 400
recirculation (%) 0.90 1.20 2.75
15 0 Method 2 14 G Method 1
BFRr (mI/mm) 200 400 200 300
recirculation (%) 5.07 12.8 1.10 1.32
14 G Method 2
BFRr (mI/mm) 400 200 400
recirculation (%) 2.54 5.26 12.94
Efficacy was estimated by KT/V = LN (bun prc hd/bun post hd) at
BFRr = 400 mI/mm, with 15G KT/V = 1.21 and with 14G KT/V = 1.22.
No statistically significant differences were appreciated.
Using a 14 G needle instead of a 15 G needle resulted in a reduction of VP
from 29.8 to 26.4% for the BRFr range studied. There was also a
reduction in AP, which correlated inversely with blood flow. The differ-
ence in BRFr and BRFa was always smaller with 14 G needles than 15 G
ones. Reduction of blood flow rate with BRFr = 400 mI/mm was 7.5% and
10.2% for 14 G and 15 G needles, respectively. There was no statistically
significant difference between the recirculation rates obtained with differ-
ent needles and the same method. The recirculation rates with the same
needle and a different method were statistically different (p < 0.001) at
different blood flow rates (200 and 400 mI/mm). Cardiopulmonary recir-
culation increased when blood flow increased, but fistula recirculation was
independent of needle diameter when BRFa were similar. Dialysis efficacy
is independent of the needle used if effective blood flow rates and similar
recirculation rates are maintained.
Percutaneous hydrodynamic thrombectomy as treatment of acute
thrombosis of vascular access for haemodialysys. J.L. Górriz, J. Palmero,
J. Martinez-Rodrigo, L. Pallardó, A. Sancho, E. Alcoy, J. Ramos G.°
Departments of Nephrology and Radiology. Hospital Dr. Peset. Valencia.
Spain. Traditionally, the treatment of thrombosed access for hemodialysis
(HD) has included surgical thrombectomy and operative revision. These
procedures lead alter the vascular wall, compromising the feasibility of
new vascular access. Other therapies, such as fibrinolitic thrombolysis, are
not free of undesirable complications. The aim of our study was to
evaluate the results of a new technique, percutaneous hydrodynamic
thrombectomy (PHT), for the treatment of recent vascular access throm-
bosis. PHT was performed by introducing a double-lumen catheter with a
distally located large side-hole and rounded tip through the thrombosed
access. Saline solution was injected at a constant flow rate, and when the
Venturi effect created a turbulence, the clot was removed by suction.
Underlying stenoses were evaluated after angiography, and angioplasty
was done when indicated. We used PHT in 20 consecutive chronic HD
patients admitted to our hospital because of acute vascular access
thrombosis (13 Brescia-Cimino arteriovenous fistulae (BC) and 7 PTFE
grafts). Mean age was 58 years (range 40—80), months in HD 51 (range
2—154). Eleven patients recived erythropoietin (hematocrit: 30.3 0.7%,
range 26.4—32.2%). Three patients were excluded from the study because
of the presence of phlebitis or aneurysmatic fistulae. PHT removed the
clots in 17 patients (100%) all of whom had more than 60% stenosis of the
lumen. Three patients had stenosis greater than 6 cm, and were referred
to a surgeon. In the 14 remaining patients, percutaneous angioplasty was
performed; a stent prosthesis was placed in 2 patients. Seven patients had
early occlusion (< 48 hours), with successful results in the remaining 7 (4
BC, 3 PTFE). Cumulative primary patency was 41%. Mean duration of
patency has been 150 86 days (range 47—276). One of the patients had
an occlusion 71 days after PHT. In the first HD performed after PHT,
blood flow was 287 30 (range 240—350) mI/mm with a venous pressure
of 147 27 (range 110—180) mmHg. There were no relevant undesirable
side effects related to the technique. In conclusion, PHT has been shown
an effective treatment for recent thrombosis of HD vascular access, with
no associated side effects.
Recirculation of central venous double lumen catheters for hemodial-
ysis. MR. Palomar, C. Garcia-Canton, A. Moreno, A. Toledo, S. Suria, P.
Rossique, N. Espaiza, T. Herndndez, F. Martinez, M.D. Checa. Departments
of Nephrology and Radiology, Hospital Insular de Gran Canada, Las
Palmas, Spain. To determine whether the site of insertion of double lumen
catheters for hemodialysis has any influence on recirculation, we per-
formed 50 recirculation tests on 43 catheters in 35 patients. Nineteen of
them had chronic renal failure and had no vascular access available and
the other 16 had acute renal failure. The types of catheters used and the
sites of insertion were as follows: 10 double lumen Hickman catheters
(13.5 French and 36 cm long) in the internal jugular vein, 6 double lumen
Mahurkar catheters (11.5 French and 19.5cm long) in the subclavian vein,
7 double lumen Mahurkar catheters (11.5 French and 13.5 cm long), 4 in
the subclavian vein and 3 in the internal jugular, 16 double lumen
Mahurkar catheters (19 cm long) in the femoral vein and 3 double lumen
Hickman catheters in the femoral vein. We performed the urea recircu-
lation test 20 minutes after the beginning of the dialysis session with the
pump at 200 mI/mm by taking arterial, venous and peripheral blood
samples simultaneously and using the formula (Up_Ua/Up_Uv)*100. To
analyze the results we considered catheters inserted in subclavia or the
jugular vein separately from those inserted in the femoral vein. The mean
rate of recirculation was 9.2 12%, N = 50; it was significatively higher
in the femoral vein (14.5 15% N = 24) than in the subclavian or jugular
(5.2 6%, N = 26, p < 0.01). There was no significant difference between
the subclavian (3.1 3%, N = 10) and jugular (6.6 7%, N = 16). No
difference was observed between the type of catheter used in subclavian
and jugular veins: Hickman 6.9 7%, N = 12, Mahurkar of 13 cm, 3.6
5%, N = 8, Mahurkar of 19cm, 4.1 4% N 6. In a 14—patient subgroup
with catheters inserted at the femoral site we repeated the recirculation
test with patients' inferior limbs at 45°, there was a significant reduction in
recirculation rate, 19 17% vs 7 6%, P < 0.01. We conclude that
catheters in femoral veins have a higher recirculation rate than the ones
located in suhclavian or internal jugular veins. This should be taken into
account when prescribing the dialysis dose, as it could be less effective with
femoral access. The higher recirculation rate of the femoral catheters
seems to he related to postural changes that improve inferior cava vein
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blood flow, as can be appreciated when inferior limbs are at 45° and blood
flow is impaired.
Comparative study of hemodialysis catheter infection with and without
subcutaneous tunnel. M. Ramirez de Arellano, F. Bella, MA. Morera, M.
Chine, M. Fuiquet, R. Cano, X. Cuevas, Nephrology, Internal Medicine and
Microbiology Departments, Hospital de Terrassa, Barcelona, Spain. To
explore the incidence of hemodialysis catheter infection and to compare
tunnel catheters (TCs) with non—tunnel catheters (NOTCs), we conducted
a prospective study for a period of 41 months (May 1992—October 1995).
Ninety catheters were inserted in 54 patients; 18 of these catheters were
subcutaneous tunnel silastic twin catheters inserted according to
"Canaud's" technique (Jugular vein = 10, femoral vein = 8) and 72 were
NOTCs, double lumen polyurethane (Jugular vein = 15, femoral vein =
14 and subclavian vein = 43). All catheters were studied in intravascular
segment culture with the semiquantitative method described by Maki. We
carried out cultures of the skin swabs and the catheter connections as well
as blood cultures when there was suspicion of infection. A catheter was
considered infected when Maki's culture evidenced 15 colony forming
units and bacteremia was considered present when the same microorgan-
ism was isolated from the blood culture and in the intravascular segment,
in the absence of another primary infection focus. Fourteen of 90
catheters (15.5%) were infected, and 5 of these demonstrated bacteremia
(35.7%). The isolated microorganisms were: S. epidermidis (64.2%), S.
aureus (35.7%) and E. faecalis (7.1%). Infected TCs had an average
duration of 71.6 54.2 days and infected NOTCs 32.1 17.3 days.
Infection Incidence
TC(10) = 1262 days NOTC(72) = 1834 days
Infection 6 (4.72°)
Bacteremia 2 (1.57°)
8 (4.36a)
3 (1.63°)
Infection Incidence by Location
TC (18) NOTC (29)
jugular (10) femoral (8) jugular (15) femoral (14)
Infection 4 (5°) 2 (3°)
Bacteremia 2 (2.5°) 0 (0°)
5 (6.9°) 1(16.1°)
1 (1.3a) 1(16.1°)
a =
episodes per 1000 catheter days
In conclusion, Canaud's type subcutaneous tunnel hemodialysis catheter
does not appear to reduce the infection incidence seen with temporary
NOTCs.
Catheterization of the femoral vein for ambulatory hemodialysis. X.
Cuevas, M. RamIrez de Arellano, M. Fulquet, M. Chine, R. Cano, R. Samo,
and J. Viladoms, Department of Nephrology, Hospital de Mollet, Hospital de
Terrassa, Barcelona, Spain. The catheterization of the femoral vein to
provide temporary vascular access for hemodialysis (HD) is a widely
known technique, but the anatomy of the area and the use of semirigid
catheters make this method applicable only to bedridden patients or to
those who need a limited number of HD sessions with the same catheter.
Using a subcutaneous tunnel silicone catheter (TSC), we explored the
viability of the femoral vein as a vascular access route in ambulatory
patients. In 9 patients (4 men and 5 women, mean age 73 Ii years), we
placed 14 TSCs (7 for end-stage renal disease and 2 for acute renal
failure), implanting two double catheters on 3 occasions and one catheter
on 8 occasions. We placed the catheters according to Canaud's technique:
percutaneous puncture of the femoral vein (7 left side and 7 right side)
and subcutaneous tunneling of the catheter (15 cm), with the distal portion
showing at the level of the leg, where it is attached to the skin, and the tip
of the catheter located in the inferior vena cava. All patients completed
ambulatory HD with no limit imposed on movement in or out of bed. With
the 14 TSCs, 345 sessions of HD were completed. The blood flow was
200—250 mI/mm and the mean venous pressure 166 54 mm Hg. The
TSCs were in place for a mean of 67 63 days (range 10—234 days). Eight
TSCs (including 2 double catheters) were removed after a mean of 67.8
45 days because internal vascular access was initiated. Four TSCs (includ-
ing one double catheter) were removed after a mean of 68 110 days
because of mechanical obstruction (and coincidental sepsis with S. Aureus
in one case). One TSC was removed after 86 days by the patient. One TSC
was still functioning at the end of the study period, 45 days after
placement. Bacteriologic evaluation performed on 10 catheters (71%)
showed the previously mentioned double catheter infected with S. Aureus
and another catheter infected with S. Epidermidis. Complications of
femoral vein catheterization included two local hematomas (one in
association with a double catheter) necessitating blood transfusion and
four instances of mechanical obstruction (one involving a double catheter)
that had to be removed. Three patients, one of whom had a double
catheter, underwent venography after removal of the catheter; no throm-
bosis of the femoral vein was observed in the iliac artery or inferior vena
cava. In conclusion, the cannulation of the femoral vein with a subcuta-
neous tunnel silicone catheter provided safe vascular access for HD in
ambulatory patients without causing functional limitations.
Anticardiolipin antibodies (aCL) in hemodialysis: fi2.glycoprotein I
dependence and clinical relevance. C. Bemis, N. Gomez, E. Muñoz de
Bustillo, E. Grnss, A. Fernandez, A. Cirugeda, G. Baird, P. Sanz, JA.
Sanchez-Tomero, 1/. Alvarez, and JA. Traver. Nephrology and Hematology
Departments, Hospital de Ia Princesa, UA.M., Madrid, Spain. Anticardio-
lipin antibodies (aCL) purified from patients with autoimmune disease
and thrombotic complications have recently been shown to interact with a
phospholipid plasma protein, f32-glycoprotein I (132-GP-I); however, aCL
from patients with infections do not interact with 132-GP-I and are not
associated with thrombosis. The aim of this study was to determine the
incidence of aCL in hemodialysis patients and whether aCL purified from
these patients interact with /32-GP-I. We studied 85 hemodialysis patients,
54 males and 31 females. The mean age of the patients was 59 14 years
and the mean time on dialysis was 28 39 months. Initial nephropathy,
type of dialysis membrane and clinical complications during one year were
documented. Blood samples were analyzed for platelet count, APIT, and
IgG-aCL and IgM-aCL via ELISA. We performed standard ELISA for
aCL (with 132-GP-I) in all patients. We performed modified ELISA
(without f32-GP-I) in patients who were positive for aCL on standard
ELISA. Positive results on modified ELISA was an indication that aCL
were present independent of 32-GP-I. Two patients were positive for
IgG-aCL independent of /32-GP-I. In 28 patients (32.9%), the presence of
aCL was dependent on the presence of 132-GP-I; 18 of these patients were
positive for IgG-aCL (mean value 64 7.8 vs. a normal value of 14 6.5),
10 patients were positive for IgM-aCL (mean value 35.5 8.4 vs. a normal
value of 8.4 3.2), and 2 patients were positive for both IgG-aCL and
IgM-aCL. There was no correlation between aCL and age, sex, initial
nephropathy, length of time on dialysis, or type of dialysis membrane. We
observed vascular access thrombosis in 3 of the 28 patients (10.7%) in
whom the presence of IgG-aCL and/or IgM-aCL was dependent on
f32-GP-I and in 9 of the 57 patients (15.7%) who did not demonstrate aCL
(P = n.s.). In conclusion, 32.9% of our hemodialysis patients demon-
strated aCL dependent on the presence of f32-GP-I, but they did not show
an increased incidence of vascular access thrombosis.
Study of the effect of induction of immunosuppression with OKT3 as
compared to conventional therapy using cyclosporine plus corticosteroids
in kidney transplantation. B. Martin, P. Garcia, J.L. Lerma, A. Bondia, L.
Corbacho, J.M. Tabernero, Servicio de NefrologIa, Hospital Clinico de
Salamanca, Spain. We evaluated the possible beneficial effect of the use of
OKT3 McAbs on cadaver kidney transplantation. Over a 2-year period, we
studied 68 patients receiving kidney grafts: two groups of 34 patients. One
kidney from each patient was assigned to a group. In one group, patients
received 5 mg/day OKT3 intravenously for four days before transplanta-
tion and on the day of transplantation, before the procedure (total of 5
days). They received steroids beginning at transplantation and cyclospor-
inc A beginning 72 hours afterwards. In the second group, patients
received cyclosporine A and steroids beginning at transplantation. In both
groups, cyclosporine A and steroids were administered according to the
same protocol. Both groups were similar with regard to age, male/female
ratio, time on hemodialysis, hot and cold ischemia time and HLA
incompatibility. We evaluated in both groups the incidence of acute
rejection, steroid-resistant rejection, acute tubular necrosis, graft survival
and serum creatinine levels. Results were:
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Acute Tubular Necrosis (X SD)° 0.35 0.43 0.44 0.50 NS"
Acute rejection (X SD)a 0.41 0.65
Steroid-resistant rejection (X so)" 0.05 0.23
Graft Survival (18 months) 88.89%
0.55 0.74
0.08 0.28
88.46%
NS'°
NS5
NS"
In conclusion, the group of patients receiving OKT3 had a lower incidence
of acute and steroid-resistant rejection and fewer of these patients had
tubular necrosis. Serum creatinine levels were less altered in the OKT3-
treated group, but the difference was not significant. At 2 years post-
transplant, graft survival was similar in both groups.
Renal transplantation: Induction immunosuppressive regimen with
ALG. Tenyears of experience. F.J. Pad! Ramos, R. Moreno, M.P. MartInez,
C. Gonzalez, A. Garbayo, L. Pastor, J. Perez, A. Sanjudn, L. Marzo, C.
Buñuel, J.A. Gutiérrez Colon, Nephrology and Hematology Departments,
Hospital "Miguel Sereet, " Zaragoza, Spain. Renal transplantation (RT) has
become thc most suitable therapeutical alternative for a great number of
patients undergoing dialysis treatment. A better knowledge of the immune
response, a well established surgical technique, a better control of
immediate post-transplant period and management of infectious compli-
cations and the development of new immunosuppressive drugs that are
more potent and selective have led to an important increase in patient and
graft survival rates. The kidney transplantation program started in our
Hospital in June 1986; 330 cadaver transplants have been done until
March 1996. Mean age for donors was 36.5 16.5 years (1—74); 66.8%
were male and 33.2% females. Death related to eraneoencephalic trau-
matisms occurred in 60.1% of donations vs. 31.9% due to hemorragic
brain events. Mean cold ischemia time was 18.1 4.3 hours (5.6 to 31.7).
Recipient's mean age was 47.5 13.5 years (17 to 71); 69.4% were male
vs. 3t).6% females. Patients' mean time of stay under hemodialysis
treatment was 44.8 36.4 months (2 to 216). Glomerular disease was the
most common cause of ESRD (39.7%) vs. 25.8% related to interstitial
diseases; 13.4% of recipients had polycystie kidney disease. All patients
received cyclosporine from the first day post-transplantation. A total of
234 patients (70.9%) were included in an inductive immunosuppressive
protocol with polyclonal antilymphocyte globulin (ALG) (10 mg/kg/day,
3—6 doses) in the immediate post-transplant period. The overall survival
rate for patients and grafts was 93.0% vs. 89.0 at 1 year, 91.9% vs. 86.2%
at 3 years, 84.7% vs. 76.9% at 6 years, and 81.3% vs. 71.1% at 9 years. The
incidence of acute tubular necrosis (ATN) (18.1%), acute rejection
epidodes (3 1.8%) and complications associated to immunosupression with
ALG wilt be evaluated in this study. The use of an induction protocol with
ALG in our kidney transplanted patients has shown an excellent graft and
patient short-term and long-term survival rate, reduced incidence of ATN
and acute rejection episodes, and a low rate of complications associated
with immunosuppression.
Perioperative changes in coagulation and in fibrinolysis; role of differ-
ent immunosuppressurs. J. Deira, J.I.. Lema, 1?. M'artIn, I. Alberca, A.
GascOn, f.M. Tahernero, Servicio de Alefrologla y HematologIa, Hospital
ClInco de Salamanca, Spain. To evaluate the effect of eyelosporine A and
of OKT3 McAbs on renal vessel thrombosis immediately after kidney
transplantation, we studied 19 transplant recipients. Ten patients (Group
A) received 5 mg/kg/day of OKT3 and prednisone for the first five days
after transplant. Nine patients (Group B) received eyclosporine hours
hefi)rc transplantation and in the post-transplant period at doses sufficient
to maintain therapeutic levels as well as prednisone at doses similar to
those given to patients in Group A. One kidney from each donor was
assigned to a group. Blood samples were collected before the surgical
procedure and at 2, 4, and 24 hours after the induction of anesthesia;
samples were immediately stored at —20°C. There were no differences
between groups with regard to age, time on hemodialysis, hemoglobin,
platelets, the usual coagulation parameters, hepatic function, HLA com-
patibility, or cold ischemia. In both groups, the following were measured:
1) coagulation activation markcrs—prekalikrein (PKK) and thrombin-
antithrombin complexes (TAT); 2) markers of endothelial damage—
thrombomodulin (TMD) and plasminogen tissue activator (tpA); 3)
suppressors or inhibitors of hemostasis—antithrombin III (AT-Ill) and
protein C (PC); and 4) markers of librinolysis—plasminogen (PGL) and
a-2 antiplasmin (n2APL). In both groups (see Table), there was a
significant activation of coagulation (PKK consumption and TAT forma-
tion) and fibrinolysis (decrease in PLG and a2APL), and a decrease in
inhibitors of hemostasis (AT-Ill and PC). These findings suggest that the
hypercoagulation state and subsequent fibrinolysis may be the result of
surgery. Patients receiving OKT3 had increased tpA levels at 2, 4, and 24
hours as compared to the group receiving cyclosporine A (P < 0.0001),
with no differences in TMD between the groups—pointing to a slight
degree of endothelial damage. In conclusion, we found that coagulation is
activated 2 hours after transplantation and persists for at least 24 hours.
Also, the fall in AT-Ill and PC levels could be responsible for the risk of
thrombosis in kidney transplantation, regardless of the immunosuppressor
used.
PK.K PLG cs2APL
Basal
2hours
4hours
24hours
94±8
84±7
88±9
66±9
OKT3
9±2
28±6
34±7
20±3
98±9
79±4
77±7
59±4
t02±5
92±8
83±5
79±5
AT-Ill PC tpA TMD
Basal
2hours
4 hours
24 hours
95 6
78±5
70 952 6
124 9
97±7
91 863 7
5 1
26±3
29 3
15 1
270 29
224±31
219 32
184 25
yclosporine A
Basal
2hours
4hours
24hours
87±6
76±5
78±6
56±4
8±1
13±4
20±3
22±4
89±3
77±4
75±4
63±3
101±2
89±2
89±4
81±3
Basal 93 4 121 9 4 1 328 22
2 hours 82 5 101 8 7 2 242 29
4hours 76±5 91±8 10±3 227±23
24hours 65±5 73±6 7±2 194±20
Effect of the new HMGCOA reductase inhibitor fluvastatin on the
treatment of hypercholesterolemia after renal transplantation and with
cyclosporine immunosuppression; preliminary results. .4. M. Castelao,
f.M. GriñO, C. Fiol, M.J. Ca.ctineiras, I. Hurtado, S. Gil Vernet, D. Serón, I.
Porta, A. Mibarro, A. Villarroya, and J. Alsina, Hospital Princeps d'Espanya.
CS. U. Bellvitge, University of Barcelona, Spain. We conducted a pilot study
to investigate the effect of Fluvastatin (Fluv) on renal transplant recipients
with persistent hypercholcsterolemia (above 6.5 mmol/liter) after 3
months of dietary lipid restriction. We treated 20 patients (12 males and
8 females, mean age 46 10 years) with Fluv, 20 mg/day, along with
cyclosporine A and prednisone, for 12 weeks. After that time period, the
9 patients with hypereholesterolemia greater than 6.3 mmol/liter were
given 40mg/day Fluv (Group I); the 10 patients with hypereholestcrolcmia
less than 6.3 mmol/litcr (Group II) continued to receive 20 mg/day Fluv.
One patient developed nausea and vomiting after three weeks and was
excluded from the study. Biochemical and lipid measurements in blood
were:
Group t Group II
0KT23 Cyclosporine A P
= median; h NS = no significant difference
TAT
Creatinine pinol/liter
Protein uria g/day
Total cholesterol
mmol/liter
After
Before 12 months Before
treatment treatment treatment
134 43" 161 64 175 41
t).35 0.27 0.64 0.8 0.48 1 0.5
7.2 0.5 5.66 0.7" 8.2 0.7
After
12 months
treatment
176 .52
0.6 0.6
6.7 0.6"
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Group I Group II
After After
Before 12 months Before 12 months
treatment treatment treatment treatment
Triglycerides mmol/ 2.8 0.8 1.66 0.9 2.6 1.8 3 1.5
liter
HDLmrnol/liter 1.6 0.4 1.42 0.4 1.2 0.4 1.2 0.3
LDL mrnol/liter 5.1 0.5 3.64 0.6' 5.9 0.6 4.3 0.4
VLDL mmol/liter 0.5 0.4 0.59 0.2 0.9 0.4 II 0.6
Apo Al gIlder 1.6 0.6 1.54 0.4 1.6 0.2 1.1 0.6"
Apo Bg/liter
______-
1.4 0.1 I 1.5 0.1 1.3 0.3
P < 0.05
There were no significant increases in ALT, AST or CPK. Plasma levels of
cyclosporine A increased significantly in week 13 of the study (from 196
50 to 229 49 nmol/liter, P = 0.05), hut decreased thereafter. After 12
months of treatment, total cholesterol had decreased 21.3% in group land
18% in group II. In conclusion, Fluv significantly reduced total cholesterol
and LDL cholesterol levels, with no severe side effects.
Induction of immunosuppression with antilymphocyte globulin after
renal transplantation; ten years of experience. F.J. PaOl Ramos, R.
Moreno, M.P. Martinez, C. Gonzalez, A. Garbayo, L. Pasta,; J. Perez, A.
Sanjudn, L. Marzo, C. Bufluel, and iA. Gutiérrez Colon, Nephrology and
Hematology Departments, Hospital "Miguel Servet, "Zaragoza, Spain. Renal
transplantation (RT) has become the most suitable therapeutic alternative
for patients undergoing dialysis. Increased graft and patient survival rates
have developed as a consequence of greater knowledge of the immune
response, experience with surgical technique, better medical control of the
immediate post-transplant course, and the advent of more potent and
more selective immunosuppressive drugs. From June, 1986, when our
transplant program began, to March, 1996, 330 cadaver kidney transplants
were performed in our hospital. The mean age of donors was 36.5 16.5
years (range, 1—74 years); 66.8% were males and 33.2% females. Death
related to cranioencephalic trauma occurred in 60.1% of donors; death
related to brain hemorrhage occurred in 31.9%. The mean cold ischemia
time was 18.1 4.3 hours (range, 5.6—31.7 hours). The mean age of
recipients was 47.5 13.5 years (range, 17—71 years); 69.4% were male
and 30.6% female. Mean length of time on dialysis was 44.8 36.4 months
(range, 2—2 16 months). Glomerular disease, occurring in 39.7% of kidney
transplant recipients, was the most common cause of end-stage renal
disease in these patients, followed by interstitial diseases (25.8%) and
polycystie kidney disease (13.4%). All patients received cyclosporine from
the first day post-transplantation. In the immediate post-transplant period,
234 patients (70.9%) were given polyclonal antilymphocyte globulin
(ALG), 10 mg/kg/day, 3—6 doses, to induce immunosuppression. Overall
survival rate for patients and grafts was 93.0% vs. 89.0% at 1 year
post-transplant; 91.9% vs. 86.2% at 3 years post-transplant, 84.7% vs.
76.9% at 6 years post-transplant, and 81.3% vs. 71.1% at 9 years
post-transplant. The incidence of acute tubular necrosis was 18.1% and
the incidence of acute rejection was 3 1.8% in the ALG-treated group. In
conclusion, the use of Al.G to induce immunosuppression has been
associated with excellent graft and patient short-term and long-term
survival, a reduced incidence of acute tubular necrosis and acute rejection
episodes, and a low rate of immunosuppression-related complications.
Predictive value of BANFF criteria in acute rejection of kidney trans-
plant. Comparison with immunohistochemical quantification of glomeru-
lointerstitial infiltrate. A. Osuna, C RamIrez, R. Esteban, F. O'Valle, .1.
Osorio, M. GOmez-Morales, C. Asensio, R. Carvia, and R.G. Del Moral,
Department of Pathology, University hospital, Nephrology Service, Vigen de
las 1\I,eves Hospital, Granada, Spain. The progressive introduction of the
BANFF criteria for the diagnosis of acute kidney transplant rejection has
facilitated the unification of pathological criteria that define rejection, and
has made it easier to reach a decision regarding appropriate treatment.
However, problems remain with the interpretation of these criteria, and
their predictive value regarding the future functioning of the transplanted
organ has yet to he determined. We present a comparative study of the
BANFF criteria and more traditional systems based on histological
classification (vascular, interstitial and severe glonierulointerstitial rejec-
tion) and on counts per mm2 of inflammatory glomerulointerstitial
infiltrates. We studied 42 biopsies from patients with acute kidney
transplant dysfunction. None of the patients had received prior treatment,
and all were diagnosed histopathologically on the basis of conventional
criteria. These biopsies were subsequently studied according to BANFF
criteria by two independent observers. When the results between the two
observers were discrepant, they were agreed on by consensus. Frozen
sections of the biopsy material were prepared for standard Counts of
glomeruli and interstitial leukocyte subpopulations, using mAbs that
recognized CD45, CD3, CD4, CD8, CD16, CD2O, CD57 and CD68.
Reclassification on the basis of BANFF criteria revealed a high proportion
of borderline rejections (28.6%) in Comparison with 7% borderline cases
found with counts of inflammatory infiltrating cells in the renal intersti-
tium. Deterioration of renal functioning, measured as serum ereatinine
level at the end of clinical treatment, was not related with the classification
obtained with BANFF criteria, or with interstitial counts of infiltrating
leukocytes in the transplanted organ. In contrast, final serum ereatinine
levels were strongly associated with glomerular infiltration determined
with CD3 (r = 0.50, P < 0.01), CD8 (r = 0.41,P < 0.05) and NK cells (r =
0.71, P < 0.001). In conclusion, (1) although the BANFF criteria facilitate
the classification of moderate and severe acute rejection reactions, they do
not firmly distinguish between slight or borderline rejection and other
causes of acute transplant dysfunction. (2) The presence of severe
glomerulitis (CD8+ T cells and NK cells) is of greater value than the
BANFF criteria in predicting progression toward renal insufficiency.
P-glycoprotein expression in peripheral blood lymphocytes in kidney
transplant patients. Relationship with acute rejection. F. O'Valle, A.
Osuna, F. Arrebola, G. Alvarez, M. Guillen, T Martinez, C. Asensio, and
R.G. Del Moral, Dept. of Pathology, University Hospital, Nephrology Service,
Virgen de las Nieves Hospital, Granada, 18012, Spain. P-170 glycoprotein
(P-gp) is a detoxicant system related with multidrug resistance (MDR) in
some tumors. The protein removes hydrophobic substances such as
chemotherapeutic and immunosuppressive agents, including eyclosporine
A (C5A), from the cell. Transplant patients who develop rejection
refractory to treatment have high levels of mRNA for P-pg in circulating
lymphocytes. We tested the hypothesis that CsA induces overexpression of
P-gp in lymphocytes in transplant patients, and this may condition the
appearance of acute rejection and the response to treatment with steroids.
We studied 123 patients: 105 with kidney transplant, treated with GsA; 18
on hemodialysis; and 15 healthy controls. Acute rejection was treated with
a holus of steroids, and if resistance was found, with monoclonal antibody
OKT3. In all patients we assessed clinical and laboratory findings, and
took blood samples to monitor P-gp with flow cytometry and indirect
immunocytochemistry using mAb JSB1, which recognizes an intracyto-
plasmic epitope of P-gp. Statistically significant differences were found
between the percentage of lymphocytes that expressed P-gp in transplant
patients (32 18), patients on hemodialysis (20.4 14), and healthy
controls (8.9 4.2) (Anova, P < 0.05). The number of P-gp molecules per
cell was also increased (17.8 8 vs 13.1 11, P < 0.1). In patients with
acute transplant rejection, the mean percent expression of P-gp was 47.9
18%, vs 29.25 17% in transplant patients without rejection (P < 0.05).
P-gp expression was highest in patients with acute rejection resistant to
steroids (52.4 25, vs 45.9.9 16 in patients with nonresistant rejection),
although the difference did not reach significance. In conclusion, P-gp is
elevated in kidney transplant patients treated with CsA, and this increase
is related to acute rejection. Measurement of P-gp in peripheral blood can
he of use in predicting acute rejection, and in detecting resistance to
treatment.
Pneumonia in patients with renal allograft. A. Solis, ii. Amenahar, 1.
Gimeno, L.M. Ruiz-Muñoz, P. Gomez-Ullate, I. I.ampreabe and L.A. Ruiz,
Nephrology Department, Cmces Hospital, Baracaldo, Basque Country,
Spain. We wanted to study the incidence, clinical and microbiological
findings of the pneumonic episodes detected in our transplanted popula-
tion. Pneumoniae registered in our renal transplantation program be-
tween l-l-85 and 3 1-12-95 have been included. Pneumonia was defined as
an inflammation of the pulmonary parenchyma with clinic and thorax RX
compatible. A total of 89 pneumonic prOcesses were found among in 807
transplant recipients. They were 59 males and 30 females with an average
age of 47 (range 15—73). The average post-transplant time was 592 841.
Seventeen patients were receiving azathioprine and prednisonc (19.3%),
33 cyclosporine and prednisone (37.5%), 37 triple therapy (41.5%), and 30
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patients had been treated in one occasion with methylprednisolone as
antirejection therapy (34%). Ten were treated more than once (11%) and
3 with Ac OKT3 (3.3%). The pneumonic episode was bilateral in 35
patients (47.3%). There was moderate-severe hypoxemia (PO2 < 60) in 13
(14.6%) and venial (PO2 < 70) in 31(34.8%). Nine required intubation.
Bronchoalveolar lavage was practiced in 39 patients (48%) and found
positive in 28 (72%). Positive hemoeultures were in 26 (31.3%) and
positive sputum cultures in 13 (16.2%). The final microbiological diagnos-
tic in 48 of 89 (55.2%) found the following microorganisms: 17 CMV
(19%), 10 M. tuberculosis (11.2%), 8 P. Carinii (9%), 7 Aspergillus (8%),
3 Pseudomonas, 2 Nocardias, 2 Salmonellas, 2 S. pneulnoniae and 9 others
(10%). In 6 of 8 cases CMV and P. Carinij coincided; in 3 of 10 CMV and
M. tuberculosis and in 3/7 CMV and Aspergillus were together. Treatment
wasn't introduced before the diagnostic attempt in 15 (17%); in 35 (39%)
the initial treatment wasn't modified, and in 29 patients (32.5%) it was
modified. The outcome in 66 cases was to recovery (74%) and in 23 to
decease (26%); in 6 episodes the responsible agent was CMV, in 4 M.
tuberculosis, in 3 P. Carinii and in 3 Aspergillus. The average hospital stay
was 26.97 19.75. Pneumonia is an important pathology among trans-
planted patients, due to both incidence and severity. Among the etiologies
CMV, P. Carinii, M. tuberculosis and Aspergillus stand out. Polymicrobial
infections are frequent and severe, being especially outstanding with
regards to CMV.
Clinical characteristics in cyclosporine-treated and non-cyclosporine-
treated adult renal cadaveric allograft recipients. I. Lampreabe, J.J. Ame-
nabar and the Spanish Transplant Cooperative Group, Nephrology Depart-
ment, Cruces Hospital, Basque Country, Spain. We investigated the clinical
transcendence of the novo cancer, in adult patients who received renal
cadaveric grafts, in relation to different immunosuppressive protocols.
This retrospective study was performed in 6292 Spanish adult renal
eadaveric allograft recipients. We included 2398 (38%) treated with
azathioprine-prednisone (CIT group) and 3985 (62%) receiving cyclospor-
me (C5A group) as part of monotherapy (CsA), double (CsA + Pr), triple(CsA + Pr + Aza) or quadruple-therapy (CsA + Pr + AZA +
ALG/ATG) protocols. Both groups were followed for 6 years. The number
of patients at risk in each annual post-transplant interval and the total
patient-year at risk were calculated. The cancer incidence in renal
transplant patients, using the patient-year method and the actuarial
survival, was estimated according to the log-rank test. Overall, 113 patients
(2.8%) in the CsA group and 71 patients (3%) in the CTI group developed
cancers. The malignancies were located in the CIT group and CsA group,
respectively: skin and lip cancers 46% and 45%, Kaposi sarcoma 5.6% and
11.4%, lymphoma 7% and 15%, and uterine cancer 2.8% and 6.2%. The
prevalence of skin cancers in transplant recipients was higher than the
same variant of cancer prevalence in general population. Furthermore,
CsA treated patients had a higher incidence of basal cell carcinoma, than
non-CsA group (P < 0.005). The squamous cell carcinoma/basal cell ratio
varied dramatically from 1.38 in the CIT group to 0.4 in the CsA group.
The diagnostic interval in lymphoma, squamous cell carcinoma and basal
cell carcinoma was shorter in the CsA group. In the actuarial analysis, the
accumulative risk in CsA group to develop skin malignancy and non-skin
malignancy, after 6 years, were 41 and 33 per 1000, respectively (P <
0.001). However, in the CIT group they were 12 and 20 per 1000,
respectively. The cummulative risk to develop hasocellular carcinoma cell,
after six years, was 33 per 1000 in the CsA double therapy group, 10 per
1000 in the CsA triple therapy group, and 4 per 1000 in the CIT group. In
the short-term, in immunosuppressive theraphy, there is a contrast
between the benefit and the risk of cancer. The incidence of skin cancer
and, especially hasocellular carcinoma cell, increased in therapy with CsA.
Malignancies after renal transplantation. Comparative patterns with
the general population. G. Fernández-Judrez, J. Pascual, L. Orojino,
F.J. Burgos, V Gómez, T Cano, A. Tato, F Liano, andi Ortuho, Servicios
de Nefrologla y Urologla, Hospital RamOn y ('ajal, Madrid, Spain. Malignant
neoplasia is a major cause of morbidity and mortality in the renal allograft
recipient. The epidemiologic patterns seem to be quite different in these
patients (pt) than in the general population. Between 1979 and 1995, 609
renal transplants (RT, 595 cad, 14 liv) in 559 pt (393 males) were
performed in our Unit. Basal immunosuppression was azathioprine and
steroids (Aza-P N = 205) or cyclosporine A and steroids (CsA-P N = 404).
Poly- or monoclonal antibodies were not used. Thirty malignant tumors
were diagnosed in 29 (5%) pt (84% male). The age at RT was 56.3 8
years and the age at the diagnosis was 60.7 9 years (mean time before
neoplasia 4.4 years post-RT, similar with Aza-P and CsA-P). The tumors
were: cutaneous carcinoma (N = 15), Kaposi (N = 3), cutaneous
T-lymphoma (N = 2), pulmonary epid carcinoma (N = 3), adenoca (N =
5) (2 native kidneys, 1 colon, 1 gastric, I prostatic), melanoma (N 1) and
astrocytoma (N = 1). The occurrence of malignant tumors was similar
with Aza-P (N = 14) and CsA-P (N = 16) (NS); the 3 lung tumors were
found in a Aza-P pt, and the 2 T-lymphomas in the CsA-P pt. We
compared observed cases (0), expected cases (E: years at risk X known
annual incidence in general population), and the O/E ratio:
Lung Gastric Colon Lymphoma Prostatic
O 3 1 1 2 1
E 0.95 0.6 0.67 0.24 0.78
O/E 3.13
—
1.65 1.47 8.02 1.26
Mortality with tumor was 35% (13% with cutaneous neoplasia, 100%
adenoca). The risk of suffering from any malignant neoplasia after RT was
multiplied by 86. The risk of lung neoplasia triplicated that of general
population and the risk of cutaneous lymphoma was multiplied by 8. No
cases of postRT B cell lymphoproliferative disease were observed (no
antibodies used!). The absence of breast or cervix cancer, frequent in
healthy females is noteworthy. The use of CsA-P since 1986 does not
represent any significant modifications in the patterns of cancer in our RT
recipients.
Influence of blood pressure and antihypertensive drugs on Doppler
spectrum analysis of the renal allograft. L. Sanchez, J. Pascual, F.J. Bur-
gos, L. Orofino, V Gómez, G. Ferndndez-Judrez, A. Tato, T. Cano, F. Liaho,
and J. Ortuño, Servicios de NefrologIa y Urologla, Hospital Ramón y Cajal,
Madrid, Spain. The prevalence of hypertension (HT) in the renal trans-
plant population is very high, and its importance as a risk factor for graft
dysfunction and patient survival is unquestionable. Doppler spectrum
analysis has been used mainly to detect renal artery stenosis, but general
patterns of blood flow and the influence of different antihypertensive
drugs on them have been less frequently assessed. During two years, 232
renal allograft patients underwent such an analysis: 111 were normoten-
sive (Group I), 92 had well-controlled HT (II) and 29 poorly-controlled
HT (III) at the time of the study. Acceleration (AC), mean velocity (MV),
peak systolic velocity (PSV) and minimal diastolic velocity (MnDV), as
well as pulsatility (P1) and resistance index (RI) were measured in the
external iliac, main renal, segmental, interlobar and arcuate allograft
arteries. Patients from Group III had higher RI in the external iliac
(ANOVA P < 0.01) and arcuata arteries, higher P1 in the external iliac
and lower PSV in the segmental and interlobar arteries (all P < 0.05).
Patients taking nifedipine (N = 62) had lower PSV in the interlobar
arteries than the remainder (24.3 1.3 vs. 27.8 0.9 cm/see, P < 0.05).
Patients taking beta blokers (N = 49) had lower MnDV in the external
iliac (10.5 1.2 vs. 13.5 0.7 cm/see, P < 0.05), higher MnDV in the
segmental artery (9.5 1.1 vs. 7.5 0.4 cm/see, P < 0.05), lower RI in the
segmental artery (0.71 0.02 vs. 0.76 (1.01, P < 0.05) and lower P1 in
the interlobar artery (1.46 0.07 vs. 1.73 0.06, P < 0.05). HT induces
renal graft blood flow changes detectable by Doppler spectrum analysis.
External iliac artery shows high RI and P1 in hypertensive patients. Beta
blokers reduce RI in large vessels and calcium antagonists lower RI and P1
in small caliber intraparenchymatous vessels. Use of combinations of these
drugs could be adequate for controlling renal transplant-associated HT.
Doppler spectrum analysis might be useful in adjusting the most favorable
combination.
Relationship between iliac artery histology and hemodynamic patterns
in the renal allograft. T Cano, .1. Pascual, F.J. llurgos, V. Gó,nez, I..
Orojino, G.F. Juárez, F. !,iaño, J. Ortuño, Seivicios de Neji-ologIay Urologla,
hospital Ramón y Cajal, Madrid, Spain. Correct assessment of aortoiliac
atheromatosis prior to kidney transplantation (KT) is essential. Doppler
ultrasound (DU) is a noninvasive technique that provides an accurate
hemodynamie study of the iliac and limb arteries, hut the correlation of
the lindings with real histology is unknown. Seventy K'l recipients were
studied with DU immediately before KT. Acceleration (AC), mean (MV),
maximal systolic (MxSV), minimal diastolic (MnDV) velocities (in Cm!
see), and pulsatility (Pt) and resistance (RI) indices were measured. We
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performed an arterial biopsy during the KT surgical procedure in 26 of
them, and a histological study was made. Total arterial thickening was
1150 48 jz (intima 92 43, medium 626 21 and adventitia 430 31).
In 19% of the patients atherosclerotic plaques were observed, 4% of them
with calcification. No relationship was found between arterial thickness
and DU parameters. Several significant differences were found in Dli
parameters between arteries with and without atheromatosis (means
SD):
AC MV MxSV
No atheroma 757 122 13 2 62 9
Atheroma 592 101 6 1 50 7
P <0.01 <0.05 <0.05
MnDV P1 RI
No atheroma 21 2 7 2 1.38
Atheroma 1.43
P
19±1 6±1
NS NS 0.1
AC, MV and MxSV are lower in iliac arteries from KT with atheroscle-
rosis. Illfemoral DU is a useful tool in the evaluation of atheromatosis and
its severity in the KT recipient, and could he used in follow-up assessment
and interventional studies.
Treatment of cyclosporine-induced gingival hyperplasia with azithro-
micyn in renal transplant patients. I. Beneylo, J.Sanchez, I. Torregrosa, J.
Garcia, J. Panadero, D. Ramos, A. Soldevila, A. Rochera, and f.M. Cvz,
Nephrologr Service, Hospital Ia Fe, Valencia, Spain. Gingival hyperplasia is
one important adverse effect of cyclosporine therapy that affects 30—70%
of renal transplant patients. It appears to he worsened by the concomitant
administration of nifcdipine or phenytoin. Until now, we could only to
advise patients of hygienic measures for oral cavity prevention, although
the hyperplasia can appear in healthy mouths as well. Recently, however,
have reported the utility of Azithromicyn in treatment of gingival hyper-
plasia. To verify the efficacy of this drug, we administered 500 mg on the
first day and 250 mg over the next four days, to a group of fourteen
patients (8 men and 6 women), aged 27 to 67 years, with gingival
hyperplasia. Eight of these patients were treated simultaneously with
nifedipine. We measured the levels of cyclosporine before and five days
after treatment. All the patients improved after treatment, only one
patient did not have any effect from the drug. At the beginning of therapy
gingival bleeding after teeth brushing disappeared, and in next days the
patients had less gingival erythema and retraction of the gums in various
degrees. Blood levels of cyclosporine and creatinine did not show any
significant change during treatment. The drug was well tolerated.
Azitromicyn is an efficient treatment of cyclosporine-induced gingival
hyperplasia, and is without adverse effects.
Risk factors predicting primary chronic dysfunction of renal allografts.
J.J. Amendbar, F. GarcIa -Lopez, P. Gómez-Ullate, 1. Minguela, ML. Muhiz,
I. Lampreabe. Nephrology Service, Cruces Hospital, Baracaldo, Epidemiol-
ogy Unit, Puerta de Hierro Hospital, Madrid, Spain. The risk factors leading
to the development of allograft chronic dysfunction are not fully under-
stood. In this study we have included 197 from a total of 250 renal
transplant recipients who participate, at our center, in a randomized trial
comparing Double Therapy (CsA + Est) and Triple Therapy (CsA +
Est + Aza). We excluded 53 patients who lost the allograft or had chronic
renal dysfunction by causes other than chronic rejection. Patients were
followed from 1 to 4 years. The slope () of 1/creatinine over time,
analyzed by simple linear regression, was calculated in every patient. A
diagnosis of chronic renal dysfunction was stated in patients with negative
, significantly different from zero (P < 0.005). Simple and multiple
logistic regressions were performed using the following covariates: recip-
ient and donor age and gender, primary cause of renal failure, time on
dialysis, number of transplants, latest and highest PRA, HLA A-B-DR
mismatches, initial graft function and cold isehemia time. The best
multiple logistic regression model is shown in the table.
Variable Coeflicient
Odds ratio
(95% CI) P
Recipient age —0.040 0.96 (0.93—1) 0.036
Female recipient —1.147 0.32 (0. 12—0.83) 0.015
Female donor
Transfusions (N = 5)2
1.154
0.001
3.17 (1.29—7.76)
1(0.99—1)
0.011
0.06
The goodness fit of this model was high. Confounding and interaction tests
were not significant. To linearize the number of transfusions (N) a square
transformation was performed. The mean of transfusions received by
patients was 5. The youngest patients, male recipients, female donors and
both non-transfunded patients and those with many transfusions are
associated with higher rate of chronic renal dysfunction.
Recurrent focal glomerulosclerosis (FGS) in the renal transplant.
Apheresis therapies. MC. Vozmediano, F. Anaya, E. Verde, L. Inchaus-
tegui, P. Rodriguez, ML. Rodriguez, I. Lorenzo, F. Gómez, and F. Valder-
rabano, Nephrology Department, Hospital "Gregorio Marañón," Madrid,
Spain. FGS is the most important recurrent glomerulopathy in the renal
transplant. Six patients (5 M; 1 F) with a histologic diagnosis of early
recurrent FGS were studied. The mean age was 20 10 years. Three
patients were treated with apheresis therapies, plasmapheresis (PF) and
inmunoadsorption (lADS), immediately after the onset of proteinuria.
The first patient was treated with six sessions of PF. He had a remission of
proteinuria and renal function has remained stable. The second patient, a
19-year-old girl who received a third transplant, had lost the previous
grafts to recurrent FGS. She was treated with two courses of PF (10
sessions) with a partial reduction of proteinuria (mean total urine protein
excretion before PF, 14 g/day; after PF, 3 g/day). A course of lADS (1
session/week) with phenylalanine was initiated during 50 days with no
changes noted in proteinuria and renal function (serum creatinine 1.5
mg/dl). When apheresis treatment was discontinued creatinine clearance
decreased significantly and hemodialysis therapy was required three
months later. The third patient, a 20-year-old man who received a second
transplant, was treated with lADS (6 sessions) rapidly after the Onset of
proteinuria. Subsequently he experienced a notorious decrease in protein-
uria. His urine protein excretion and renal function has remained stable
with a serum creatinine levels about 1.8 mgldl, which are unchanged in last
5 months. Apheresis therapies were not used in three of the six patients.
Proteinuria remitted spontaneously in one of them. Renal function
deteriorated and long-term dialysis was required in the other two patients.
In conclusion, recurrent FOS in renal transplant is a severe disease,
usually leading to graft loss. FGS is generally unresponsive to conventional
treatment. Our experience indicates that apheresis therapies could be
effective in the treatment of recurrent FGS.
Effect of angiotensin converting enzyme inhibitors (ACEI) on the
progressive graft failure and proteinuria in kidney transplant (KT)
patients with chronic rejection. D. Paredes, R. So/a, L. Guirado, .J. Ibeas, I.
Agraz, D. Vizcarra, F. Alga ha, A. Oliver, Kidney Transplant Unit, Nephrology
Service, Fundacion Puigvert, Barcelona, Spain; Department of Nephrology,
Medical School, Universidad Nacional de Colombia, Bogota, Colombia;
Section of Pathology and Service of Laboratories, Fundacion Puigvert,
Puigvert, Spain. Chronic rejection (CR) is a progressive graft failure (GF)
appearing in some KT months or years after transplant, which is usually
resistant to modifications in immunosupressive treatment. It could he due
to immunologic and nonimmunologic mechanisms, such as a compensa-
tory glomerular hyperfiltration (GHF) of the remanent nephrons, when
multiple factors (isehemia, acute rejection, etc.) decrease an already
reduced nephron population (single KT, suhoptimal donors), such as in
diabetic nephropathy (DN). A protective effect of some ACEI has been
described in DN by decreasing this GHF. By analogy, we studied the
effects of eaptopril and enalapril in patients with CR assuming that they
have UHF. From patients with KT performed between January 1984 and
December 1994, we selected 21 patients: 15 male and 6 female, ages
ranging from 14 to 62 years. The chronic inmunosupression (CI) was
respectively cyclosporine and prednisone (PDN), both in combination
with azathioprine (AZA), or PDN with AZA in 13, 6 and 2 patients. When
other treatable causes of GF have been ruled out, CR was suspected when
a progressive proteinuria (Protu), a sustained increase in serum creatinine
(Cr) or both, were present (5, 3 and 13 cases). A kidney biopsy (KB)
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confirmed the diagnosis of CR (Banif classification). Eleven patients
started captopril (25 mg/day) and 10 enalapril (5 mg/day), and continued
indefinitely. The final doses were adjusted to blood pressure. If necessary,
in the 17 previously hypertensive patients other antihypertensive therapies
were modified. Clinical evaluation, Cr, 24 hour Protu, cyclosporine A
levels, and other hematological and biochemical index were performed
quarterly. The medium values of Cr, reciprocal of Cr (1/Cr) and Protu are
shown in the Table, begining 9 months before ACEI started, until 2 years
of follow-up. The follow-up was 1 year in all patients, 2 years in 14, and 3
years in 11 patients. For statistical analysis a MANOVA (SPSS) for
repeated measures was used. Comparing the periods before and after
ACEI, the tendency in the increase in Cr and the respective reduction in
1/Cr were stopped to remain stable. The sustained increase in Protu was
reversed, especially in the first semester and remained stable too. The
differences in both tendencies were statistically significant (Table). These
results were independent of the ACEI used, the grade of CR, the
antihypertensive therapy and the type of CI. No adverse effect was
observed with AECI.
-9m -6m -3m AECI +3m +6m
Cr p.mol/liter 156.4 165.1 171.4 187.6 192.1 194.2
1/Cr (X 10) 7.14 6.81 6.58 6.15 6.01 5.96
Protug/day 0.75 1.34 1.85 2.84 2.22 1.32
+9m +12m +24m P
Cr pinol/liter 192.3 204.8 192.4 0.044
1/Cr (X 10—i) 6.09 5.89 6.19 0.012
Protug/day 1.27 0.97 1.05 0.014
In our group of patients with CR, the patients use of an ACEI reduced the
progressive GF and the degree of proteinuria significantly, and patients
continued to be stable after two years of follow-up. Those effects could be
due to the hemodynamic actions of the ACEI in decreasing a supposed
already established GHF.
Natural killer cell subsets and coexpression of activated antigens in
TCRa3 and TCRyI5 T-lymphocytes in peripheral blood of patients with
acute rejection of renal allograft. A. Gascón, A. Oifao, J.L. Lerma, J.
Ciudad, A. L6pez, E. Iglesias, f.M. Tabernero, S. Nephrology and Cytomet,y,
University. Hospital, Salamanca, Spain. The allospecific cytotoxie immune
response by T lymphocytes and/or NK-cells plays an important role in the
pathogenesis of acute rejection of renal allograft (ARRA). The aim of the
present study was to analyze the coexpression of the CD25 and HLA-DR
activation-associated antigens in both the TCRa+/CD3+ and the
TCR-yb+/CD3+ T-cells, and the distribution of different NK-cell subsets
(CD3-CD16+CD56+, CD3-CD16+CD56-, CD3-CD16--CD56+) in
peripheral blood (PB) of patients with histologically well-defined ARRA.
A total of 11 patients and 18 healthy controls were studied. PB samples
were analyzed by three-color flow cytometry analysis. Results expressed in
absolute numbers and percentage of the total TCRa, and the total
TCRyb and NK-cells in brackets are shown below.
TCRcsJ3+ o/3+CD25+ nf3+DR+
CONT
RA
1-test
1092
605
P < 0.01
347(32%)
343 (62%)
153 (14%)
333 (55%)
TCRyb+ yb+CD25+ yb+DR+
CONT
RA
t-test
68
29
P < 0.02
18(17%)
5(11%)
10(14%)
19(53%)
NK Total CD16+CD56+ CD16+CD56- CD16—CD56+
CONT 351 301 (86%) 30 (8%) 20 (6%)
RA 150 69 (46%) 33 (20%) 59 (34%)
t-test P < 0.01 P < t).001 P < 0.05
In summary, our results show that there is an increased percentage of
TCRn+ cells that coexpress the CD25 and HLA-DR activation associ-
ated antigens in patients with ARRA. Interestingly, the expression of
HLA-DR on the yfi T-eells, but not that of CD25, is also increased. These
results indicate that different mechanisms may be involved on the activa-
tion of a/I and yb T-cells in acute rejection of renal allograft. The ARRA
induces a redistribution of the PB NK-cell subsets with a significant
decrease of the mature CD3—CD16+CD56+ cells and a significant
increase of the immature CD3—CDI6—CD56+ NK-subset, suggesting
that ARRA patients may have a decreased NK-celI cytotoxic activity.
Prednisone withdrawal more than five years after cadaveric renal
transplant. P. Gómez-Ullate, if. Amenabar, I. Minguela, ML. Mu/liz, M.P.
Martinez, S. Zdrraga, and I. Lampreabe, Se,vicio de Nefrologla, Hospital de
Cruces, Bilbao, Spain. We evaluated the safety and clinical benefits of
withdrawing prednisone (P) in 50 cadaveric renal transplant patients who
had stable renal function for at least 5 years and who were receiving P and
cyclosporine A (CsA) for immunosuppression. All patients had received a
first cadaver transplant in the time period July 1980 to December, 1988.
All patients were over the age of 15 years, and all had a serum creatininc
(Sr) level less than 2 mg/dl, proteinuria less than 0.50 mg/mm, and PRA
less than 25%. None of the patients had experienced acute or chronic
rejection of the transplanted kidney. All patients gave their written
permission to be included in the study. We selected 25 patients at random
to continue receiving both CsA and P, and 25 patients for the P-
withdrawal group. There were no differences between the groups with
regard to age, gender, B-DR mismatches, previous transfusions, immedi-
ate graft function, age of donor, or cold ischemia time. In the P-withdrawal
group, doses of P were gradually tapered over a period of 3 months. There
were no episodes of rejection in the control group. There was no graft loss
or death in either group. Five patients in the P-withdrawal group (20%)
who experienced acute rejection were treated with oral or intravenous
6-MP pulses and returned to the double therapy regimen. Clinical
tolerance of P withdrawal was good in 18 of the 25 patients (72%), average
in 3 (12%) and poor in 4 (16%). One patient could not tolerate the
protocol and was withdrawn from study. None of the patients in either
group exhibited a change in body weight. The incidence of hypertension
was reduced from 64% to 52% in the P-withdrawal group and from 68%
to 62% in the control group. In the P-withdrawal group, significant
differences (P < 0.01) were documented between pre-withdrawal values
and 2-year post-transplant values for: S, (1.15 0.26 to 1.25 0.24), C.
(84.9 28.55 to 74.28 23.25), BUN (21.25 5.56 to 24.7 7.11), CsA
dosage (2.95 0.61 to 3.19 0.66), total cholesterol (257 35.56 to
241 55.28), glucemia (82.16 9.36 to 87.33 9.1) and albumin (4.02
0.19 to 4.2 0.25). After one year, there were no differences in
phospho-calcium metabolism or in bone densitometry results in either
group. The prevalence of cataracts was decreased from 54% to 31% in the
P-withdrawal group after one year and increased from 45% to 53% in the
control group. There were no changes in dermatological effects. In
conclusion, in 76% of the selected patients with graft survival exceeding 5
years, the withdrawal of P was possible and well tolerated. There was a
20% incidence of acute rejection but no graft loss. A discreet hut
non-progressive decline in renal function was hiund 2 years after P
withdrawal. Some patients experienced clinical and metabolic improve-
ments.
Elfect of kidney transplantation (KT) and cyclosporine treatment on
sexual performance and hormonal profiles in males with chronic renal
failure. J. Pa.scual, F.J. Bwgos, V Górnez, L. Omfino, T Cano, A. Tato,
G.E. Juárez, F. Liuño, and .1. Orb/b, Servicios de JVefrologIa y Urologla,
Hospital Rarnón y Cajal, Madrid, Spain. Sexual dysfunction manifested by
decreased libido and crectile failure is frequent in male ESRD patients.
We have prospectively assessed the effect of KT on male sexual perfor-
mance and hormonal profiles. Between 1991 and 1995, 50 male nondia-
hetic patients on dialysis were interviewed, evaluating libido, erection,
ejaculation, orgasms and satisfaction. Plasrnatic FSH, LH, testosterone
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(TT), estradiol (ES) and prolactine (PRL) levels were measured. The
mean age was 45.6 5.9 years and duration of dialysis 15 6 months. All
of them received a cadaveric KT anastomosed to external iliac artery. A
new questionnaire and hormonal profile were undertaken 16 2 months
post-KT. Blood pressure was similar pre- and post-KT, 60% needed drugs
pre-KT and 80% post-KT. Nifedipine was more frequently used post-KT(20% vs. 80%, P < 0.05). Maintenance immunosuppression was cyclo-
sporine (CsA) and prednisone (Pred) in 65%, azathioprine (AZA)-Pred in
7.5% and CsA-AZA-Pred in 27.5%. Complaints of reduced libido and
reduced potency decreased after KT (40 vs. 30% and 60 vs. 45%,
respectively, P < 0.01). FSH and LH levels were not different before and
after KT and were directly correlated with time on dialysis. TT increased
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after KT (43.7 22.3vs. 298 25.1 nM/liter, P < 0.00 1) and ES and PRL
decreased (79.2 12.9 vs. 28.4 2.3 pmol/liter and 35.9 8.7 vs. 11 3.2,
respectively, both P < 0.05). Antihypertensive type or doses did not
influence the results. CsA-Pred treatment was associated with lower FSH
and ES levels at any given level of graft function (P < 0.05 vs. the other
regimens), and ES was inversely correlated with CsA dose. TT was directly
correlated with hemoglobin and inversely correlated with Se., (both P <
0.05). KT improves libido and erectile function in some ESRD males,
restoring a more adequate sexual hormonal profile (increases TT and
reduces ES and PRL levels). CsA-Pred therapy seems to show more
favorable effects than regimens with AZA. However, sexual dysfunction
remains an important problem after KT.
